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ABSTRACT 
Chronic obstructive pulmonary disease (COPD) is characterised with a poorly reversible airflow 
limitation. It is a major public health challenge in many developed countries. Cardiovascular 
complication is a common co-morbidity in COPD and is linked to hypoxia and inflammation. Arterial 
stiffness is also correlated with emphysema severity in COPD patients, with a suggestion that this 
might be related to systemic inflammation.  
In this thesis, we have investigated the influence of inflammatory mediators and hypoxia on vascular 
dysfunction in an in vivo and in vitro rat model. In addition, we looked to identify a potential 
interaction of hypoxia and inflammation upon arterial stiffness of alpha-1 antitrypsin deficient 
(AATD) subjects. 
We found that TNF–α (2-6hrs) had a significant effect upon isolated rat pulmonary artery dilatation 
in response to carbachol and sodium nitroprusside. Unlike tempol, allopurinol has completely 
restored the carbachol response whereas none of the antioxidants had any effects on sodium 
nitroprusside response. Thus suggesting that TNF–α impaired carbachol response via xanthine 
oxidase pathway. Hypoxia applied for 1-2 weeks in vivo then acute (1hr) TNF-α challenge (in vitro) 
had no effect upon vascular reactivity. However, when combined acute hypoxia and TNF–α 
simultaneously (in vitro, 1hr) pulmonary artery vasodilatation was impaired. These data suggest that 
prolong inflammation or combination of acute inflammation and hypoxia can have a combined and 
detrimental effect upon vascular reactivity and so provide a potential model for studying these 
exacerbations in vitro.  
Also, our results have shown that the serum TNF–α level of AATD subjects correlated positively and 
significantly with arterial stiffness as measured by pulse wave velocity (PWV). Multivariate 
regression analysis revealed that TNF–α is not an independent predictor of PWV, unlike age and 
systolic pressure. However, the model that entered age, sex, Forced Expiratory Volume in 1 second, 
systolic pressure and gas transfer factor TLCO and TNF–α as the independent variables was found to 
effectively predict PWV (independent variable). There was no significant interaction observed 
between hypoxia and inflammation to modulate arterial stiffness.  
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1 INTRODUCTION  
1.1 Chronic obstructive pulmonary disease and its impact on 
healthcare 
Chronic obstructive pulmonary disease (COPD)  is characterised by  poorly 
reversible airflow obstruction (1-5)  and is associated with abnormal inflammation in 
the lungs (3, 6). This phenomenon arises due to an irregular inflammatory response 
to harmful substances or gases, mainly cigarette smoking (7). The World Health 
Organisation has reported that COPD is the fourth leading cause of mortality in the 
world and by 2025 is projected to become the third (8-10). Therefore, COPD 
presents a major challenge towards the public health sectors in both developed and 
developing countries. In the UK alone, it is estimated that COPD affects 3 million 
people (1, 11) and accounts for 1 in 8 hospitalisations. In the USA, COPD is the 
fourth leading cause of death(12). The BOLD study 2011, reported prevalence of 
Gold Stage II or higher in 22% of men and 17% of women in South Africa (13). Also, 
between five cities in the southern cone of Latin America, COPD prevalence ranges 
from 8% in Mexico City to 20% in Montevideo (5). Millions of people are affected by 
COPD throughout the world and many may die prematurely from the disease or 
consequent to its complications; this problem is anticipated to increase in the years 
to come due to persistent exposure to COPD risk factors as well as the aging 
population (5, 8, 10, 13-16).  
The economic cost of COPD on the UK economy is substantial. According to the 
National Institute for Health and Clinical Excellence (NICE) (17) the total annual cost 
of COPD to the NHS is projected to be over £800 million for direct healthcare costs, 
which is equivalent to £1.3 million per 100,000 people. This stresses the significance 
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of undertaking research to investigate to understand the disease in order to identify 
new potential cost effective remedies.  
1.1.1 Diagnosis of COPD 
COPD is diagnosed by spirometry, which measures airflow obstruction by means of 
forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) and 
measures of reversibility of these after bronchodilating drugs (7, 18) . Reduction in 
the ratio of FEV1 to FVC defines the existence of airflow limitation whereas a 
decrease in FEV1 is used to determine disease severity (19) . Almost all global 
bodies and national guidelines accept the use of spirometry based diagnosis of 
COPD (1, 11, 12, 20-22) although definitions vary (Table 1.1).  
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) was the earliest 
agreement or declaration, produced in 2001 (23).  This was based on the use of a 
fixed FEV1/FVC < 0.7 as well as a fixed FEV1 to determine its severity (20). This 
definition does not account for the differences in population, age or sex; therefore it 
is prone to misclassifying the diagnosis.  Using a fixed FEV1/FVC <0.7 can over-
diagnose COPD in elderly patients especially among non-smokers (24-28).  
In 2004, the American Thoracic Society (29) and European Respiratory Society 
(ERS) published a joint statement to promote the implementation of the lower limit of 
normal (LLN) rather than a fixed FEV1/FVC < 0.7 to diagnose COPD (4). LLN is 
defined as “the lower fifth percentile of the frequency distribution of a reference 
population, to define pulmonary function abnormalities” (19, 24) and can be 
determined by deducting 1.64 times the standard deviation from the mean or 
expected value(19). There is still an on-going debate to determine which of these 
definitions is more accurate. More recently far greater characterisation of patients 
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has been proposed as a means of categorising COPD patients into groups whose 
clinical features or outcomes differ (30, 31). Additional tests might be undertaken that 
include computed tomographic (CT) (32) scanning of the chest to evaluate the 
severity and distribution of emphysema, gas transfer measurement, assessment of 
co-morbid disease, exercise capacity or rapidity of decline in FEV1 over time (16, 30, 
31, 33-36). Exercise capacity can be measured by six minute walk test (34, 37) or 
endurance shuttle test(37) and contributes to prognosis when assessed as part of 
the BODE (body mass index, airway obstruction, dyspnoea and exercise tolerance) 
index (33) .  
Common co-morbidities in COPD include cardiovascular disease, muscle 
dysfunction, osteoporosis, anxiety and depression (2, 38-42) –their prevalence, 
relationship to lung disease in COPD and pathophysiology has been reviewed 
elsewhere (43). Patients with COPD may also experience episodes where their 
condition worsens, termed exacerbations. Their frequency is also recognised as an 
important feature of disease (44). Exacerbations are defined as ‘an event in the 
natural course of the disease characterised by a change in the patient's baseline 
dyspnoea, cough and/or sputum beyond day-to-day variability sufficient to 
necessitate a change in management (4).  
NICE 20042 ATS/ERS 20041 GOLD 201151 BTS/NICE 20109 
FEV1 % 
predicted 
FEV1/FVC <0.7 <LLN <LLN FEV1/FVC <0.7 
≥80  Mild Stage I: Mild Stage I: Mild 
50-79 Mild Moderate Stage II: Moderate Stage II: Moderate 
30-49 Moderate  Severe Stage III: Severe Stage III: Severe 
<30 Severe Very severe Stage IV: Very severe Stage IV: Very severe 
Table 1.1.1: Classification & severity of COPD disease 
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1.1.2  Classification of COPD   
COPD is often an umbrella term denoted to respiratory diseases typified by airway 
obstruction(45) and comprises of a number of overlapping phenotypes(46). These 
can include chronic bronchitis, emphysema, bronchiectasis, bronchiolitis or a 
combination of these(46, 47). It is a destructive inflammatory process causing 
partially reversible airflow limitation that defines COPD (48). The inflammation is not 
solely confined to the lungs and there are often systemic consequences(49) (see 
1.1.3). The pathologies of COPD are briefly detailed below.  
Chronic bronchitis is typified by inflammation of the bronchial tubes (tubes that carry 
air to the lungs) which might cause the individual to develop a persistent cough. In 
COPD, chronic bronchitis involves various clinical manifestation that consist of 
accelerated decline in lung function, higher risk of air flow limitation (mainly in 
smokers), susceptibility to lower tract infection, increased frequency of exacerbation 
and overall increase in mortality (50). Chronic bronchitis is mainly caused due to 
hypersecretion and excessive production of mucus by the goblet cells. This 
phenomenon is responsible for worsening airflow limitation of the small airways and 
epithelial remodeling(50). In addition, the surface tension of the airways might be 
altered due the accumulation of mucus thereby making the making it airway surface 
susceptible to collapse (50).   
Emphysema is a lung condition that is associated with shortness of breath. It is 
characterised with damage to air sacs in the lungs (alveoli). Progressively, the inner 
walls of the air sacs weaken and rupture leading to formation of enlarged air spaces 
rather than several small normal ones. Consequently, the surface area of the 
respiratory alveoli is reduced thus minimising the amount of oxygen transferred into 
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bloodstream. People with emphysema also struggle to exhale the air that gets 
trapped in the lungs thereby precluding entry of fresh oxygen rich air.  
Current research evidence suggest that the majority of people with emphysema also 
suffer from chronic bronchitis, hence small airway pathology was associated with 
poor clinical outcome, worsen mortality and reduced  augmentation of the lung 
function post lung volume reduction surgery (50). In fact, unlike the classic COPD 
spectrum definition that classified individuals into chronic bronchitis at one end and 
the emphysema on another, it is established that majority of COPD patients found 
themselves somewhere in the between. 
Moreover, bronchiectasis is associated with a permanent expansion of bronchi and 
bronchioles that consequently cause airway obstruction due to abnormal mucus 
secretion similar to what is observed in chronic bronchitis. However, evaluation and 
treatment are different between the two disease conditions(51). A study Arram & 
Elrakhawy (51) has reported that  about 48% (33 of 69) of COPD population they 
had studied were found to have both bronchiectasis and chronic bronchitis. Further 
investigation using higher resolution CT scan suggests that bronchiectasis with 
chronic bronchitis might exhibit severe airway dysfunction, frequent exacerbation 
and increased bacterial colonization (51). Smoking is the main cause of COPD 
though there is specific genetic condition that might make individuals more 
susceptible to developing emphysema. The genetic contribution to COPD is detailed 
in sections 2.1 & 3.1 Treatment may slow the progression of COPD, but it can't 
reverse the damage. 
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1.1.3 Role of inflammation in COPD 
COPD is characterised by chronic airway inflammation, which represents a key 
component of disease development and pathogenesis (3). Studies of 
bronchoalveolar lavage have reported elevated inflammatory cells, such as 
neutrophils, in sputum from COPD patients compared with controls (52). Keatings et 
al (52) also found significant levels of inflammatory cytokines such as interleukin–8 
(IL-8) and tumour necrosis factor–alpha (TNF–α) in sputum from COPD patients 
compared with healthy smokers and non-smoking controls, suggesting these are 
implicated in COPD (52). Numerous other studies have confirmed these findings (6, 
53-58), although significant day to day variability occurs (58).  
Furthermore the relationship of pulmonary to systemic inflammation is not yet clear. 
Several studies have reported elevation of various inflammatory markers such as 
TNF–α, IL–8, IL–6 and C–reactive protein (CRP) in the serum (59-61) of patients 
with stable COPD suggesting that inflammation is not confined to the lungs. Levels 
of inflammatory mediators might also increase in COPD patients during 
exacerbations, which in turn is associated with cardiovascular events (62) 
suggesting that systemic inflammation promotes advancement of cardiovascular 
diseases (63). In COPD this is thought to occur by various mechanisms including 
endothelial dysfunction (64), arterial stiffness (65) and increased platelet activation 
(66).  
Erythropoiesis (EPO) is also influenced by pro-inflammatory mediators such as IL–
1α, IL–1β, IL–6, IL–10, TNF–α and interferon-gamma (IFNγ). The main stimulus for 
EPO production is the fall of tissue PO2, therefore increased production was 
observed under hypoxic condition in the kidney and other organs such as the liver 
and brain (minor amounts). Thus low red blood cells count and high EPO levels 
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signals a cellular hypoxia (67). During inflammation, EPO production by kidney and 
liver  cells may be reduced  and increased hepcidin production occurs, which down-
regulates iron efflux from body stores, thereby minimizing the iron level for 
erythropoiesis and impairing haemoglobin secretion and bone marrow reaction to 
erythropoietin (68-71). This mechanism has not directly been linked to COPD, 
however, inflammation and hypoxia were implicated in the increased production of 
hepcidin by the liver, and thus it might be relevant to explore the association of this 
mechanism with COPD. It will principally be important in finding alternative therapies 
for aneamic COPD patients as previous studies showed increased levels of pro-
inflammatory cytokines (IL-10, IFN-y, CRP, TNF–α) and erythropoietin in anaemic 
COPD patients compared to non-anaemic controls (54, 72). The prevalence of 
aneamia in patients with COPD varies from 7.5% to 33% (73).  
1.1.4 Hypoxia and use oxygen therapy in COPD 
COPD patients with severe hypoxaemia at rest may receive long term oxygen 
therapy (LTOT), defined as oxygen use for ≥12 hours/day, and is indicated when 
PaO2 <7.3kPa (55mmHg) at rest when well, or <8.0kPa in the presence of cor 
pulmonale (74, 75). LTOT improves their daily activity, and reduces mortality (22, 74-
77). Ambulatory oxygen is defined as the use of supplemental oxygen during 
exercise and activities of daily living41. Ambulatory oxygen therapy is often used for 
patients on LTOT during exercise, or for non LTOT users who achieve some 
subjective and/or objective benefit from oxygen during exercise (1, 22, 76, 77). The 
latter group of COPD patients, who are not severely hypoxaemic at rest, might 
experience considerable breathlessness, due to hypoxia, on exertion. However, 
there is no conclusive evidence to justify the use of ambulatory oxygen in patients 
not on LTOT. Consequently, international guidelines differ, and clinical practice 
15 
 
varies. One of the main treatments to improve symptoms in COPD is pulmonary 
rehabilitation (35, 78, 79), which includes exercises to improve fitness; ambulatory 
oxygen might also be used under these circumstances, although again the evidence 
base has not been thoroughly explored, or consistent in its results. 
Findings from various studies have revealed potential contribution of tissue hypoxia 
in the development of skeletal muscle disease in COPD (80). These might be 
summarised in the following points. Chronic hypoxia inhibited protein synthesis in 
muscle cells which caused net loss of amino acids and limited production of myosin 
heavy chain isoforms (81). Also, muscle mass loss was reported in healthy 
individuals at high altitude (82, 83). In addition, skeletal muscle derived from patients 
with COPD and chronic respiratory failure exhibits structural (decrease of type I 
fibres) and functional (upregulation of mitochondrial cytochrome oxidase) alterations 
proportional to the severity of arterial hypoxaemia. If tissue hypoxia plays a 
pathogenic role, domiciliary oxygen therapy may have a beneficial effect upon 
muscle disease in COPD. 
1.1.5 Genetic susceptibility to COPD: Role of Alpha-1-antitrypsin deficiency  
Alpha-1-antitrypsin deficiency (AATD) is broadly recognised as the sole genetic 
factor that makes the subjects susceptible to COPD. Based on a disease registry in 
the West Midlands, it is estimated that 670 people in England have emphysema 
caused by AATD (84). In North America, the prevalence of AATD is about 1 in 3000–
5000 people (85). Globally, it was eestimated that 1-5% of patients with diagnosed 
COPD have AATD (85, 86).  
AATD was first described in 1963 by Laurel and Eriksson. They have recognised 
alpha-1 (α1) band were missing on protein electrophoresis of human serum (87). 
Generally, when serum isolated from healthy individuals undergoes electrophoresis, 
16 
 
separates the serum proteins into 5 main bands: alpha-1-globulins, alpha-2-
globulins, beta globulins, gamma globulins and albumin. However, the major 
composition of alpha-1-antitrypsin is the alpha-1-globulins, hence the absence of this 
band results in AATD (87). Interestingly, the absence of alpha-1-globulins band was 
associated with early onset of emphysema thus suggesting a potential role for AATD 
in the disease pathogenesis. Alpha-1-antitrypsin (AAT) is regarded as an acute 
phase glycoprotein which is mainly synthesised by hepatocytes then released into 
the plasma (88). In addition, tiny amount of AAT is generated from alveolar 
macrophages, circulating monocytes and lung epithelial cells (89-91).  
 
1.1.5.1 Clinical features  
Previous studies have suggested that AATD was associated with disease 
pathogenesis of COPD (such as emphysema, chronic bronchitis, and 
bronchiectasis), neonatal jaundice, vasculitis, panniculitis and liver cirrhosis (92).  
While AATD is a susceptibility factor to COPD phenotypes including emphysema, 
the condition does not lead all patients to develop the pulmonary disease. The 
difference in the clinical phenotype might be due to variations in environmental 
factors (for example; cigarette smoking) that might be predisposed by other genetic 
factors. Subjects were mostly diagnosed with AATD post pulmonary or liver disease 
investigation. However, this process might be subjective to the local and national 
common practices, especially where a neonatal screening is available (93). For 
example; in countries that implement screening programme might diagnose subjects 
at birth, rather than when the disease symptoms were observed. Most of the 
symptoms of AATD are non-specific; therefore, subjects might experience variety of 
symptoms such as cough, wheeze and chest infection(93). These experiences might 
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interfere with the disease diagnosis thus delaying the diagnosis of the condition 
shown by many by nearly 6 years from the onset of the symptoms (94). The typical 
presentation of AATD is with progressive dyspnoea, plus or minus chronic bronchitis, 
comparable to typical COPD and despite younger age and less smoke exposure 
(92). The regression analysis of UK AATD population reveals that features of 
emphysema may occur in late teenage years (93), whereas usual COPD 
presentation occurs at middle age (at approximately 45 years).  
The current guidelines in the UK suggest testing for AATD only in subjects below the 
age of 45 or in people with disease severity inconsistent with their level of exposure 
to cigarette smoke (95). Typically, cigarette smoke exposure is estimated by pack 
years. One pack year is equal to one pack of cigarette per day (i.e 20 sticks per day). 
Majority of COPD subjects had 10 years or more exposure to cigarette smoke 
whereas the AATD subjects had far less exposure (92).  
The lung function tests AATD mostly indicate feature typical to COPD; for example 
airflow obstruction, plus or minus as small gas transfer and elevated static lung 
volumes. In addition, it common to observe in AATD subjects, changes mostly 
associated asthma such as post bronchodilator reversibility (96). This has been 
shown in the initial assessment of NHLBI AATD registry, where reversibility post 
bronchodilator administration stands at 12% of baseline FEV1 in 28% of the subjects 
(96). Besides, normal lung function might be observed mainly both asymptomatic 
subjects though is not entirety. Exposure to smoking is probably the most essential 
determinant of lung function as variation was reported between smokers and non-
smokers in late teen years (~ 18 years), as well as a significant association between 
smoking and lung function decline in adults, with the  average decline per year in 
FEV1 from 70mL to 47mL in current smokers and never smoked respectively (97). 
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Other features such as male sex, low body mass index, frequent exacerbations and 
severity of upper zone emphysema were all recorded as alternative determinants to 
rapidly declining lung function (98).    
Currently, high-resolution computerised tomography (HRCT) scanning is commonly 
used in the assessment of COPD and AATD as a direct consequence of improved 
interpretation of the images obtained with this the technique (99). The scan can be 
useful to diagnose emphysema and bronchiectasis, as well as their distribution and 
severity levels (99, 100). It has been shown that emphysema distribution in AATD 
has a relationship to the lung function (101). AATD subject predominantly develop 
lower zone emphysema, whereas in COPD, upper zone disease predominates. In 
addition, it has been reported that bronchiectasis occurs in the majority of AATD 
subjects mainly together with emphysema (100).  There are specific test for 
assessment of AATD that involves quantifying the serum level of AAT levels (< 11ɥM 
regarded as pathophyiologically significant), phenotyping technique (protein 
electrophoresis) or genotyping to identify common diseases linked with variants such 
as Z allele (100). 
1.2 Vascular Wall Composition and Classification of arteries 
Generally, the vascular wall comprises of three main layers. This includes the tunica 
intima, tunica media and tunica externa, and these are referred sometimes as the 
internal, middle and outer layers respectively (102).  Locating in the intima, are the 
endothelial cells that release of essential mediators such as neurotransmitter, 
hormones and vasoactive substances to regulate vascular function (103). The 
vascular tone and blood pressure are maintained primarily through the actions of the 
endothelium and smooth muscle cells. The main role of the arteries is to supply 
oxygenated blood to all organs with high pressure; however, pulmonary artery 
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delivers deoxygenated blood to the lungs. Based on the size, anatomical feature, 
location and functionality, the arteries were divided conducting arteries, 
macrovasculature (conduit arteries) and microvasculature (resistance) (104, 105).  
The conducting arteries are rich in elastic tissues that give the vessels flexibility to 
expand and recoil in order to respond to changes in blood pressure. Examples of 
conducting arteries include the aorta, large pulmonary and carotid arteries (105, 
106). Conducting arteries subdivide to form conduit arteries such as small muscular 
pulmonary arteries, femoral, radial, and brachial arteries that are specialised in 
regulating the flow of blood to specific organs and areas of the body (107). Conduit 
arteries further divide to form resistance branches of arteries that comprise mainly of 
smooth muscle cells with extensive networks of sympathetic nerves. The resistance 
arteries constrict and dilate in response to sympathetic activities thereby regulating 
the flow of blood to tissues (105, 108). 
1.3 Regulation of Vascular Tone 
Vascular tone denotes the general contractile state of a vessel or vasculature region 
(109). It is a term commonly used to characterise the degree of constriction 
experienced by a blood vessel relative to its maximally dilated state. Under basal 
conditions, arterial and venous vessels manifest a level of smooth muscle 
vasoconstriction, which influences the vessels diameter and tone. Vascular tone is 
determined by opposing vasoconstrictor and vasodilator stimuli acting on the blood 
vessels (110).  
1.3.1 Vascular Smooth Muscle Contraction 
The wall of blood vessels contain layers of smooth muscle cells, similar to the wall 
lining of a variety of organs such as stomach, intestine, airways and uterus (111). 
Generally, contraction causes shortening of the smooth muscle cells that result in 
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changes in the diameter of the vessel. These changes cause the lumen contents to 
be pushed along the vessel thus allowing it to regulate flow. The contractile state of 
the smooth muscle cells are controlled by neural innervation from the autonomic 
nervous system, hormones (paracrine or autocrine) and local chemical stimuli (111).  
1.3.2 Mechanism of contraction 
The smooth muscle cell contraction is mainly controlled via the induction of 
mechanical (stretch) and receptor that cause the contractile proteins (myosin and 
actin) to be stimulated. The myosin and actin interaction that results from the 
phosphorylation of myosin light chain (MLC) by myosin light chain kinases (MLC 
Kinase) is an essential step for any contraction to happen. ATP generated via 
myosin ATPase activity is utilised as fuel to cycling of the myosin cross-bridges and 
actin contraction. Therefore, MLC phosphorylation state is used as a determinant of 
the contractile activity of a vascular smooth muscle. When there is no receptor or 
stretch stimulation, the phosphorylation state of the MLC remains low, a 
phenomenon referred as smooth muscle tone (111).  
1.3.3 Contraction of Smooth Muscle is Ca2+ dependent 
Ca2+-mediated alterations in the thick filaments results in the initiation of contraction 
of the smooth muscle cells (111). The smooth muscle reacts to the stimulation of a 
variety of external stimuli (including vasoconstrictor agonists), by increasing [Ca2+]i. 
Sarcoplasmic reticulum and receptor-operated Ca2+ channels both contribute to the 
elevation of [Ca2+]i  via release of Ca
2+ from intracellular stores and influx of Ca2+ from 
the extracellular space into the cytosol respectively (111, 112). The free calcium 
forms a complex with a special calcium binding protein called calmodulin, which 
triggers stimulation of MLC kinase that subsequently activate LCM (111) (Figure 
1.1).  
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Moreover, upon binding to a heterotrimeric G protein coupled receptor, 
vasoconstrictor agonists (such as norepinephrine, thromboxane A2, angiotensin II, 
endothelin and vasopressin) induces Gα subunit dissociation (in the case of a 
contractile Gq-coupled receptor the Gαq unit) and activation of phospholipase Cβ 
(PLCβ) enzyme (112). Activated phospholipase C, catalyse phosphatidylinositol 4, 5-
bisphosphate (membrane lipid) to generate the second messengers, inositol 
trisphosphate (IP3) and diacylglycerol (DG). IP3 activates IP3 receptors (IP3R) on the 
sarcoplasmic reticulum to induce a rapid release of Ca2+ into the cytosol, whereas 
DAG activates receptor operated channels (ROC), possibly formed of transient 
receptor potential proteins such as TRPC6, which mediate Na+ and Ca2+ entry (112). 
In addition, cluster of IP3R cause localized elevation of Ca
2+ that subsequently 
stimulate ryanodine receptors to trigger Ca2+ induced Ca2+ release (CICR), thereby 
potentiating the rise in Ca2+ and leading to regenerative Ca2+ oscillations (113, 114). 
Increased level  of cytosolic Ca2+ initiate smooth muscle contraction through 
formation of Ca2+-calmodulin and subsequent activation of myosin light chain kinase 
(MLCK), resulting in the phosphorylation of the 20 kDa regulatory myosin light chain 
(MLC) and cross bridge cycling. The extent of MLC phosphorylation is proportional to 
force, and is determined by the balance of activity between MLCK and the MLC-
dephosphorylating enzyme myosin light chain phosphatase (MLCP) (112). Also, 
activation of PKC increases the myofilament force sensitivity to [Ca2+]i and MLC 
phosphorylation, and maintains vascular smooth muscle contraction (115). In 
addition, mechanical activity of the smooth muscle cells results in membrane 
depolarisation that leads to the opening of voltage-operated L-type Ca2+ channels to 
increase intracellular free Ca2+ level (111). 
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1.3.4 GPCR-induced Rho/ROCK mediated Ca2+ sensitization 
Increased MLC phosphorylation can also occur as a consequence of Ca2+-
sensitization, which involves inhibition of MLC phosphatase (MLCP). Rho/Rho 
kinase and PKC mediated signaling pathways mainly control the activity of MLCP 
(112). This Ca2+ independent pathway modulate the Ca2+/camodulin activation of 
MLCK and the subsequent phosphorylation of MLC through inhibition of MLCP that 
results in augmented phosphorylation of MLC and subsequent increase in the level 
of smooth muscle contraction for any given elevation of cytosolic [Ca2+] (112, 116). 
This phenomenon is known as   Ca2+ sensitization (116, 117). It is suggested the 
mechanism might involves monomeric G-protein RhoA and activation of its main 
downstream effector Rho kinase (ROCK) though is not clarified (112).  
 
Figure 1.1: Regulation of smooth muscle contraction. Various agonists (neurotransmitters, hormones, etc.) 
bind to specific receptors to activate contraction in smooth muscle to increase phospholipase C activity via 
coupling through a G protein. Phospholipase C produces two potent second messengers from the membrane 
lipid phosphatidylinositol 4,5-bisphosphate: diacylglycerol (DG) and inositol 1,4,5-trisphosphate (IP3). IP3 binds 
to specific receptors on the sarcoplasmic reticulum, causing release of activator calcium (Ca
2+
). DG along with 
Ca
2+
 activates PKC, which phosphorylates specific target proteins. Activator Ca
2+
 binds to calmodulin, leading to 
activation of myosin light chain kinase (MLC kinase). This kinase phosphorylates the myosin light chain, and, in 
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conjunction with actin, cross-bridge cycling occurs, initiating shortening of the smooth muscle cell leading to 
contraction. Rho kinase inhibits myosin phosphatase activity to maintain the contractile state via Ca
2+
-
sensitizing mechanism. Though the mechanism is not fully elucidated, this involve activation of Rho A by 
nucleotide exchange factor (RhoGEF) and migration of RhoA to the plasma membrane, which subsequently 
result in increased Rho kinase leading to inhibition of myosin phosphatase. Adapted from (111).  
 
1.4 Endothelium-Derived Vasoactive Substances 
In the early 1980s, Robert Furchgott observed that acetylcholine released a 
substance that produced vascular relaxation, but only when the endothelium was 
intact (118, 119). This observation opened this field of research and eventually led to 
his receiving a Nobel Prize. Initially, Furchgott called this substance endothelium-
derived relaxing factor (EDRF), but by the mid-1980 he and others identified this 
substance as nitric oxide (NO) (109, 110). Furchgott and Zawadzki (120) studied the 
obvious inconsistency that acetylcholine could not always generate vasodilatation in 
vitro. They conducted investigations to unravel this mystery which led them to the 
finding that blood vessels isolated with intact endothelium consistently elicited 
acetylcholine–mediated vasodilatation. In addition, rubbing the intimal surface of 
segments of rabbit aorta vessel in order to remove the endothelium prevented the 
observed acetylcholine–mediated vasodilatation response. Moreover, Furchgott and 
Zawadzki (120) has shown that Ach acts on the muscarinic receptors found on the 
endothelium cells, which stimulates release of a substance(s) that causes 
vasodilatation of the vascular smooth muscle. At this point, the significance of 
endothelial cells in vascular biology became recognised, hence, the earliest 
demonstration of the notion that endothelial cells generated mediators that has the 
potential to modulate vascular function (120). This has been the cornerstone of 
several investigations undertaken from the 80s to uncover substances that affect 
vascular tone (121, 122). Therefore, numerous mediators of vascular tone were 
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identified and suggested to act in a similar manner to acetylcholine(121). The 
findings suggest that endothelium perform a critical role in the regulation of vascular 
function in both disease and health conditions. It is well documented that the 
endothelial cells synthesises and release a host of heterogeneous vasoactive 
substances that are essential in cardiovascular homeostasis and this process is 
controlled by well-organized local, systemic responses or interaction between the 
two in complex mechanisms (110). Some of this explained below:  
Vasoactive mediators synthesised or released from endothelial cells might be 
divided broadly into two main groups; the endothelium-derived relaxing factors 
(EDRFs) and endothelium-derived contracting factors (EDCFs)(123). Examples of 
EDRFs include nitric oxide (NO), prostacyclin (PGI2), whereas, EDCFs include 
endothelin, angiotensin, thrombin, superoxide anion (110, 122, 124). The third group 
referred to as the endothelium-dependent hyperpolarizing factor (EDHF) is also 
known to be involved in the maintenance of vascular tone especially in the absence 
or blockage of EDRFs (125). We have used a synthetic mimetic of Ach called 
Carbachol (Carbamoylcholine chloride) in our experiments. 
EDRFs and EDCFs might act via variety of mechanisms. These range from specific 
receptors to second messenger systems that consequentially modulate the smooth 
muscle cell response. The endothelium-derived mediators might act in autocrine 
(directly on endothelium cells themselves) or paracrine (indirectly on the vascular 
smooth muscle cells) manner. Hence, it is important to be able distinguish the 
features of the various endothelium-derived factors which are generated 
endogenously and might produce various responses in different vascular beds. This 
is due to the complex nature of the communication that exists between these 
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mediators because the observed physiological processes were not entirely due to a 
single vasoactive substance. Relevant endothelium-derived vasoactive substances 
such as NO will be discussed more broadly in the next sections. 
1.5 Nitric Oxide  
1.5.1 Nitric Oxide plays a variety of roles in different systems 
A variety of cell types such as vascular endothelium cells, smooth muscle cells, 
leukocytes, platelets and neurones synthesise and release NO. In addition, nitric 
oxide has been implicated in a variety of conditions thus playing different roles. 
These include regulation of immunity (126), inflammation (127), apoptosis (128), 
central nervous system signaling (129, 130). However, the most prominent role of 
NO is the regulation of vascular tone and blood pressure (131).   
In the cardiovascular systems, nitric oxide plays a major role as a signaling 
messenger (132). NO contributes to several significant biological functions within the 
cardiovascular physiology beside its key role as an endothelium-derived relaxing 
factor. NO promote maintenance of the vascular integrity by inhibiting platelet 
aggregation (133, 134), platelet adhesion, leucocyte–endothelium adhesion (135-
137) and vascular smooth muscle proliferation (138), as well as promotes platelet 
disaggregation (139). These help maintain anti-atherogenic state of the endothelium 
under non-pathological or resting conditions (140). Within an In vivo context, NO 
exerts these beneficial effects continually, under normal condition, as NO is 
constitutively released from the vascular endothelium cell via shear stress as result 
of the blood flow (141). The physiological range of shear flow is from 2 – 10 
dyne/cm2. In addition, shear-stress and pulsatile stretching of the vascular wall 
induce an uninterrupted release of NO which is essential in the generation of tonic 
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NO-induced vasodilation, which subsequently encourages local blood flow and 
maintenance of  low peripheral vascular resistance (142).  
1.5.2 NO synthesis 
As earlier stated, the release of NO from the endothelium was and the its 
subsequent effect on the vascular tone was first reported by Furchgott in the 80’s 
(118-120). The actual identity of this gaseous relaxing molecule; NO, was not 
uncovered until couple of years following the initial discovery of the activity (143). 
The road to the discovery of NO was reviewed by elsewhere by  Moncada and Higgs 
(144). Currently, the pathway of NO synthesis is widely recognised in the literature. 
The amino acid L-arginine is the natural precursor for NO synthesis. In the presence 
of co-substrates NADPH and oxygen molecule (O2), L-arginine get oxidised in a 
reaction catalysed by nitric oxide synthase (NOS) to generate L-citrulline and NO 
(145) (Figure 1.2). The NO produced can go on to perform variety of function locally 
and regionally within the vasculature such as bringing about vascular relaxation as 
detailed in the schematic diagram (Figure 1.3). Fleming and Busse (142) have 
established that other redox-active cofactors such as terahydrobiopterin (BH4), 
heme, calmodulin (CaM), Flavin mononucleotide (FMD) and flavin adenone 
dinucleotide (FAD) are prerequisite for NOS catalysis.  
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Figure 1.2: Enzyme–catalysed nitric oxide (NO) synthesis from L-arginine. Hydroxylation of l-arginine 
produces N-hydroxy-l-arginine as an intermediate. The second step converts N-hydroxy-l-arginine to generate 
NO and citrulline as products. Adapted from (145) 
 
1.5.3 Isoforms of nitric oxide synthase and activation 
NO is a free radical produced by NOS in two step five-electron oxidation of the 
terminal  nitrogen of l-arginine as detailed above. There are three isoforms of NOS 
that have been characterised. These include neuronal NOS (nNOS), inducible NOS 
(iNOS) and endothelial NOS (eNOS) (125) and these are referred  sometimes as 
NOS I, NOS II and NOS III respectively. In addition, nNOS and eNOS are called as 
constitutive NOS (cNOS) (125, 146). As we can probably tell from their names, the 
three isoform of NOS are derived from different genes and might be regulated by 
variety of signaling pathways. eNOS and nNOS are constitutively expressed in cells 
that are mainly regulated by the Ca2+ influx which subsequently binds with 
calmodulin (145). However, iNOS expression is mainly stimulated by inflammatory 
cytokine (such as TNF–α, LPS, IL–1β, IL–2  and so on) and once generated, iNOS 
remain stable at normal intracellular  Ca2+  concentration [Ca2+]i, thus iNOS is 
suggested to be Ca2+ independent (145).   
Endothelial NOS generates NO, a process that is critical in cardiovascular 
homeostasis. It is well established within the literature that eNOS activation was 
Ca2+/calmodulin-dependent due the fact numerous agonist activated the enzyme 
only when the intracellular free calcium concentration [Ca2+]i  was increased(147, 
148). Interestingly, shear stress was initially considered the most fundamental 
physiological element required for constant production of NO as viscous drag 
mediated phosphorylation of eNOS to modulate its enzymatic activity (141, 149). 
Stefanie et al (150) revealed that serine/threonine protein kinase Akt/ protein kinase 
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B (PKB) activated eNOS that resulted into increased generation of NO. However, 
reduced serine phosphorylation and lack of eNOS activation was observed with the 
blockage of phosphatidylinositol-3-OH kinase/Akt pathway or mutation of the Akt site 
on eNOS protein (at serine 1177). Moreover the eNOS activity and sensitivity to Ca2+ 
was altered by Serine 1177 phosphorylation analogue was used that generated 
optimal enzymatic activity at below physiological intracellular calcium concentration 
[Ca2+]i. This observation confirms that the Akt activation of eNOS is Ca
2+ 
independent (150).  
1.5.4 Actions of NO 
The enzymatic action of nitric oxide synthase converts amino acid L-arginine to NO 
in the endothelial cells. NO is a non-polar molecule that can diffuse freely across the 
cell membrane (151). Therefore, NO rapidly diffuses from the endothelium into the 
adjacent vascular smooth muscle cells. It binds and activates soluble enzyme 
guanylyl cyclase (GC) which then dephosphorylate guanosine-5’-triphosphate (GTP) 
to cyclic guanosine monophosphate (cGMP) thus increasing the level of cGMP. 
Subsequently, cGMP serves as second messenger that signal smooth muscle 
relaxation. The relaxation of smooth muscle cells could be induced by cGMP via 
several mechanisms such as by increasing the level of intracellular cGMP, which 
oppose calcium entry into the cell. This is achieved variety of mechanisms, 
knowledge of which is ever evolving. However, they include  inhibition of voltage 
gated Ca2+ channels thus reducing [Ca2+]I and activation of large conductance 
potassium (BK) channels (that results into hyperpolarisation and relaxation) and 
induction of a cGMP–dependent protein kinase G (PKG) leading to stimulation of 
myosin light chain (MLC) phosphatase, an enzyme which dephosphorylates MLC 
leading to smooth muscle relaxation (110, 152). Hence, the activation of cGMP-
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dependent PKG is the main mechanism through which NO acts to stimulate 
relaxation in vascular smooth muscle. 
Rembold et al. has shown that elevated cGMP levels might cause reduction of 
vascular tone through phosphorylation of heat shock protein (hsp) – 20 that binds 
with thin actin filaments thereby inhibiting cross-bridge formation or cycling. The 
cellular mechanisms response of cGMP was reviewed by Francis et al (152). They 
suggested that mechanism NO stimulates vascular relaxation were unlikely to be 
due to a single pathway (152). However, together the pathways might be interacting 
to effect changes on the vascular tone, although evidence may indicate relative 
significance of variety of pathways locally or regionally (152). Biosynthesis of NO and 
generalised action is summarised below (Figure 1.3). This in-vivo vascular tone 
regulation mechanism is amenable to investigation ex-vivo.  
 
 
Figure 1.3: NO synthesis and generalised action on VSM relaxation. The enzymatic action of nitric oxide 
synthase converts amino acid L-arginine to NO in the endothelial cells. NO rapidly diffuse into the VSM to 
activate guanylyl cyclase (GC) which then dephosphorylate Guanosine-5-triphosphate (GTP) to cyclic 
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Guanosine monophosphate (cGMP). Some vasodilator drugs can acts via receptor bound GC to increase CGMP 
level. The build-up of cGMP then activate PKG to phosphorylate a relevant protein to bring about relaxation 
((110). *GC= Receptor bound GC, R=Receptor. 
 
1.5.5 Physiological roles of NO in cardiovascular systems 
The physiological role of endogenously generated NO has been one the fastest 
growing areas of biomedical research (153). The evidence gathered suggests a 
prominent role for this tiny molecule in a variety of physiological function that 
included regulation of vascular tone and proliferation of mesenchymal cells (154). 
Enormous efforts have been rendered in finding the role of NO in pulmonary 
circulation, both in the normal state and during pulmonary hypertension (153).  
In cardiac cells, NO regulates cardiac contractility (155). In addition, availability of 
sufficient amount of NO is critical to maintain normal vascular physiology to face 
challenges of reduced NO bioavailability, endothelial dysfunction, which might 
predispose to atherosclerotic disease (139, 156). Hence, NO signaling deficiency 
has been associated with atherosclerosis, diabetes mellitus, congestive heart failure, 
hypertension, hypercholesterolemia, thrombosis and stroke (139, 156-158). The 
important of NO in the physiology and pathogenesis of disease can be shown 
through genetic manipulation of enzymes that generate NO in mice or studies where 
NO generation has been nullified. Specific inhibition of NO generation by L-arginine 
analogues such as NG-monomethyl-L-arginine (L-NMMA) or via genetic knock-out 
mice, demonstrated a significant elevation of central blood pressure in subjects with 
sepsis. Moreover, NO has been shown to diminish action of several vasoconstrictors 
such as noradrenaline, angiotensin II and vasopressin, as well as inhibited response 
of endothelin (159, 160). Therefore it can be suggested that balance between 
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vasoconstrictor and vasodilator substances is a cornerstone of maintenance of 
homeostasis in the vascular system (161).  
1.6 Reactive oxygen species & chemical characteristics  
Reactive oxygen species refers to a group of molecules that encompasses the free 
radicals that are naturally produced as by-products of oxygen metabolism as well as 
non-radical species. Most ROS are free radicals (such as superoxide anion (O2
−·), 
hydroxyl racial (HO·) and lipid radicals) (157), due to the presence of unpaired 
electrons (162). Other reactive oxygen species, such as hydrogen peroxide (H2O2), 
peroxynitrite (ONOO−), hypochlorous acid (HOCl) ozone (O3), and lipid peroxide 
(LOOH), are non-free radical species. However, they do possess oxidizing 
capabilities that promote oxidant stress.  
Several studies have reported ROS as an intermediate that acts as second 
messenger in signaling pathways. Superoxide and hydrogen peroxide the 
commonest ROS involved in cell signaling pathways (162).  Electrically charged O2
−· 
is highly reactive and is rapidly dismutated into H2O2, while the enzyme, catalase, 
decomposes H2O2 to water and oxygen (162, 163). O2
−· exist in small concentration 
(picomolar–nanomolar range) within the cells and has limited ability to readily diffuse 
thus acts as intracellular messenger, whereas, the increased cellular levels of H2O2 
(high nanomolar-micromolar range) which can readily diffuse across the hydrophobic 
cellular membranes to act as intra- and inter-cellular second messenger (163). 
Through the process of the generation of ROS within the cell, a variety of other free 
radicals are generated via radical chain reactions (164). For example, reactions 
between radicals and polyunsaturated fatty acids within cell membrane may result 
peroxyl radical that attack the side chains of adjacent fatty acids to initiate production 
of other lipid radicals. Lipid radicals produced in this chain reaction might be stored 
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in the cell membrane and might subsequently cause cellular function abnormalities 
such as leakage of the plasmolemma and dysfunction of membrane-bound receptors 
(164). 
There are several sources of ROS in mammalian cells. These include the 
mitochondrial respiration, arachidonic acid pathway enzymes lipoxygenase and 
cyclooxygenase, cytochrome p450s, xanthine oxidase, NADH/NADPH oxidases, NO 
synthase, peroxidases, and other hemoproteins (157). ROS generation sites exist in 
the lungs, endothelial cells, alveolar macrophage, eosinophils and alveolar epithelial 
cells. Moreover, in the pulmonary vasculature, ROS is mainly formed by complexes 
within the cell membrane (Nicotinamide Adenine Dinucleotide Phosphate (NADPH) –
oxidase), cellular organelles (such as peroxisomes and mitochondria) and cytoplasm 
(Xanthine Oxidase). Besides, limited levels of eNOS co-factors or substrates such as 
L-arginine and BH4 can result to  uncoupled eNOS, thus producing a shift from NO 
generation to ROS production(165). Several mechanisms were recognised with ROS 
production in hypoxia associated PH and these involves but not limited to 
dysfunctional mitochondria, uncoupled NOS, xanthine oxidase and NADPH oxidase 
(NOX). However, in the vasculature, NADPH and mitochondria were reported to be 
the main source of ROS production (166, 167), hence this will covered in detail in the 
next sub-sections. 
1.6.1 NADPH Oxidase 
Investigating the source of ROS in the homogenates of endothelial and vascular 
smooth muscle cells has revealed that NADH is the main substrate feeding the O2−· 
generation. Also, NADPH generated smaller proportion of O2−· (168). Variety of 
factor such as cytokines, hormones and mechanical forces were suggested to have 
a role in the regulation of the vascular NADH/NADPH oxidase during pathogenesis 
33 
 
of vascular disease (157). These have been demonstrated by the increased activity 
of vascular ROS production and NADH/NADPH oxidase activity in vascular smooth 
muscle cell that was stimulated by angiotensin II, thrombin, platelet-derived growth 
factor, tumor growth factor-α, and lactosylceramide (169-172). Furthermore, when 
human umbilical endothelial cells (HUVEC) were subjected to a unidirectional 
laminar shear stress, this caused transient increase of NADH-dependent O2−· 
production, contrary to the observed sustained elevation in oxidase activity when 
oscillatory shear stress was utilised (173). All these evidence demonstrate the role of 
NADH/NADPH oxidase in ROS generation. In cultured rat vascular smooth muscle 
cells stimulated with angiotensin II resulted in O2−· production due to increased 
activity NADH/NADPH oxidase (170). Likewise, a sudden rise in O2−· generation and 
NADH/NADPH oxidase activity was demonstrated in chronic angiotensin II infused 
hypertensive rats (174).  
The NOX system is a transmembrane mutimeric protein structure that catalyses an 
electron reduction of O2 to generate O2
−· by utilising NADH/NADPH as a donor(168). 
There are seven catalytic homologs (such as NOX1–5 and Duox1–2) that make up the 
NADPH oxidase family. However, the pulmonary vascular smooth muscle cell 
expresses NOX1, NOX2, NOX4 (166) and NOX5 (162).  Each of these NOX 
isoforms has specific adapter sub-units that are essential for the enzymatic action of 
the complexes. This is demonstrated by the protypic NOX isoform, NOX2 that 
constitutively combined with p22phox (175-177) in the membrane and without the 
latter adapter sub-unit, NOX2 becomes unstable (178). NOX 2 is stimulated on 
binding to the cytosolic p47phox (organiser sub-unit) which gets phosphorylated and 
promote recruitment of other sub-units such as the p67phox (activator sub-unit) and 
p40phox subunits into the NOX2 complex (179). The last step of the complex 
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formation is when a small GTPase RAC1 directly binds to the NOX2 and 
consequently interact with p67phox thus activating the sub-unit (180, 181). 
Subsequently, the assembled NOX2 complex has the ability to produce O2−· by 
donating an electron to molecular O2 in the luminal or extracellular space from the 
NADPH in the cytosol (182).  NOX1 activation is different from NOX2 as its activation 
requires interaction with cytosolic sub-units p47phox, p67phox, NADPH oxidase 
organiser 1 (NOXO1) and NADPH activator 1 (NOXA1) accordingly (183). NOX4 and 
NOX 5 are constitutively active and do not rely on interaction with the cytosolic 
homologues such as p47phox, p67phox, p40phox and GTPase Rac1 (162, 166) (184, 
185), although NOX4 requires interaction with the membrane sub-unit p22phox (162).  
Moreover, NADPH oxidase might be stimulated due to various stimuli growth factors 
(PDGF, EGF and TGF-1β), inflammatory mediators/cytokines (such as TNF-α, IL-1 
and platelet aggregation factors), metabolic factors (for example; hyperglycemia, 
hyperinsulinemia, free fatty acids, advanced glycation end products, mechanical 
factors (cyclic stretch, laminar and oscillatory-shear stress) and G protein-coupled 
receptor agonist (such as serotonin, thrombin, bradykinin, ET-1 and Ang II) (162, 
186-188). Contrastingly, statins, esradiol and peroxisome proliferator-activated 
receptor (PPAR) agonist diminish activation of NADPH oxidase (189, 190). 
Superoxide derived from NADPH was revealed to chiefly contribute in vascular 
dysfunction associated with a variety of animal models of PH including hypoxia-
induced PH (162, 191). 
1.6.2  Mitochondrial dysfunction 
The mitochondrial dysfunction is associated with ROS production and this has been 
noted in the pathophysiology of variety diseases including PH (192, 193). In the 
cardiovascular system, mitochondria are one of the main sources of ROS generation 
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(166, 167). ROS production in the mitochondria likely takes place in the electron 
transport chain (ETC)  which involves the Flavin site, complex I (ubiquinone reducing 
site), complex II (Flavin site) and complex III (ubiquinol oxidizing site) (194). 
However, complexes I and III were reported to be responsible for majority of ROS 
produced by the mitochondria (195). Tissue heterogeneity of complexes is a useful 
determinant of the individual roles of complexes in ROS generation as suggested 
due to findings from the following studies. In neonatal pulmonary artery myocytes 
exposed to hypoxia, inhibition of complex III blunted ROS generation (196), whereas 
complex II was shown to generate most of the mitochondrial ROS produced by 
hypoxic mouse lung (197). In addition, increased activity of complex II resulted in 
predominantly complex II derived ROS production in monocrotaline-induced rat 
models of PH (198). Moreover, PASMC exposed to hypoxia showed elevated ROS 
production in the mitochondrial inter-membrane space and reduced ROS in the 
mitochondrial matrix thereby suggesting that ROS production is differentially 
regulated in the mitochondrial compartments (199). In hypoxia induced pulmonary 
hypertension, ROS synthesised from the mitochondria caused elevated [Ca2+]i, 
depolarisation or hyperpolarisation of the membrane potential of mitochondria, 
PASMC constriction and growth leading to pulmonary vascular remodeling (200-
202). Also, hypoxia exposure caused mitochondrial derived ROS to triggered 
proliferation of PASMC which was later considered to be due to opening of K+ ATP 
channels, elevated ROS production  that consequently led to stimulation of redox 
sensitive transcription factors (AP-1) (203). Contrastingly, others have showed 
pulmonary hypertension and moderate hypoxia gave rise to a hyperpolarised the 
mitochondrial membrane potential, reduced mitochondrial derided ROS production 
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and attenuated K+ current thereby causing Ca2+ influx, depolarised plasma 
membrane and PASMC contraction (204).  
It estimated that about 3% of electron flux via the METC is constantly utilized within 
the mitochondria to generate O2−· (205). Manganese superoxide dismutase 
(MnSOD) or SOD2 converts O2−· within the mitochondria matrix to H2O2 that is 
subsequently broken down to H2O by glutathione peroxidase (GPX) (205) (Figure 
1.4). Copper and zinc superoxide dismutase (Cu-Zn-SOD) or SOD1 breaks down the 
O2−· within the intermembrane space  which then get scavenged and recycled by 
cytochrome c or  transmitted through voltage-dependent anion channels (found on 
the outer mitochondrial membrane) into the cytosol (206, 207).  
Moreover, a variety of antioxidant protective mechanisms reside with the cytosol 
which includes SOD1, catalase, GPX, GSH and scavengers (such as heme or 
sulphur-containing protein residue) (208, 209). Superoxide is a major precursor for 
variety of other ROS and radicals including peroxynitrite (which results from the 
reaction between NO and O2−·) and has the ability to decrease reducing equivalents 
such as the oxidation of GSH to GSSG. Superoxide is readily reactive and mainly 
membrane impermeable. However, superoxide can travel via anion channels and is 
quickly dismuted by SOD to the more stable peroxide (205). Therefore, superoxide 
and SOD levels are used as a significant marker to define cellular oxidant stress and 
redox state (210) .  
Catalase and/or GPX together with glutathione (GSH) break down H2O2 to oxygen 
and water (Figure 1.4). In addition, H2O2 can be decomposed by transitional metals 
like Fe(II) to form a more sensitive OH in a reaction commonly known as Fenton 
reaction. H2O2  has a higher stability, portability and permeability compared to O2
−· 
thus peroxide was considered as the most probable ROS to mediate HPV, though 
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some researchers proposed that superoxide might cause direct activation of Rho 
kinase (205, 211). 
 
 
 
Figure 1.4: Generation of reactive oxygen species: Molecular oxygen (O2) reacts with an impaired electron (e
−
) 
to form the superoxide anion (O2
.-
). The enzyme superoxide dismutase converts superoxide anion to hydrogen 
peroxide (H2O2). Hydrogen peroxide undergoes spontaneous conversion to the highly reactive hydroxyl radical 
(
.
OH). Alternatively, it can be detoxified via either glutathione peroxidase or catalase to water (H2O) and 
oxygen (GSH, reduced glutathione; GSSG, oxidised glutathione) adapted from (164). 
 
1.6.3 Xanthine Oxidase 
In the process of purine metabolism, xanthine oxidase (XO) is an oxidoreductase 
enzyme that catalyses the oxidation of hypoxanthine and xanthine. XO can exist in 
two interchangeable forms; either as xanthine oxidase or xanthine dehydrogenase. 
The former reacts with molecular oxygen leading to the generation of ROS 
(superoxide anion; O2−· and hydrogen peroxide; H2O2), whereas the latter reduces 
NAD+ (157).  
 A soluble cytokine; interferon (IFN)–γ, can increase the expression of XO and its 
activity in the endothelial cells (212). In spontaneously hypertensive rats, it has been 
shown that XO generated O2−· that consequently reduced NO bioavailability, 
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however, when SOD was added, this significacntly reduced blood pressure in 
hypertensive rats. In addition, XO inhibitor; oxypurinol reduced blood pressure in the 
same rats thus suggestion a role for XO in the pathogenesis (213). This coupled with 
the prevention of the initially elevated free radical levels in the microcirculation of 
SHRs by XO inhibitor (214).  
1.6.4 Endothelial Nitric Oxide Synthase 
Endothelial NOS is known as a cytochrome p450 reductase-like enzyme that 
catalyses Flavin-mediated electron transport from the donor NADPH to a prosthetic 
heme group. In order to bind near the heme group to transfer electrons to guanidino 
nitrogen of L-arginine to generate NO, eNOS require BH4 (157). However, in the 
absence of BH4 oxidation or L-arginine, eNOS will generate O2
−· (and H2O2) thus 
contributing to the ROS formation. This observation is commonly referred to as NOS 
uncoupling and several studies have indicated this phenomenon (215, 216).  
Extensive evidence has suggested that eNOS can become uncoupled in various 
pathophysiological conditions in vivo. This has been shown in the aorta of stroke-
prone spontaneously hypertensive rat, where O2−· generation was increased that 
was reversed by exposure to L-NAME or removal of the endothelium (217).  
 Similarly, it was suggested that increased O2−· generation observed in aorta of mice 
due to  deoxycorticosterone acetate–salt induced hypertension, might have come 
due to eNOS, as the effect was prevented by L-NAME treatment, endothelium 
denudation and was not observed in eNOS deficient mice with deoxycorticosterone 
acetate–salt hypertension. Moreover, endothelium-dependent vascular relaxation 
has been impaired in rat made insulin resistant via feeding on high fructose and this 
effect was normalised by BH4 supplementation (218). Besides, in chronic smokers, 
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intra-arterial infusion of BH4 demonstrated an improved endothelium-dependent 
vasodilatation. These, therefore, suggest that depletion of BH4 might play a role in 
converting eNOS to superoxide anion (157).  
Moreover, eNOS uncoupling in the endothelium might stimulate oxidative stress and 
endothelial dysfunction via at least three mechanisms. Firstly, instead of reacting 
with NO, free radicals might attack other cellular targets due reduction of enzymatic 
production of NO. Finally, it is likely that eNOS become partially uncoupled, thereby 
forming both O2−· and NO· simultaneously. This provides a platform for eNOS to 
form peroxynitrite thereby leading to increase in oxidative stress (157). 
 
1.7 Role of ROS in endothelial dysfunction 
Endothelium dysfunction mainly referred to damage of endothelium-dependent 
relaxation due to due to loss of NO bioavailability in the vascular wall (219). 
However, other defined endothelium dysfunction, as the impairment of basic 
endothelium function such as changes of the anti-coagulant and anti-inflammatory 
characteristics due to pathological conditions, which eventually cause damage with 
vascular growth and irregular vascular remodeling (220).  The reduction of NO 
bioavailability might be due to diminished level eNOS (221), absence of co-factors or 
substrate for eNOS (215), changes to cellular signaling, consequent to inappropriate 
activation of eNOS (222) and rapid degradation of NO by ROS (157). Early studies 
have demonstrated that EDRF might be deactivated by superoxide anion, a 
phenomenon that was prevented by the presence of superoxide dismutase (SOD) 
(223). The EDRF molecules is currently known as NO, thus the chemical interactions 
are widely documented. NO reacts rapidly with superoxide anion (with a reaction rate 
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of 6.7x109 mol/L-1), which is almost 3 times quicker than the reaction rate between 
superoxide and SOD (224). Because of this rapid reaction rate, superoxide anion 
always has a potential to react with some NO with the cells and extracellular space. 
Therefore, endogenously generated anti-oxidant can help circumvent this interface 
under physiological conditions. Whereas in disease conditions, inhibitory measure is 
changed thereby allowing superoxide to react freely with NO to form peroxynitrite 
thus minimising bioavailability of NO to the vascular relaxation (157).   
Moreover, it has been demonstrated in several animal models that impairment of 
endothelium-dependent vasodilatation is linked increased degradation of NO by 
ROS. This has been shown to be implicated in animal models of hypertension, 
diabetes, cigarette smoking and heart failure (225-227). 
1.8 Cardiovascular disease in COPD 
COPD is associated with a relative risk of ischaemic heart disease, stroke and 
sudden death almost double that of healthy individuals, even after accounting for 
smoke exposure (43). Patients with COPD exhibit increased systemic arterial 
stiffness (42, 65), which relates to severity of lung disease (228), and could predict 
subsequent cardiovascular events. Whether systemic vascular disease is present in 
early COPD has not been well studied, although it is intriguing that therapies 
traditionally thought to target systemic atherosclerosis may influence outcome in 
COPD. A reduction in exacerbations in patients with COPD has been seen in several 
observational studies using statins (229-231), as well as reductions in FEV1 decline 
(230) and mortality, particularly when combined with ACE inhibitors (231). 
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It is also, well known that the pulmonary vasculature may be affected in COPD. 
Pulmonary vascular remodeling, in the form of intimal hyperplasia, is regarded as the 
main driver of pulmonary hypertension (due to lung disease), and secondary right 
heart failure in COPD. This occurs even in mild COPD (232), and in smokers with 
normal lung function (233) and may be driven by inflammation. This contrasts with 
the long held belief that pulmonary hypertension in COPD is a consequence of 
hypoxia. Consistent with this observation, LTOT rarely normalizes pulmonary 
pressures and does not impact on cardiac output in COPD (234). Consequently 
there has been interest in drugs initially developed to target vascular remodeling in 
primary pulmonary hypertension in usual COPD. These include endothelial receptor 
antagonists and phosphodiesterase-5 inhibitors. Thus far, clinical trials have been 
small, few in number and largely negative (235).  
There is also growing evidence that interactions between vascular endothelium and 
smooth muscle are a major contributor to regulation of  local pulmonary vasculature 
(236). Together these are linked to the development of pulmonary hypertension and 
chronic heart failure (237). Pulmonary arterial endothelial dysfunction occurs in 
COPD (238, 239) and in chronic hypoxic rats (240, 241). Endothelial dysfunction 
contributes to a reduction in secretion of vasodilators such as NO and prostacyclin 
that leads to vascular remodeling (236, 242). This in combination with endothelial 
damage and dominant production of vasoconstrictors favours pro-coagulants and 
vascular obstruction. The abnormal vasoconstriction following alterations in 
pulmonary vascular function that comes about in both endothelium and vascular 
smooth muscle are thought not to be dependent on variations in blood vessel 
structure (243), rather they are dependent on production of vasoactive mediators 
either locally by vascular endothelium, airway epithelium, vascular smooth muscles 
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or nerve fibres, or distributed globally via the blood (236, 244).  This may be 
investigated ex vivo by determining the effects of acute vs. chronic hypoxia on 
development of vascular tone, and by assessing the influence of putative 
inflammatory markers on vascular reactivity.  
1.9 Pulmonary Hypertension in COPD 
1.9.1 Pathophysiology of pulmonary hypertension 
Pulmonary hypertension refers to a group of heterogeneous clinical disorders that 
share a similar pathological characteristic. According to World Health Organisation 
(WHO), pulmonary hypertension is categorised into pulmonary arterial hypertension 
(group I), pulmonary venous hypertension (group II), Pulmonary hypertension 
associated with hypoxia (group III), Pulmonary hypertension associated with chronic 
thrombotic disease (group IV) and pulmonary hypertension with unclear multifactorial 
mechanisms (group V) (162, 245).  Pulmonary hypertension is a progressive disease 
characterised by increase in pulmonary vascular resistance, a mean pulmonary 
arterial pressure (PAP) >25 mmHg at rest or >30 mmHg during exercise (246). 
Histological studies have demonstrated that Pulmonary hypertension is generally 
associated with small muscular peripheral arteries, the media of the muscular 
arteries undergoing hypertrophy, lack of small pre-capillary arteries, development of 
neointima and in the advance stages of the disease, endothelial proliferate to form 
plexiform lesion, which is an abnormal channel on the vessel lumen and in the 
adventitia. These vascular changes  together are known as pulmonary vascular 
remodeling (162). 
This PhD is focused on hypoxia-induced pulmonary hypertension (PH) which also 
involves a diverse group of diseases sharing the common feature of chronic hypoxia-
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induced pulmonary vascular remodeling (247). Generally, hypoxic PH is 
characterised with mild to moderate pulmonary vascular remodeling that is mostly 
reversible, as opposed to the WHO group 1 pulmonary arterial hypertension (PAH) 
(247). However, the burden of significant morbidity and mortality remain as PH 
worsens. Pulmonary hypertension is a well-recognised complication of chronic 
hypoxic lung diseases, which are among the most common causes of mortality and 
disability worldwide (248). PH development independently predicts reduced life 
expectancy (248). Recently, Stenmark and colleagues (247) suggested that a subset 
hypoxia induced PH might develop irreversible severe pulmonary vascular 
remodeling similar to WHO group I PAH.   
Moreover, in COPD, long-term oxygen therapy might improves pulmonary 
hypertension and greatly increases the chance of survival and quality of life, though 
only a partial correction of alveolar hypoxia and PH was observed (248). Increased 
understanding of the regulation vascular smooth muscle tone suggest a role for 
chronic vasoconstriction in the pathogenesis of hypoxic PH (248, 249) (Figure 1.5) 
and potential for less contribution of structural changes as earlier thought (248). It 
was illustrated in Figure 1.5 that acute hypoxia can rapidly induced HPV within 15 
minutes that was sustained for hours and when this continues over a long term can 
lead into development of pulmonary hypertension.  
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Figure 1.5: Hypoxic Pulmonary Vasoconstriction Demonstrates acute and chronic hypoxic vasoconstriction of 
pulmonary arteries with the latter leading to pulmonary hypertension. Adapted from (249) 
 
Evidence from an existing vasodilator trial revealed that hypoxic PH was ameliorated 
and systemic oxygen delivery improved in carefully selected patients (248). 
However, systemic hypotensive reaction limited influenced of the doses applied 
(248). To overcome this challenge, McLoughlin’s group recently suggested that 
blockage of vasoconstrictor pathways selective for the pulmonary circulation might 
reduce hypoxic PH without causing systemic hypotension, and thus provide potential 
targets for novel therapeutic strategies. Moreover, it has been suggested that in all 
cases of hypoxia-related vascular remodeling and PH, inflammation, particularly 
persistent inflammation may play a role (247). This will be discussed in detail in later 
sections. 
1.9.1 Cardiovascular consequence of hypoxic PH: Right heart failure in 
COPD 
Heart failure is a complicated clinical disorder that limits efficiency of the heart due to 
damage to its ability to pump blood. It is mostly caused by left ventricular systolic 
dysfunction, coronary artery disease or pulmonary hypertension (250-252). In UK 
nearly 1 million people are diagnosed with heart failure (253). Left heart failure does 
not have a direct association with COPD. Therefore, the focus is on right-sided heart 
failure which has a direct link with COPD, and impacts upon oxygen prescription to 
patients. Right-sided heart failure (also known as cor pulmonale) is common in 
severe COPD patients. In severe COPD, PO2 falls, the walls of the main blood 
vessels, pulmonary arteries in the lungs change, the pressure inside them rises and 
is known as pulmonary hypertension. The heart’s right ventricle pumps blood 
through the PAs into the lungs. Pulmonary hypertension puts excess strain on the 
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right ventricle, which over time becomes stretched and dilated, and fails to pump 
blood effectively. Right-sided heart failure causes fluid to accumulate in the legs and 
abdomen, a condition known as oedema. There is an increased risk of deep vein 
thrombosis or blood clot with leg swelling that can travel to the lung to cause 
pulmonary embolism.  
1.9.2 Role of reactive oxygen species in chronic hypoxia-induced 
inflammation and pulmonary hypertension 
Reactive oxygen species (ROS), including superoxides (O2
·−), contribute to chronic 
hypoxic pulmonary hypertension; hypoxia increases their production in the 
pulmonary artery (254-260). Despite some ambiguity regarding the production of 
ROS within the hypoxic pulmonary artery, it is known that NADPH oxidases, 
mitochondrial electron transport chain, cytochrome p450, nitric oxide synthase, and 
xanthine oxidase contribute to their generation (162, 261). Endothelium, SMC, 
neutrophils, macrophages, and epithelial cells may all contribute to ROS generation 
in hypoxic pulmonary circulation. However, vascular adventitia is particularly 
interesting as this compartment is affected quicker and greater than any other 
compartment; and remains the source of ROS that contribute to”outside-in” effects 
on pulmonary vasoconstriction and vascular remodeling (262-264). NADPH oxidase 
(NOX) isoform 1, 2 and 4 are understood to contribute the most towards ROS 
generation within vascular adventitia (262, 265-267) (Figure 1.6). ROS production 
from local adventitia fibroblasts promotes mononuclear cell/macrophage recruitment. 
This generates more ROS, probably via inflammatory cell NOX and xanthine oxidase 
(268); affecting not only the local compartment’s redox state but also that in other 
compartments (262, 269) (Figure 1.6). Superoxide (O2
·−) act rapidly; they can 
modulate targets directly or impact cell signaling pathways indirectly following their 
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enzymatic dismutation to hydrogen peroxide. They therefore can modulate the 
phenotype of a number of cells by affecting proliferation, migration, differentiation, 
and matrix production (269). ROS also act as signaling molecules and they are 
known to target HIF, NF-κB, Nrf2, MAPK, K
+ channels, and even BMPR2 signaling 
(162, 262, 269). Xanthine oxidoreductase (XOR), another source of ROS in 
pulmonary circulation also contributes towards hypoxic pulmonary hypertension and 
inflammation (255, 262, 270). Although how exactly does xanthine oxidase 
contribute to hypoxic pulmonary hypertension remains undefined, its activation in 
leukocytes under hypoxia appears to be important factor in mediating vascular 
dysfunction (Figure 1.6). Studies show that XOR regulates leukocyte adhesion in 
vivo (271-273) and  its inhibition protects airways in COPD (274), ischemia 
reperfusion injury (275), acute lung injury (276), as well as in other respiratory 
disorders or conditions that exhibit a hypoxic-inflammatory component (277). More 
recently, XOR is understood to promote inflammation of pulmonary mononuclear 
phagocytes thought to have effects on hypoxia-inducible factor (HIF)-1α (278). 
During hypoxic conditions, HIF 1 and 2 heterodimeric transcription factors that 
comprised of HIF-1α and HIF-2α accordingly, forms a dimer with a constitutively 
expressed β subunit (279). The dimerised subunits then bind to hypoxic response 
element located within the promoter regions of the target genes. Several factors 
(including oxygen level, growth factors, oncogene activation and tumour suppressor 
limitations) control expression of HIF-α protein. The α-subunits of the protein are 
degraded by von Hippel-Lindau (VHL) ubiquitin E3 ligase complex under normal 
oxygen tension, whereas hypoxia prevent hydroxylation thereby allowing the 
stabilization of the HIF-α heterodimer and subsequently causing transcriptional 
activation of targeted genes (279-281).  
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 Moreover, HIF-2α degradation by intermittent hypoxia is understood to be mediated 
by XOR (and not the NOX)-derived ROS (282). XOR has also been identified as an 
important molecular signature of sepsis-induced systemic inflammation in many 
organs – including lungs (283). Importantly, microenvironment of cigarette smoke is 
understood to promote epigenetic modifications via XOR (a source of both ROS and 
reactive nitrogen species) promoted DNA double-strand breaks and H2AX histone 
activation (284). Moreover, XOR-derived ROS also play a significant role in the 
epigenetic changes of inflammation-induced colorectal cancer (285). These studies 
strongly support the role of XOR (i.e., XOR-generated ROS) as an important 
inflammatory mediator and perhaps it’s likely involvement in chronic hypoxic 
pulmonary vascular remodeling. 
The presence and localization of high expression of a dominant antioxidant enzyme, 
extracellular superoxide dismutase (SOD 3), in vascular adventitia supports the 
importance of ROS in regulation of vascular structure / function under hypoxic 
conditions (286, 287). Hypoxic and pulmonary hypertension models show that the 
overexpression of SOD in the lungs protects against medial and intimal wall 
remodeling (259, 288-290). Conversely, hypoxia induced pulmonary hypertension is 
exaggerated in SOD1 knockout mice (291).Collectively, these studies show that that 
there is good evidence for hypoxia-induced ROS generation; these molecules play a 
crucial role in the activation / regulation of signaling pathways that are involved in 
chronic hypoxia-induced pulmonary vascular remodeling and pulmonary 
hypertension.    
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Figure 1.6: Reactive oxygen species generation in pulmonary hypertension -The major sources of ROS in the 
vasculature include uncoupled eNOS, mitochondrial dysfunction, NADPH oxidase, and XO. In PH, all of these 
sources contribute to the development of oxidative stress. Endothelial NOS uncoupling is mediated by limited 
L-arginine availability, as a result of increased degradation by arginase upregulation and attenuated synthesis 
by the downregulation of ASS and ASL, the enzymes responsible for the conversion of L-citrulline to L-arginine. 
Moreover, a sustained increase in ADMA levels, due to a decrease in DDAH2 activity, competes with L-arginine 
for binding to eNOS. In addition, in PH, eNOS function is impaired by a decrease in BH4, an essential co-factor 
for NO generation. GCH1, the rate-limiting enzyme in BH4 biosynthesis, is ubiquinated and targeted for 
degradation by Hsp70/CHIP. Therefore, the low GCH1 levels, limit the production of BH4. Finally, The 
disruption of the zinc tetrathiolate (ZnS4) cluster by oxidative attack disrupts the eNOS dimer, which is 
accompanied by decreased NO generation and increased ROS production. Further, in PH, several markers of 
mitochondrial dysfunction are observed, including increased levels of uncoupling protein-2 (UCP-2), decreased 
levels of the mitochondrial antioxidant, superoxide dismutase-2 (SOD2), and the impaired function of 
complexes I, II, and III of the respiratory chain. Interestingly, ADMA appears to promote these changes in the 
mitochondria, and also augment mitochondrial ROS generation and decrease ATP production. In addition, 
several subunits of NADPH oxidase, including p47phox, p67phox, gp91phox, and Rac1, are upregulated in PH, 
increasing ROS production in the vasculature. Increased levels and activity of XO also contribute to oxidative 
stress and vascular dysfunction in the early stages of PH. Adapted from (162). 
                                 
1.10 Effects of hypoxia on pulmonary vascular constriction 
Hypoxia refers to supply of oxygen to cells, tissues and organs below normal 
physiological levels. In COPD especially in emphysema, airway obstruction can 
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reduce the amount of oxygen present in the blood (hypoxemia) thereby limiting the 
supply of oxygen that reaches the cells and tissues of the body thus leading to 
hypoxia. Interestingly, in the pulmonary circulation moderate hypoxia results to an 
acute physiological response characterised with a profound vasoconstriction and 
consequent increase in pulmonary vascular resistance. This response is commonly 
referred to as hypoxic pulmonary vasoconstriction (HPV), which is unique to the 
pulmonary vasculature; whereas the systemic circulation mainly demonstrates 
vasodilatation during hypoxia. von Euler and Liljestrand in 1946 were the first to 
define HPV and it remain the only known vascular feedback control mechanism in 
the lung (292).  
1.10.1 Characteristics of HPV 
Bradford & Dean first observed HPV in 1894 and they referred to it an “active 
constriction of the pulmonary vessels” in dogs (293, 294). However, it was not until 
1946 when von Euler and Liljestrand  revealed comprehensive information about 
HPV, hence, they were credited with the discovery (295). They observed that the 
pulmonary and systemic circulation in cats responded differently to hypoxia and 
suggested HPV’s contribution to ventilation perfusion (V/Q) matching. Motley et al 
(296) reported that 10% oxygen doubled pulmonary vascular resistance (PVR) in 
humans (296). Hypoxia acutely increased PVR from 1.2 ± 0.3 to 2.9 ± 0.3 Wood 
units in healthy controls whereas the systemic vascular resistance decreased 
accordingly (296, 297). HPV plateaus within 2 hours and thereafter PVR remains 
constant for the duration of hypoxic ventilation of 8 hours (297, 298). 
Investigation by Marshall and Marshall has revealed that alveolar PO2 (PAO2) 
provides the main stimulus for HPV but not the mixed venous PO2 (PvO2) (299). 
They reported that PAO2 had a greater effect on HPV compared to PvO2 due to O2 
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exchange between alveolar gas and blood in small PA. Hence the pair and others 
concluded that mixed venous PO2 is not strong enough to trigger HPV, whereas the 
small muscularized resistance arteries adjacent to the alveoli that experienced 
alveolar PO2 were mostly strong enough to exhibit HPV (300-302). 
1.10.2 Potential Mechanisms of HPV 
In mature lungs, HPV mainly occurs within the small pulmonary arteries. The 
phenomenon was conserved in isolated perfused lungs as well as in pulmonary 
artery sections dissected from the lungs (303-305).  Hence, the mechanisms that 
mediate HPV must be intrinsic to the pulmonary system and not directly dependent 
on circulating neuronal feedbacks and humoral modulators (306). However, various 
mediators secreted the cells within the pulmonary vasculature might play key role in 
initiation of HPV (306). Therefore, the fact that hypoxia induced vasoconstrictor 
agonists release from perfused lungs that reportedly generated similar response to 
hypoxia in isolated pulmonary vessels and showed selectivity for pulmonary over 
mesenteric arteries in rats (307). It is yet to be established whether this substance is 
critical for HPV initiation.  Over the years, several other potential vasoconstrictors 
were tested but none proved to be essential for HPV.  The specific site of HPV 
initiation is not confirmed, even though, there is a consensus that it occurs within the 
vasculature. Therefore, many vascular cells such as endothelial and vascular 
smooth muscle cells were investigated for their possible contributions (306).  There 
remain different thoughts on whether endothelial or vascular smooth muscle cells 
mediate the action hypoxia to effect release of vasoactive substances to cause the 
constriction, thus it was suggested that HPV might involve several factors to 
generate  optimum response (303, 308). A review conducted by Sylvester et al (205) 
concluded from isolated lung studies that the increase in pulmonary pressure as a 
51 
 
response to hypoxia was due to vasoconstriction and that HPV does not rely on 
neural or humoral stimuli from outside the lungs. This findings were in accordance 
with the views of von Euler and Liljestrand (295) that pulmonary vasoconstriction 
was due to local mechanism triggered by hypoxia leading to regulation of the local 
ventilation-perfusion relationship (205).  
Sylvester et al (205) postulated two general hypotheses as potential mechanisms of 
HPV. Firstly, through indirect activation and/or deactivation vasoconstrictor and 
vasodilator responses respectively by hypoxia leads to pulmonary vasoconstriction 
thus subsequently causing contraction of pulmonary vascular smooth muscle. 
Secondly, hypoxia induces pulmonary vasoconstriction via direct contractile effect on 
pulmonary vascular smooth muscle (205). To address the first hypothesis, several 
researchers conducted studies on intact animals and isolated lungs and their results 
revealed numerous endogenous substances that elevated pulmonary vasomotor 
tone, however, none proved be a unique mediator of HPV (309, 310). 
As far as the second hypothesis is concerned, a study by Bergofsky and Holtzman 
(311) showed that hypoxia raised intracellular [Na+] and reversibly decreased 
intracellular [K+] in pulmonary artery segments stripped of adventitia and intima 
though did not affect a similarly treated pulmonary veins or systemic artery 
segments. These changes were attributed to the depolarisation of pulmonary artery 
smooth muscle as a consequent of direct effects of hypoxia treatment on the cells. 
Further evidence, by McMurtry et al (312) revealed that blockers of the L-type 
voltage-operated Ca2+ channels (found in the pulmonary artery smooth muscle) 
significantly inhibited the pulmonary artery pressure increased observed with hypoxia 
in isolated lungs. This coupled with other findings by Madden et al (313, 314)  that 
hypoxia exposure was associated with both constriction and depolarisation in small 
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pulmonary arteries in cats, supported the earlier reports by Bergofsky and Holtzman. 
Other studies have later confirmed the central role of pulmonary artery smooth 
muscle cell (PASMC) in HPV, as they have showed hypoxia to be responsible for 
both depolarisation and contraction in isolated PASMC thus concluding that the 
essential sensor, transducer and effector mechanisms of HPV are enclosed within 
the pulmonary arterial myocyte (205, 304, 315, 316). 
1.10.3 Modulation of pulmonary artery smooth muscle cell contractility by oxygen 
In the absence of the endothelium, hypoxia resulted into enhanced vasoconstriction 
thus suggesting that the endothelium might not be essential for HPV (305). Madden 
et al (304) then Sham et al (317), have shown that in the absence of other cell types, 
hypoxia induced vasoconstriction in isolated pulmonary artery myocytes (205, 304). 
Bakhramov et al (318) suggested that this observation might be due increased 
intracellular calcium concentration [Ca2+]i as hypoxia  was associated with rise in 
[Ca2+]I in isolated pulmonary artery myocytes (306). These evidences together 
swayed the direction towards the pulmonary artery smooth muscle cells as the 
ultimate sensor of hypoxic stimulus to propagate HPV, although the precise 
mechanism PASMC senses O2 is not well understood (306). Moreover, various 
mechanisms were investigated, which included an inhibitory action of hypoxia on 
transmembrane potassium channels, initiation of store-operated Ca2+ entry 
(capacitative Ca2+ entry), stimulation of the release of Ca2+  release from the 
sarcoplasmic reticulum (40) and the contraction generating proteins sensitisation to 
Ca2+, as a possible O2 sensing pathways in pulmonary vasculature (306). 
The fact that hypoxia caused vasoconstriction in isolated PASMC confirmed the 
notion that sensor, transduction, and effector mechanisms of HPV are present in 
these cells (205). Broadly two methods were utilised to measure contraction in 
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PASMC. These first one involves the use of flexible polymerized polydimethyl 
siloxane membrane for cell growth and once cells were attached to the membrane, 
contraction is assessed by determining the level of wrinkling and/or distortion. 
However, it was shown that the main or branch pulmonary arteries isolated from fetal 
calf myocytes exposed to normoxic conditions (PO2 equivalent to 145 mmHg) 
developed minor wrinkling thus suggesting basal contractility (315). Moreover, the 
reduction in PO2 from 20–30 mmHg caused a significant increase in the level of 
wrinkling observed and this was reversed by re-oxygenation. Similar experiments 
conducted in PASMC indicated that hypoxia resulted in phosphorylation of myosin 
light chains comparable to active contraction (205).  
The other method used to measure contraction in PASMC uses microscopic field 
images or a reticule in the eyepiece of the microscope to quantify cell length. 
Hypoxia was shown to cause decrease in cell length in distal pulmonary arteries 
isolated from cats or pigs (304, 317), though the influence of hypoxia on proximal 
arteries remained inconclusive as both unchanged and decreased in cell length were 
observed (304, 317, 319). Hypoxia contraction in the distal pulmonary arteries was 
attributed to myosin phosphorylation (304). This has been reviewed in greater details 
by Sylvester et al (205). Hypoxia caused reduction PASMC length similar to what 
was observed with KCL, norepinephrine, phenylephrine, PGF2α and 5–HT (304, 317, 
319). The decrease of the initial PASMC length due to hypoxia ranges between 9–
24% and was maximal between 5–30 minutes (304, 317, 319).  
1.10.4 Mediation of HPV 
It is widely established that mechanism intrinsic to PASMC such as  O2 sensing, 
signal transduction and smooth muscle vasoconstriction  were essential in the 
mediation of HPV response (205).  
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Several potential candidates have been identified as the O2 sensor that trigger HPV 
thus it was challenging to identify a particular O2-sensor responsible for the hypoxic 
response. Different O2 sensitive mechanisms responding to varied ranges of PO2 
have been identified and potentially serving a variety on function (320-323). 
Oxygen and proteins interact via biochemical reactions using O2 as substrate or a 
reversible binding of molecular O2 resulting into allosteric modifications of the protein 
that enable the initiation of the signaling cascade (example, heme-ligand 
association) (Figure 1.7).  The former category could occur with or without the initial 
heme-binding phase. The other category of the interaction between proteins and 
oxygen is sub-divided into bioenergetic hypoxia (due to inadequate PO2 levels to 
preserve usual cytochrome aa3 function), high-energy phosphates and redox state 
of pyridine nucleotides and metabolic hypoxia that happens due to inadequate  PO2 
to preserve the usual function of O2-dependent enzymes different from cytochrome 
aa3 (205). 
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Figure 1.7 Shows potential O2 sensing pathways. Biochemical interactions between O2 and proteins to initiate 
signaling cascade leading activation of HPV effectors. ROS, reactive oxygen species. (205) 
 
Oxygen-sensitive systems were broadly sub-divided into, direct modification of 
protein residues, heme and oxygenase. Oxygen and redox states has the ability to 
alter sulfur-containing protein residues directly and reversibly to produce disulfide 
bonds or sulfoxide which leads to modification of the protein structure thus alter 
function(205). Heme is a typical O2 binding molecule and consists of four pyrrole 
rings joined to a central iron atom. The iron on binding to O2 get reduced or 
converted from ferrous (Fe[II]) to ferric (Fe[III]). The heme proteins such as 
mitochondrial cytochromes, NADPH oxidase, cytochrome -P450, NO synthase, 
guanylate cyclase, catalase, cystathionine β-synthase, and heme oxygenase are 
notably implicated in oxygen sensing. Moreover, oxygenases were characterized as 
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an oxidoreductase enzyme that speed up reversible reduction-oxidation (redox) 
reactions, where one substrate acts as an electron or H+ donor and is oxidized, and 
the other acts as acceptor and become reduced. The O2 sensing systems including 
relevant examples has been extensively been reviewed by Sylvester et al (205). 
1.10.4.1 Mitochondria  
Elevation of intracellular [Ca2+] is a precondition for HPV as confirmed by studies in 
isolated PASMC and endothelium-denuded pulmonary arteries exposed to hypoxia.  
The studies confirmed that the major O2 sensor definitely located within the PASMC 
(205).  Therefore the sensor is required to be triggered by a suitable range of PO2 
that is probably dependent on rate and site of O2 consumption of a cell, as well as, 
the obstruction of the O2 diffusion to those particular sites (320).  Mitochondria are 
the most important O2 consumption sites within the cell (320) and serve as signaling 
organelles and energy production (324, 325). Mitochondria-dependent factor such as 
[ATP], energy state, redox state, and ROS generation can be influenced by low PO2 
thus hypothetically leading to HPV. Mitochondria were shown to control Ca2+ level of 
the sarcoplasmic reticulum (SR) in vascular smooth muscle (326, 327). Several 
investigators have reported that blockage of oxidative phosphorylation had a strong 
and selective influence on HPV (202, 205, 207, 328-332). In addition, depletion of 
mitochondrial DNA by treating PASMC with ethidium bromide rendered the cells non 
responsive to hypoxia (207, 333) and this might be attributed to absence of a 
working mitochondrial electron transport chain (METC). It suggested that METC is 
an essential precondition for O2 sensing in PASMC, carotid body type1 and neonatal 
chromaffin cells (320, 322, 334-336). Hence, mitochondria are apparent contenders 
for the O2 sensor in HPV. See the review by Sylvester et al (205) for comprehensive 
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details on mitochondria and O2 sensing in HPV with evidences drawn from cellular 
and molecular studies.  
1.10.4.2 Redox State  
The equilibrium between cytosolic oxidizing and reducing counterparts give rise to 
the cellular redox state and this includes the main redox couples such as the 
reduced and oxidized glutathione (GSH/GSSG) and NADH and NAD+ as well as the 
equilibrium between ROS generation and degradation. Mitochondrial tricarboxylic 
acid (TCA) and METC and the key source and sink respectively for reducing 
equivalents of NADH. In PASMC and carotid body glomus cells, exposure to hypoxia 
resulted into more reduced state due to elevated ratio of GSH/GSSG and 
NADH/NAD+ (332, 337-339).  
Studies have reported that blockage of oxidative phosphorylation generated similar 
effect as hypoxia on pulmonary vessels (205, 340) and showed oxidant mediated 
reversal of HPV (341). This was the basis for the Redox Hypothesis of HPV which 
suggested that the inhibition of oxidative phosphorylation due to hypoxia resulted 
into further reduced cytosolic redox state and lowered the ROS content. This 
subsequently triggered a cascade of events including inhibition of K+ current (IK) 
leading to depolarization of PASMC, influx of CA2+ through the voltage-gated CA2+ 
channels and vasoconstriction (Figure 1.8A). 
1.10.4.3 ROS 
Reactive oxygen species, sources and characteristics was detailed in section 1.6. 
The most prominent ROS are O2
.-, RO2
. and .OH (208). ROS is originally considered 
a harmful byproduct of metabolism. However, ROS are currently viewed as a 
signaling molecule with a variety of functions in several regulatory mechanisms in 
vascular smooth muscle and endothelium (205, 342). Hence, in PASMC, ROS was 
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noted as hypoxic signal leading the way for several pathways such Ca2+ release 
from ryanodine-sensitive stores (343, 344) promote production of cADPR (345), 
stimulation of AMP kinase (346) and activation of Rho kinase-mediated Ca2+ 
sensitization (347), src kinase (348), stimulate Ca2+ entry via nonselective cation and 
TRP channels (349, 350) and other signaling pathways (351) involved in HPV (205).  
Research evidences have suggested that superoxide and peroxide as the major 
ROS species involved HPV mediation (205). However, significant disagreements 
remained of the origin of the ROS species and effector mechanisms and whether 
they are increased, reduced or have any specific association (334, 352, 353).  As 
opposed to the expectation due to Redox Hypothesis (since O2 was the substrate for 
ROS formation), hypoxia caused increased in mitochondrial ROS synthesis in a 
variety of cells types including PASMC (202, 205, 207, 328, 354, 355) (Figure 1.8B). 
1.10.4.4 Energy state  
Cellular functions utilise readily available ATP as source of energy.  Though more 
ATP were generated by mitochondrial oxidative phosphorylation than glycolysis, 
surprisingly, only about 30% of ATP was derived from glycolysis during normoxia 
compared to 65% of ATP production by glycolysis during hypoxia (205, 356). 
Hypoxia augmented glycolysis and increased smooth muscle ATP synthesis partly 
due enhanced glucose uptake (205, 355).   
Phosphocreatine (PCr) is a tiny diffusible molecule that plays a crucial role in energy 
transfer between sites. PCr is critical for moderately immobile ATP and ADP and 
energy utilisation. Creatine kinase uses ATP to phosphorylate creatine to 
phosphocreatine that then transferred into the sites of energy utilisation and the 
reaction is reversed (Lohman reaction: ATP + Cr ↔ PCr + ADP + H+). Moreover, 
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adenylate kinase reaction ensures high-energy phosphate transfer from one ADP to 
another whilst retaining the ATP concentration. During hypoxia, the collective 
influence of PCr, adenylate kinase and glycolysis in the presence of glucose, 
contribute to conserve the PASMC [ATP] and maintain optimum contractile activity in 
the event of lack of working METC (202, 207, 260, 328, 329, 355).  
Furthermore, phosphorylation potential ([ATP]/[ADP][Pi])  and AMP/ATP and AMP-
activated kinase are utilised index of energy states. Phosphorylation potential plays 
an important role in the control of oxidative phosphorylation, membrane transport, 
meberane transport, actin myosin cross-bridge cycling thereby affecting vascular 
reactivity (205, 357-359). During metabolic tensions such as  hypoxia or lack of 
glucose, elevation of AMP/ATP levels   trigger AMP-activated kinase (AMPK) to 
increase synthesis and reduce utilisation of ATP which ensure a conserved 
ADP/ATP ratio to circumvent the challenges(205). Inhibition of AMPK with compound 
C (a non-selective AMPK inhibitor) prevented HPV in rat pulmonary arteries and 
reduced intracellular Ca2+ concentration in human PASMC (205, 360, 361). This 
phenomenon is consistent with the hypothesis (Figure 1.8C), though the exact 
mechanisms remains unclear.  
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Figure 1.8: Diagrams illustrating potential mechanisms that demonstrate how hypoxia gives rise to 
constriction in pulmonary arterial smooth muscle, as suggested by the Redox (A), ROS (B), and energy 
state/AMP kinase (C) hypotheses. Black and gray arrows represent the main and alternative pathways 
respectively. KV, VOCC, SOCC, and NSCC, voltage-dependent K
+
, voltage-operated Ca
2+
, store-operated Ca
2+
, 
and nonselective cation channels, respectively; Em, membrane potential; cADPR, cyclic ADP ribose; AMPK, 
AMP kinase; SR, sarcoplasmic reticulum (205). 
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1.10.5 Role of the endothelium in oxygen sensing 
Many investigators have revealed that endothelium is essential for HPV due to 
inhibition of the response in its absence that was reported in a variety of species 
(303, 308). However, other studies have shown HPV to be independent on the 
endothelium as endothelium removal did not alter the response and even augmented 
it at times. This conflicting outcome could not be linked to the difference between 
species as both endothelium dependence and independence were shown in the 
same species (362-365). Though the variation could be attributed to variation in 
experimental protocol applied, size of the vessel utilized (306). HPV is likely to result, 
if the action of hypoxia on the vessel caused minimised release of vasodilators and 
increased release of constrictors.  Besides, there is no consensus on the direct 
involvement of endothelium-derived nitric oxide in HPV due to inconsistence 
response seen. Studies have exhibited that hypoxia can induced or inhibited release 
of NO, which might indicate that HPV is not dependent on its release. Other 
endothelium-derived vasodilators such as prostanoids were also investigated at, but 
again, no consistent result as HPV showed both dependence and independence on 
prostacyclin release. 
Therefore, based on the evidences so far, endothelium cell or its mediators could not 
be regarded as essential mediator of HPV but it would be ideal to consider it as a 
modulator of the response.  
1.11 Cytokines and endothelial dysfunction 
Pro-inflammatory cytokines elevation has been associated with endothelial 
dysfunction in different cardiovascular diseases such as congestive heart failure, 
atherosclerosis, septic shock, diabetes, hypertension and aging (366-371). Cytokine 
might influence impairment of the endothelium-dependent relaxation there by 
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precluding the endothelium response to circulating autacoids or hormones. 
Therefore, this makes the vessel susceptible to spasm, thrombosis and/or 
atherogenesis (372). The effect of pro-inflammatory cytokines was investigated in 
both conductance and resistance arteries in both hum and animals (372). 
In vivo studies of human forearm resistance artery revealed that exposure to TNF–α 
for 1 hour has resulted into increased baseline vascular resistance due to elevation 
of baseline vasoconstrictor prostanoids bioavailability and diminished NO 
bioavailabilty (373).  Moreover, exposing isolated rat aorta to IL–1β treatment for 1 
hour had increased the vasoconstrictor activity of angiotension II via mechanisms 
that include prostaglandin thromboxane A2 (374). 
Different investigators studied variety of exposure times to various cytokines to 
investigate their effects on endothelium-dependent vasodilatation in isolated 
mesenteric resistance arteries and the results yield was not conclusive (372).  A 
previous study has demonstrated that 3 days exposure of rats to IL–1β and IL–6 in 
vivo, caused impairment of the acetylcholine mediated relaxation of perfusion 
pressure, on rat isolated mesenteric vascular bed (252). The mesenteric arteries 
were incubated in organ culture for 14 hours with IL–1β  and this treatment nearly 
eliminated the acetylcholine mediated vasodilatation, perhaps due to enhanced 
superoxide anion generation (375).  However, mesenteric arteries incubation with 
IL–1β (100pM) for 30 minutes had not altered acetylcholine mediated relaxation, 
though TNF–α (1nM) treatment for the same period caused impairment of 
acetylcholine and bradykinin response but not on the sodium nitroprusside mediated 
endothelium-independent relaxation (376). 
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Hence, it could be suggested that the observation might be due to the effectiveness 
of TNF–α to substantially elevate production of superoxide anion and 
consequentially reducing nitric oxide expression (376). Moreover,  Nedeljkovic  et al 
(377) has reported that TNF–α resulted into sustained superoxide anion production 
due via activating NADPH oxidase. Similarly, Hernanz et al (378) has shown that 
isolated rat middle cerebral arteries exposure to lipopolysaccharide (LPS – 10 μg/ml 
for 1–5 h) in vitro, has significantly blunted bradykinin mediated endothelium-
dependent vasodilatation, via mechanism including increased generation of nitric 
oxide and superoxide anion from inducible nitric oxide synthase (iNOS) and 
potentially due to cyclooxygenase-2 (COX-2) respectively.     
Cytokines might exert their influence on endothelial function via variety of signaling 
mechanisms. Hence, TNF–α has the ability to cause damage to endothelial nitric 
oxide synthase (eNOS) mRNA (367). Besides, it has been shown that cytokines and 
LPS might stimulate expression iNOS in endothelial cells and vascular smooth 
muscle cells and this inevitably induce elevated baseline NO level thereby 
contributing to impairment of endothelium-dependent vasodilatation (379, 380).  
1.12 Definition of Arterial Stiffness, effect on haemodynamic and 
mechanisms 
Practically, arterial stiffness causes changes in the mechanical behaviours of the 
structural characteristics of the artery wall thus effecting alterations in the wall 
geometric properties and wall tension (381). The material properties were defined in 
term of the proportion of strain (deformation due to an applied force per unit area 
(stress)”. It is part of the innate mechanical characteristics for arteries that their walls 
become stiffer as results of distending pressure (381).  This phenomenon might be 
because rise in the proportion of stiffer collagen fibres being recruited with increased 
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distension (381). It has been reported that arterial stiffness might act as a primary 
determinant of vascular impedance, thereby influencing arterial pressure and flow 
relationship (381). 
The basic mechanism behind this stress/strain relationship include complex interplay 
between the structural properties of connective tissue and cell signaling pathways 
that changes the inherent and collective function of elastin, collagen, proteoglycans 
and glycoproteins of the extra-cellular matrix of the artery wall (381). A number of 
reviews have been conducted with regard to the mechanism of arterial stiffness with 
the suggestion that depending on the extent of the stimulus, the specific 
mechanisms can interact by way of positive or negative feedback pathways (381). 
1.12.1 Factors regulating arterial stiffness 
Blood pressure is an important factor that has a complex interplay with arterial wall 
properties. The PWV varies along the arterial segment and this is based on 
distending pressure mainly represented by the mean arterial pressure (MAP). 
Increase in MAP cause equivalent circumferential pressure increase with greater 
recruitment of inelastic collagen fibre and this might lead to higher stiffness 
measured, hence MAP status most be considered during PWV measurement (382). 
In addition, a longitudinal study showed that progression of arterial stiffness could be 
determined by increased blood pressure (383).  
Other factors that affect arterial stiffness include structural characteristics of the 
artery wall that determine arterial elasticity through vascular smooth muscle tone. 
Therefore factors associated with arterial stiffness can be considered in terms of 
structural and functional changes to the endothelium or the medial layer affecting 
smooth muscle cells, the elastic lamina or the connective matrix (382).  
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1.12.2 Functional changes associated with arterial stiffness 
When the smooth muscle tone is altered, endothelial function affects arterial stiffness 
although in humans the impact is more marked in the smaller arteries than in the 
aorta which has a smaller percentage of smooth muscle cells within the media (382). 
Schmitt et al (384) demonstrated that iliac artery stiffness in human was affected by 
nitric oxide modulation. They infused glyceryl trinitrate and highest dose of NG-
monomethyl-l-arginine via catheter and both significantly reduced velocity by 
31.43±5.80% (mean±SEM; P<0.01; P=0.02 for comparison) and 27.25±8.20% 
(P=0.001; P=0.02 for comparison) respectively and there was no change in mean 
arterial blood pressure throughout the studies. These results suggest that at rest, 
local NO production modulates human iliac artery dispensibility and that exogenous 
NO increases arterial distensibility (384). In addition, administration of endothelin-1 
via infusion caused elevation of PWV, whereas an endothelin-1 blocker prevented 
this effect (385, 386). Endothelial function has been associated with aortic PWV in 
healthy humans and in addition to acute modulation of vessel tone this may be a 
mechanism by which cardiovascular risk factors cause chronic changes to the vessel 
wall (382). 
 
1.13 Hypothesis & Aims from this PhD 
This PhD will examine the mechanisms behind cardiovascular disease co-
morbidities associated with COPD. Specifically, the relationship between 
inflammation and hypoxia in modulating the pathogenesis of vascular changes 
associated with the disease will be explored using animal model.  
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A. Humans 
To quantify inflammatory mediators in the serum samples of alpha-1-antitrypsin 
deficient (AATD) subjects and investigate the relationship of inflammation with 
arterial stiffness (PWV, measured from carotid artery or aorta), hypoxia and lung 
function test parameters measured. Interaction between inflammation and 
hypoxia in modulating arterial stiffness in AATD will be investigated.   
B.  Rats 
The influence of acute and chronic inflammation of vascular (pulmonary and 
systemic) reactivity in vitro will be investigated. Also, effects of both acute and 
chronic hypoxia will be explored. The combination effects of inflammation and 
chronic hypoxia or intermittent hypoxia on pulmonary and systemic arteries will 
be investigated. Finally, stiffness assessment will be completed on isolated 
systemic (iliac) arteries. 
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Chapter 2 
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2 METHODS & MATERIAL 
2.1 Clinical assessment of AATD patients  
2.1.1 Subject selection  
Subjects were recruited from the UK national registry for AATD, which is which is 
located in Birmingham, UK. The registry is under is overseen by ADAPT (Antitrypsin 
Deficiency and Assessment Programme for Treatment). This programme was 
initiated in 1996 with the funding provided by a non-commercial grant from Bayer 
Biological (USA). Referral of the subject to the registry comes through health care 
professionals which includes chest physicians and general practitioners. 
Occasionally, subjects might be identified through family screening of those related 
to someone with AATD. ADAPT has obtained ethical approval to carry out clinical 
and genetic studies on registered participants (South Birmingham Local Ethics 
Committee 3359 and 3359a). At registration, participants have given an informed, 
written consent and this consent form has been provided as an Appendix I. The 
diagnosis of all subjects registered with ADAPT was confirmed by genotyping 
(Heredilab, Salt Lake City, USA). A total of 181 subjects with a stored serum sample 
suitable for cytokine quantification were included in this thesis. The procedures 
described in this section are those for all subjects attending ADAPT.  
Clinical data was collected by all research fellows and nurses in the department and 
I have conducted cytokine assays on the samples and analysed the data. 
2.1.2 Demographic data collection  
All relevant basic demographic information such as gender, date of birth, height, 
weight and home address were documented. In addition, full smoking history, 
including amount smoked per day, age started and age quit. The information is used 
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to pack year exposure that is calculated by dividing the number cigarettes per day by 
20 and multiplying by number of years smoked. A full clinical history was collected at 
the baseline assessment, which included the symptoms required to diagnose chronic 
bronchitis (387) and frequency of exacerbations (388). Subjects were classified as 
either index case or non-index cases based of on whether AATD was diagnosed 
after investigation of their symptoms or via family screening respectively. This 
information about classification was available for all subjects; however, it is 
significant solely in familial replication dataset. Therefore, no emphasis will be placed 
on the classification in this thesis. 
2.1.3 Lung function  
Trained respiratory physiologists within the Lung Investigation Unit at University 
Hospitals Birmingham, UK conducted all the all the lung function measurement and 
compared to predicted values derived from standard reference equations for 
Caucasian adults. Spirometry was performed before and after nebulised short acting 
bronchodilators were provided as a baseline measurement (389). An increase of 
more than 200ml and greater than 12% predicted of FEV1 is regard as a positive 
bronchodilator reversibility (390). This definition was applied to calculate for all 
subjects on this basis of the raw data held in AADAPT databases (391). At 
subsequent annual visits spirometry was performed only after bronchodilatation, 
such that changes in lung function over time were derived from post-bronchodilator 
values. Annual follow up has been offered throughout the period that ADAPT has 
been established, such that those registered in the early years of the programme 
may have up to 12 years data available, with correspondingly fewer years for those 
registered later.  
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Static lung volume measurements including total lung capacity (TLC) and residual 
volume (RV) were assessed using helium dilution (392). Gas transfer measurements 
(DLCO) were obtained by the single breath carbon monoxide method(392). Together 
these values were used to calculate the uptake of gas per unit of effective alveolar 
volume (KCO). All these values were determined only after bronchodilatation.  
2.1.4 ADAPT databases  
The ADAPT programme comprise 2 clinical databases, the older of the two was 
used to collect data from 1996, the newer one started in 2000 to improve both the 
quality and quantity of data collected. There is also a microbiological database and a 
laboratory database containing information on the location and type of stored 
samples. Data was extracted from all four sources, and unified with a project 
database, set up in Access 2000 and employing referential integrity to link all data 
types to individuals. Additional data from CT scan reports was extracted from 
medical notes and intranet based hospital records.  
2.2 Enzyme-linked immunosorbent assay (ELISA) 
This technique was used to measure the level of human TNF–α, IL–8 and IL–1β 
levels. We illustrate the method for TNF–α which basically the same principle for 
measuring the expression IL–8 and IL–1β cytokine. 
2.2.1 Reagent Preparation  
All reagents were allowed to warm in order to reach the room temperature before 
use. The Wash Buffer diluted in deionised or distilled water in a ratio of 1:25 then 
mixed gently until the crystals were completely dissolved (for example, 20mL Wash 
Buffer in 500mL of distilled water). 
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2.2.2 TNF-α and Standard 
TNF–α was reconstituted in deionised or distilled water, according to the 
manufacturer label on the vial to generated a stock solution of 10,000 pg/ml. The 
standard stock was kept on gentle agitation prior to making the dilutions for 15 
minutes.   
2.2.3 Serial Dilutions 
Suitable pipette was used to transfer 900μL of Calibrator Diluent RD6-35 into tube 1 
and 100μL of a known standard to make up 1000 pg/ml tube. 500μL of Calibrator 
Diluent RD6-35 was added into tube 2–6 and so on. Take 500μl from tube 1 and into 
the next tube, mix thoroughly then repeat the step with next tube and so on. The 
appropriate Calibrator Diluent serves as the zero standard (0 pg/mL).  
 
 
 
 
2.2.4 Assay procedure 
 Once all reagents and standards are prepared according to the instructions 
mentioned in the above section, 50μL of Assay Diluent RD1F was added into each 
well of the 96 well plates. The diluent mixture should be properly mixed prior to use 
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then 200μL of the standard, sample or control per well (in duplicates) was added and 
cover with adhesive strips. The plate was kept at room temperature for 2 hours. An 
example plate layout is shown Table 2.2.1. 
Table 2.2.1: illustration of ELISA plate with standard and samples duplicates.  
Std= Standard, P.S = Patient Sample 
 
All liquid was removed from the plate and washed with the wash buffer (400μL) four 
times. We made sure all liquid was removed by inverting the plate and blotting 
against a clean tissue paper. Then 200μL of TNF-α Conjugate was placed into each 
well and the plate was covered with a clean adhesive strip. After 2 hours at room 
temperature, the washing and aspiration steps were repeated. The substrate solution 
was then prepared by mixing together equal volumes of Reagent A and B, 15 minute 
prior to use and ensuring sunlight did not come into contact with the solution. Then 
200μL of substrate was added into each well and allowed the plate to stand for 20 
minutes, before adding 50μL of Stop Solution into each well. The reaction between 
the substrate and the stop solution will cause the colour in the well to changes from 
blue to yellow. The microplate reader used to read the plate and the reader was set 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0 
pg/ml 
0 
pg/ml 
P.S  
1 
P.S  
1 
P.S  
9 
P.S  
9 
P.S 
17 
P.S 
17 
P.S 
25 
P.S 
25 
P.S 
33 
P.S 
33 
B Std  
1 
Std  
1 
P.S  
2 
P.S  
2 
P.S 
10 
P.S 
10 
P.S 
18 
P.S 
18 
P.S 
26 
P.S 
26 
P.S 
34 
P.S 
34 
C Std 2 Std 
2 
P.S  
3 
P.S  
3 
P.S 
11 
P.S 
11 
P.S 
19 
P.S 
19 
P.S 
27 
P.S 
27 
P.S 
35 
P.S 
35 
D Std 
3 
Std 
3 
P.S  
4 
P.S  
4 
P.S 
12 
P.S 
12 
P.S 
20 
P.S 
20 
P.S 
28 
P.S 
28 
P.S 
36 
P.S 
36 
E Std 
4 
Std  
4 
P.S  
5 
P.S  
5 
P.S 
13 
P.S 
13 
P.S 
21 
P.S 
21 
P.S 
29 
P.S 
29 
P.S 
37 
P.S 
37 
F Std  
5 
Std  
5 
P.S  
6 
P.S  
6 
P.S 
14 
P.S 
14 
P.S 
22 
P.S 
22 
P.S 
30 
P.S 
30 
P.S 
38 
P.S 
38 
G Std  
6 
Std  
6 
P.S  
7 
P.S  
7 
P.S 
15 
P.S 
15 
P.S 
23 
P.S 
23 
P.S 
31 
P.S 
31 
P.S 
39 
P.S 
39 
H Std  
7 
Std  
7 
P.S  
8 
P.S  
8 
P.S 
16 
P.S 
16 
P.S 
24 
P.S 
24 
P.S 
32 
P.S 
32 
P.S 
40 
P.S 
40 
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at 450nm, to quantify the level of expression of the target cytokine in each well, 
which was measured as optical density (OD).  
2.2.5 Calculation of the results 
The average of the zero standards was subtracted from the average optical density 
(OD) readings for each standard, sample or control. Standard curve was constructed 
with the OD on the y-axis versus the known concentration of TNF–α, IL–8 or IL–1β 
(standard) on the x-axis. Line of best fit was generated by regression analysis. The 
equation the line of best fit is used to calculate the concentration of the samples from 
their obtained OD (Figure 2.1 A & B).   
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y = 0.0019x + 0.0061 
R² = 0.9804 
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Figure 2.1 A & B: Illustrate the process of calculating the concentration of the samples from their obtained 
O.D and standard equation. A) TNF-α & B) IL–8  
y = 0.0066x - 0.0015 
R² = 0.9733 
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[TNF-α] pg/ml  
TNF-α Standard 
OD Corrected
Linear (OD Corrected)
[TNF-α 
STND] 
pg/ml 
OD1 OD2 Mean 
OD 
OD 
Corrected 
62.5 0.567 0.416 0.4915 0.3975 
31.25 0.456 0.223 0.3395 0.2455 
15.625 0.163 0.151 0.157 0.063 
7.8125 0.139 0.132 0.1355 0.0415 
3.90625 0.145 0.114 0.1295 0.0355 
1.953125 0.105 0.104 0.1045 0.0105 
0.976563 0.108 0.1 0.104 0.01 
0 0.09 0.098 0.094 0 
[IL-8 
stnd]pg/ml 
OD1 OD2 Mean 
OD 
OD 
Corrected 
62.5 0.2 0.199 0.1995 0.130 
31.25 0.131 0.133 0.132 0.063 
15.625 0.104 0.101 0.1025 0.033 
7.8125 0.083 0.083 0.083 0.014 
3.90625 0.082 0.082 0.082 0.013 
1.953125 0.086 0.095 0.0905 0.021 
0.976563 0.113 0.079 0.079 0.009 
0 0.068 0.071 0.0695 0.000 
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2.3 Bronchoalveolar lavage 
2.3.1 BAL Collection  
2.3.2 Reagents/Equipment 
 
PBS with 0.05% EDTA 
PBS with 2% formaldehyde 
10% formal saline 
PBS    
      
2.3.3 BAL proceedure 
Rats were exposed to chronic hypoxia (2 weeks at 12% O2). The animals had ad 
libitum access to food and water at all times. At the completion of the two weeks, rats 
were euthanized by anaesthetic overdose (Sodium pentobarbital (Euthatal) 
200mg/kg, intraperitoneal injection) and then cardiac puncture was performed. Once 
the rat was confirmed dead due to non-responsiveness toe pinching and lack of 
heartbeat and respiration, the chest cavity was open to expose lungs. The trachea 
was uncovered   by carefully teasing away the lymph node and surrounding tissues. 
A loop suture was made under trachea (this is not tied at this point). This followed by 
making a small incision into the trachea. A cannula was inserted then tied in place 
with the suture. The lungs was gently inflated with 5ml BPS with 0.05% EDTA in a 
syringe and flushed twice. The syringe containing BAL was removed, while leaving 
the cannula in place.  
2.3.4 Processing BAL Fluid 
The BAL fluid collected in the syringe was placed in Eppendorf tubes. The tubes 
containing BAL fluid was spin at high speed to pellet the cells. The aliquot BAL 
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supernatant was stored at -20°C to be used for cytokine array assay and the cells re-
suspended in 200-1000µl PBS for cytospin assay.  
2.4 Proteome Profiler Array – Panel A – Rat Cytokine Array Assay 
2.4.1 Reagents Supplied 
Rat Cytokine Array Panel A,  
Detection Antibody Cocktail,  
1X Wash Buffer and  
Chemi Reagent Mix  
2.4.2 Array Procedure  
All reagents were allowed to come to room temperature while samples are kept on 
ice. Glover was worn throughout to avoid contamination. All samples and reagents 
were prepared according to the manufacturer’s guidelines (R&D Systems). Use the 
block buffer; Array Buffer 6 and pipette 2ml into each of the 4-Well Multi-dish to be 
used. Flat tip tweezers were used to remove a remove a membrane from between 
the protective sheet and placed in a well of 4-Well Multi-dish with the number on the 
membrane facing upwards. The blue dye from the spots on the membrane will 
disappear upon contact with the Array Buffer 6, however the capture antibody are 
retained in their specific locations. This was incubated for 1 hour on a rocking 
platform shaker.  
The BAL samples were prepared according to the manufacturer’s instruction while 
waiting. In a tube, 1mL of the BAL Sample, 0.5ml of Array Buffer 4 and 15μL of 
Detection Antibody Cocktail prepared were mixed and incubated at room 
temperature for 1 hour. Then the Array Buffer 6 was removed and washed from the 
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well of the 4-Well Multi-dish and samples/antibody prepared was added. The 4-Well 
Multi-dish was covered with a lid and incubated at 2–8°C overnight on a rocking 
platform shaker. Then, the membrane were then removed and placed into individual 
plastic containers with 20mL of 1X Wash Buffer. The 4-Well Multi-dish was rinsed 
with deionized or distilled water and dried thoroughly for future use. The membrane 
was washed and repeated three times with 1X Wash Buffer on a rocking platform 
shaker, 10 minute each. Prepare Streptavidin-HRP in Array Buffer as instructed by 
manufacturer. Remove each membrane from wash container carefully and let drain 
excess buffer from the membrane. Place the membrane in the 4-Well Multi-dish 
containing the diluted Streptavidin-HRP, cover the well with the lid and incubate for 
30 minutes at room temperature on a platform shaker. Then the each membrane 
was washed as described earlier. The membrane then removed from the wash 
container and drained excess Wash Buffer using a paper towel. Each membrane 
was then placed on a plastic sheet protector with identification number facing 
upwards. 1mL of the prepared Chemi Reagent Mix was placed evenly to cover each 
membrane fully. The membrane was carefully cover with the top sheet of the plastic 
protector, air bubbles removed and incubated for 1 minute. The top plastic sheet was 
removed and excess Chemi Reagent Mix blotted off. The membrane was left on the 
bottom plastic sheet protector and covered gently with a plastic wrap completely 
around the membrane and the bottom plastic protector, making sure air bubbles 
smoothed out. The membrane with the identification number was placed in an 
autoradiography cassette that is not used with radioactive isotope detection. Then 
the membrane was exposed to X-ray film with multiple exposure times between 1-10 
minutes.                                                    
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2.4.3 Data Analysis  
The signal observed on developed film was identified by placing a transparency 
overlay template and aligning it with the pairs of reference in the three corners of 
each array. Each array can capture up to 30 different cytokines or chemokines as 
indicated by the results.  Pixel densities on developed X-ray film can be collected 
and analysed using a transmission-mode scanner and imageJ analysis software. 
The average signal (pixel density) of the pair of duplicate spots representing each 
cytokine was determined and the average background signal was subtracted from 
each average signal and corresponding signal on different arrays was used to 
determine relative change between samples.  
2.5 Myography 
2.5.1 Principles of the multi-chamber wire myograph system  
The multi-chamber myograph (Model 610M, Danish Myo Technology A/S, Aahrus, 
Denmark) is used for multiple assessment of vessel reactivity (Figure 2.2  & Figure 2.3). 
The four chambers are arranged in parallel in a single unit and are good for high 
throughput experiments, offering the potential to compare vessel responses to a 
wide range of pharmacological compounds. Individual chambers have inbuilt valves 
to control oxygenation, automatic suction and selectable force ranges.  
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Figure 2.2: The interface of myograph (left top) and individual loading chambers (bottom right) (Adapted 
from AD Instruments manual). 
 
Vessel segments can be maintained under physiological conditions, in an isometric 
state, with any changes to basal tension being accurately recorded with a high 
degree of sensitivity. In addition, the basal tension of each vessel segment can be 
determined through a normalisation process (2.5.6). The vessel segment (~2mm) is 
mounted on myograph with two wires inserted through it, tightened at the transducer 
and micrometer ends, respectively. The tension is measured by parallel wires 
attached to the transducer, and micrometer used to set initial tension. The responses 
were recorded by the PowerLab acquisition system and assessed using a LabChart 
software.  
2.5.2 Animals 
Wistar Rats (250–300g) were used. Charles River, Laboratories International, 
Margate, UK, supplied all the rats used in the experiments. Rats were housed in the 
biomedical services unit (University of Birmingham) maintained in a controlled 
environment. Rat chow and water were available ad libitum. 
CH animals were housed in a normobaric hypoxic chamber (Oxycycler, model  
A84XOV, Biospherix) with an ambient oxygen concentration controlled at 12% 
oxygen (6kPa), the equivalent to an altitude of 4000m, for a period of 1 or 2 week(s)  
prior to the experiment. Testing and handling of the animals were conducted in 
accordance with the Animals (Scientific Procedures) Act 1986. 
2.5.3 Tissue isolation and preparation for myograph 
The rats were killed by an overdose of anaesthesia (induced in an airtight induction 
chamber using 4% isoflurane in medical O2 administered at flow rate of 1.5–3 
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mL/min) with cervical dislocation, as approved by the UK Home Office. Immediately 
after death, the chest cavity was opened, the lungs were dissected then placed in 
ice-cold Krebs solution (393) containing (mM): 118 NaCl, 24 NaHCO3, 0.435 
NaH2PO4, 1 MgSO4, 4 KCl, 5.56 glucose and 1.8 CaCl2, and the lobes were 
separated.  
2.5.4 Dissection of small pulmonary arteries from rat lungs 
The dissection protocol and guideline used for pulmonary artery was informally 
received  from Dr Vlad Snetkov at King’s College London, the guideline followed 
were established method used by Professor JPT Ward and his group at Kings 
College London and many other researchers around the world apply similar 
techniques. 
Rat lung is divided into several lobes and pulmonary arteries could provide 
appropriate size of the pulmonary segments required for these experiments. The 
large lobe can provide at least 4 arteries and the small ones can provide one each. 
 First, I ensured the microscope is set accordingly so that sharp clear image could be 
obtained. Fine dissecting forceps and small dissecting scissors were used for the 
dissection. A lobe from the lungs was placed in cold kreb solution on a Sylgard-filled 
dissecting dish. Excess blood was washed away from the surface of the lobs. The 
lungs is organised in such a way that arteries, veins and veins run in parallel. The 
lobes were oriented on the dissecting dish in such a way that the main vein can be 
seen entering the upper surface of the lobe. The selected lobe was pinned in an 
appropriate orientation with 3 or 4 small needles which are position at the edges.  
Keeping the forceps and the scissors straight, the main airway was opened up and 
then located it severed proximal end with the lower blade of the scissors and cutting 
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horizontally and longitudinally through the upper surface. The remains of this 
longitudinal cut airway were then carefully removed without damaging the arteries 
underneath. Once the main airway was opened, excess blood was removed out this 
need to be washed away. Following the side branches of the main airway by cutting 
through it will lead to the pulmonary artery segments of interest in our experiment. 
This sits just below the side branches of the main airways. Small PAs of second to 
third order branching were dissected according to established protocols (393). Under 
a dissecting microscope excess fat and connective tissue were stripped off the PAs 
(53) and cut into small (2mm) segments ready to be mounted on the myograph (Figure 
2.3).  
 
Figure 2.3: Diagrammatical representation of 
different lobes of rat lungs showing visible 
pulmonary arteries. The sections marked with 
darker line are the similar sized PA branches ideal 
for use our experiments. 
 
 
In order to assess the reactivity of systemic vessels, I also dissected iliac artery (IA). 
Following the location of the spine, cotton buds were used to gently tease away 
other organs to reveal the abdominal aorta in association with the veins. Further 
clearing revealed branching of the abdominal aorta into the common IAs. Fine 
forceps were used to clear away other tissue, using blunt dissection to separate the 
IA from the vein and perivascular nerves. Fine spring-bow scissors were then used 
to cut the IA distally, with care not to stretch the vessels during clearing from the 
proximal end, and placed straightway in ice-cold Krebs solution. The IA was freed 
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from excess adventitia under the microscope in a dissecting dish placed on ice, and 
cut into small vessel segments. 
Segments of vessel types were mounted in a temperature controlled multi myograph 
system at 37°C and gassed continuously with 95% air and 5% CO2 (pH 7.35) 
depending on the experimental protocol. When mounting rings of vessel segments 
into each of the four channels of the myograph, the chambers were filled with 5ml 
ice-cold Krebs solution. Then small wires (20µm diameter) were inserted through 
each vessel lumen, with care taken not to damage the endothelial lining, and 
tensioned by screws at the transducer end, then a second wire tightened at the 
micrometer gauge end. The wires going through the vessel were kept straight and 
parallel to the myograph jaws. Once all vessels in the myograph bath reached the 
target temperature, the PAs and IAs were normalised to an equivalent pulmonary 
pressure of 25mmHg and systemic pressure of 100mmHg, respectively.  After 
normalisation, the vessel rings were left to equilibrate at baseline tension for 45mins 
to permit the vessels to stabilise. The overall set up of the experiment is shown 
diagrammatically in Figure 2.4.  
Also, at the beginning of my research I was using physiological salt solution (as 
mentioned above) gassed continuously with 95% O2 and 5% CO2 (pH 7.35). 
However, due to undesired effects associated with the use of too much oxygen and 
best practices in field, we decided to replace this with 95% air and 5% CO2. This 
became the gas used for majority of our experiment. Therefore, unless otherwise 
stated, consider the gas used as 95% air and 5% CO2. 
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Figure 2.4: Schematic representing of the components used in the practical quantitative measure of vascular 
reactivity. The responses of a functional tissue are translated into an electrical signal which can be processed 
and subsequently analysed. 
 
2.5.5 Calibration  
To achieve acceptable level of accuracy in the recording, the wire myograph was 
subjected to a weight calibration prior to carrying out any of the experimental 
protocols (and subsequently re-calibrated each month throughout the study). This 
synchronisation procedure allows for the correct interpretation of the output voltage 
signal derived from the myograph, and the conversion of this signal, via PowerLab 
(AD Instruments, Oxford, UK), into a measure of force in LabChart. 
2.5.5.1 Internal myograph calibration 
The signal developed during the myograph calibration is subsequently converted into 
the correct units of force measurement for calibration of the LabChart system. 
Calibration of the myograph was accomplished via a weight calibration kit, consisting 
of calibration-bridge, balance and a 2g weight. All 4 of the chamber units were 
calibrated individually and in sequence before set-up, whereby the 2g weight was 
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used to calibrate the force transducer with a standard mass equivalent to a force of 
20mN.  
The principle of this calibration is that as the 2g weight is placed on the horizontal 
“pan” arm of the balance, the vertical “transducer” arm exerts a force on the 
mounting pin that mimics the contractile force of a tissue section. The unit is weight 
calibrated to a force of 9.81mN, which is derived from the relationship between the 
weight, the relative lengths and 90o angle of the balance arms, and the standard 
acceleration of gravity (9.81 m/s2).  
2.5.5.2 Calibration with LabChart 
A 2-point units conversion can be performed from the degree of change in amplitude 
of the LabChart trace before and after the calibration weight is added, enabling the 
output voltage to be translated into mN. These 2 points are selected from regions of 
the trace either side of the weight addition, where the signal is constant and devoid 
of any artefacts. The successful calibration is achieved when the voltage signals are 
set to corresponding tension values of 0mN and 9.82mN (see Figure 2.5).  
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2.5.6 Normalisation 
As well as calibration of the myograph, standardisation is also achieved by 
normalising the tissue preparation after loading each of the segments. This 
procedure is vital as it determines the basal tension of the vessel, by which any 
active responses can be accurately identified and quantified. Considering that there 
is variation in the elastic properties between vessels, as well as between individual 
vessel segments, by normalising the internal circumference of each segment via the 
same mathematical relationship, observed responses can be compared.  
The normalisation procedure used is based on the typical transmural pressure found 
within the specific vessel segment. The pressure is set at 25mmHg and 100mmHg 
for pulmonary and iliac arteries respectively. The internal circumference (IC100) that a 
relaxed vessel has at this pressure is calculated by a series of stepwise distensions ( 
in micrometer) and the measurements are correlated with the force generated (mN). 
This provides values for the internal circumference (μm) and vascular wall tension 
(mN), which are plotted against each other to produce an exponential curve. This 
curve will cross that extrapolated isobar corresponding to the transmural pressure 
(100mmHg), and via the Laplace relationship the site of intersection can be used to 
derive the value for IC100 (see Figure 2.6).  
Figure 2.5: Typical LabChart trace for the 2-point conversion. (Taken from AD Instruments manual). 
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The normalised internal circumference and the corresponding micrometer values are 
then calculated through the multiplication of IC100 by a specific factor. This factor 
represents the proportion of the internal circumference which would generate the 
maximal tension; for small rat arteries the factor used is 0.9. By adjusting the 
micrometer on each unit according to the calculated values (XI value on Figure 2.6 ), 
each vessel segment is tuned to its set normalised tension for equilibration (see 
Figure 2.7). After normalisation and leaving the vessel rings to equilibrate at baseline 
tension for about 45 minutes, the chambers were regularly washed out and the 
buffer solution replaced with a fresh one. 
 
Figure 2.6: Extrapolated normalisation curve following the step-wise distension procedure. The intersection with 
the transmural pressure isobar reveals the value for IC100, from which the normalised internal circumference can 
be obtained. Adjusting the myograph to the calculated micrometer denomination allows the baseline vessel 
tension to be set. 
XI = the value extrapolated as the basal tension to set that particular channel 
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Figure 2.7: Primary trace displaying each distension step during normalisation. Vessel segments are increasingly 
stretched and the micrometer values logged to calculate the normalised basal tension. 
The above normalisation steps have always worked well for the iliac vessels used in 
this project. However, for the small pulmonary arteries used in the experiments, it 
was not reproducible as the baseline line tension had to be set manually at times in 
order for the agonist response to be observed. This was noticed at the very 
beginning of the research project. After several attempt to troubleshooting we then 
decided to adopt a well-established manual protocol of setting baseline tension for 
pulmonary arteries at about 3mN used by Jeremy Ward and his group at King’s 
College, London.  The latter method worked well with PA vessels as expected and 
generated consistent reproducible data. 
2.5.7 Drug treatment to stimulate vascular response 
The contractile function of vessel segments were tested against pharmacological 
agents by direct administration to each chamber containing 5ml oxygenated buffer 
solution at 37oC. In order to check vessel viability and to normalise the series elastic 
component, vessels were exposed to physiological salt solution (393) containing 
80mM high K+ (PSS, using isotonic replacement of NaCl by KCl). This also acts as a 
reference contraction to compare other responses from vasoconstrictor and 
Basal tension = X1 at 0.9 
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dilatators agents to be used. KCl should produce maximum electrogenic, non-
agonist mediated constrictor tone by the vessels. This is because K+ causes a 
depolarisation and contraction through activation of ion channels, and does not rely 
on receptors on the vascular smooth muscle. The response from other agents can 
be expressed as percentage of KCl vasoconstriction to compare vascular reactivity 
from the same tissue, and also between control and treated groups. This helps 
eliminate discrepancies given the biological variation in baseline tension between 
vessel rings. Once the KCl response has peaked, the chambers were emptied and 
washed a few times to allow the tension return to its baseline position.  
Then the vessel segment would be treated with a range of drug concentrations (10-11 
M to 10-5M) using phenylephrine (PE) to construct a cumulative dose-response curve 
for vasoconstriction. For the thromboxane A2 agonist, U46619, the dose used 
ranges from 20nM to 1000nM. The agonist is washed off and then stimulated with 
EC80 of PE or U46619 (R & D Systems) concentration, and increasing doses of 
carbachol–CC or sodium nitroprusside–SNP (R & D Systems) was added to observe 
endothelium-dependent and independent relaxation respectively. This helps to 
confirm integrity of the endothelium to ensure it was not damaged during dissection, 
mounting or application of tension to vessels. It also confirms the vasoconstrictor 
effect is actually from the treatment not due to endothelial damage. The drug 
treatments used are summarized in Table 2.5.1 below. 
Tube# [Stock] Volume fom 
the stock 
(uL) 
Final Volume 
(mL) 
Final 
Concentration 
[Log] 
7 1 nM 50 5 10 pM (10-11m) 
 
-11 
6 10 nM 50 5 100 pM (10-10m) 
 
-10 
5 100 nM 
(0.1uM) 
50 5 1 nM  (10-9m) 
 
-9 
150 5 3 nM (3*10-9m) -8.5 
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Table 2.5.1: Shows a summary of the vasoconstrictor/vasodilator drugs added to individual chambers of 
myograph bath.  
 
Through the course of my project we have changed vasoconstrictor from 
phenylephrine due to inconsistency observed with vasoconstriction response 
generated, especially in pulmonary arteries, which might be attributed least stability 
of the agonist or minimal sensitivity of PAs to the vasoconstrictor. For example, at 
times the freshly made aliquot of phenylephrine might induce response and when the 
same does is used again after 30 minute later on the same vessel, might not induce 
a response, or the freshly made aliquot of phenylephrine generating no response. 
However, when another vasoconstrictor (such as U46619) was used on the same 
vessel, vasoconstriction was observed.  Therefore, we used U46619, a synthetic 
analogue of thromboxane A2 agonist, which provided a more consist results.  
2.5.8 Inflammatory stimulus  
Tissue isolation and preparation for myograph were conducted as described in 
section 2.5.3.  Pulmonary and systemic vessels were then exposed to 80mM KCl, 
treated with either a vasoconstrictor or vasodilator agent and one of each vessel pair 
was incubated with tumour necrosis factor alpha (TNFα; 1000U/mL or IL–8; 50ng/mL 
 
4 1 uM 50 5 10 nM (10-8m) 
 
-8 
 
150 5 30 nM (3*10-8m) 
 
-7.5 
3 10 uM 50 5 100 nM (10-7m) 
 
-7 
150 5 300 nM (3*10-7m) 
 
-6.5 
2 100 uM 50 5 1 uM (10-6m) 
 
-6 
150 5 3 uM (3*10-6m) 
 
-5.5 
1 1 mM 50 5 10 uM (10-5m) 
 
-5 
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or IL–1β; 20 ng/mL – R&D System) for 1 hour. The extended inflammatory challenge 
involve incubation of pulmonary artery with TNF–α for 2 or 6hr in Dulbecco's 
Modified Eagle's medium (DMEM – Sigma-Aldrich ) Subsequently, the initial 
stimulation with vasoconstrictor or vasodilator drugs was repeated, then finally 80mM 
KCl added at the end to ensure the vessels were still viable. 
2.5.9 Hypoxia Treatment in vitro 
2.5.9.1 Concurrent Acute Hypoxia and TNF–α Treatment in vitro 
Pulmonary artery vessels were isolated, mounted myograph, normalised as 
described and baseline tension was set. After stabilisation of the vessel, KCL 
response was perform to ensure viability of the vessel and then hypoxia was induced 
on the myograph bath by bubbling the Kreb Solution containing the vessel with 95% 
N2 and 5% CO2 for the duration of the protocol (1 hour). Then agonist response was 
tested (see results in 6.3.6). 
2.5.9.2 Effects of acute TNF–α Treatment   on HPV  
Pulmonary artery segments were mounted on the myograph, baseline tension set 
and vessels were allowed to become stable. Then KCL response tested. HPV was 
generated by bubbling the Kreb Solution containing the vessel with 95% N2 and 5% 
CO2, post pretone generation with prostaglandin F2α (3–7ɥM). Then the vessels 
were incubated with/without TNF–α for hour then HPV generation was repeated (see 
raw HPV trace in Figure 6.3.5).  
The second HPV values was taken as percentage of the first HPV generated for 
phase 1 and 2 respectively and results plotted as bar chart (this was not shown and 
results was insignificant). We have also calculated HPV phase 1 and 2 as 
percentage of high K+ ( % High K+ [80 mM]), averaged the results for all vessels and 
plotted as a bar chart (Mean ±SEM) (see results in 6.3.5).  
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2.5.10 Stiffness Measurement Protocol 
In this protocol, w attempted to measure vascular stiffness in systemic vessels (iliac) 
isolated from rats to compare with the pulse wave velocity measured in human 
alpha-1-antitrypsin deficient subjects. Unfortunately, we had no access to pressure 
myography, therefore we had to develop a manual method to help us derive some 
form of stiffness measure. 
Vessels were mounted on a 4-channel myograph then applied a series of stepwise 
distensions (ɥm) and the measurements are correlated with the force generated 
(mN), similar to the normalisation step observed in earlier section (2.5.6). The values 
for the corresponding distension and tension extrapolated from LabChart trace (Figure 
2.8). These values were plotted as an exponential curve graph as in a sample ( 
Figure 2.9).   
IC100 was identified from the graph and from this, the IC89 and IC91 were 
calculated for the circumference and diameter of the vessel. The circumference at 
IC89 and IC91 were calculated by multiplying IC100 by either 89 or 91 and divided 
by 100 (IC100 x IC89 or 91/100). The diameter calculated by dividing the 
circumference at IC89 and IC91 by 𝜋 (3.142) respectively. The changed in 
circumference and diameter were then calculated by subtracting IC89 from IC91. 
This value is denoted as delta X–axis for the circumference and diameter.  
Then we used the known X values at IC89 and IC91 (calculated above) in the 
exponential curve equation to calculate the Y values at IC89 and IC100 respectively 
and subsequently subtracted Y at IC89 from Y at IC100 to derive change in the Y-
axis.   
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The slope of the change in Y divided by change in X, was used derive circumference 
(mN/um) and the change in Y was divided by the change in X/𝜋 (calculated above) to 
derive the diameter (mN/um). 
We then differentiated the exponential equation (y = 0.3038e0.1421x ; R²=0.981) and 
used this differential equation [(0.3038*0.1421)*(EXP(0.1421*IC90)] to again find the 
circumference (mN/ɥm) which gave the same answer as the slope calculation. Then 
the circumference (mN/ɥm) was divided by (3.14) to generate the diameter (mN/ɥm).  
These steps were repeated for each of the four channels or different treatments and 
the experiments repeated to collect replicates. The replicates of calculated IC90, 
circumference (mN/ɥm) and diameter (mN/ɥm) were plotted as bar chart to provide 
an idea about stiffness of the vessel. 
Please note all values, graph and trace provided were arbitrary and were used for 
demonstration purpose only. 
 
 
 
 
 
Figure 2.8: Demonstrates a sample step by step distension trace of a vessel 
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Figure 2.9: A) showing the data extrapolated from distension trace (B) exponential curve of the data. Note: 
All values were arbitrary. 
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3 DO HYPOXIA AND INFLAMMATION INTERACT TO EFFECT CHANGES 
IN ARTERIAL STIFFNESS IN PATIENTS WITH α1-ANTITRYPSIN 
DEFICIENCY?   
3.1 Chapter Introduction and Overview  
 
According to  the World Health Organisation (8), COPD is a global public health 
problem and affects millions of people each year. Generally COPD refers to 
diseases such as emphysema and chronic bronchitis. Emphysema arises as a result 
of damage to air sacs in the lungs leading to shortness of breath during activity as an 
early symptom of the disease, a phenomenon that can later be observed at rest as 
the disease worsens.  
Smoking and environmental factors are the major causes of emphysema. However, 
there is growing evidence that genetic factors such as Alpha-1 Antitrypsin Deficiency 
(AATD) can predispose to the development of emphysema. AATD is considered a 
rare hereditary disorder, though still significantly underdiagnosed (394-396), even 
though AATD is among the commonest autosomal genetic disorders found in human 
(397). AATD was first reported to increase the risk of developing emphysema in 
1963 (398), as well as a number of other phenomena, such as liver cirrhosis (391). 
People with AATD do not have sufficient amount of the protein known as alpha-1 
antitrypsin in their blood, a problem which arises due to polymerisation of AAT in 
most cases (399) 
Alpha-1 antitrypsin is one of the key proteins found within the blood which is mainly 
manufactured by the liver cells and is then transported into the blood stream as a 
protective mechanism against inflammation. This is achieved by preventing the 
effects of enzymes such as elastase which usually accompany leucocytes that 
96 
 
protect delicate lung tissues by eliminating bacteria and neutralising small particles 
inhaled into the lungs. Once elastase completes its function, it is neutralised by 
alpha-1 antitrypsin. Hence, in the absence of alpha-1 antitrypsin, elastase 
concentrations can continue to build up thereby leading to alveolar damage.  
The normal genotype is usually described as PiMM, due to the nature of the protein 
movement on phenotyping (medium mobility). This results in a normal level of alpha-
1 antitrypsin in the blood stream. An extensive number of genetic variants of alpha1-
antitrypsin have so far been identified, there could be more than 100 resultant 
variants of the protein (397, 400).  The predominant genetic variants linked with 
AATD  are  Z (Glu342Lys) and S (Glu264Val) mutations, triggered by substitution of 
a single amino acid; glutamic acid at position 342 and 264 with lysine and valine 
respectively (395). It is possible for some individuals to inherit a single abnormal 
gene (e.g. genotype such as PiMZ) which increases the risk of developing 
emphysema in a smoking population from 20% (among smoker with normal allele) to 
50% (smokers with PiMZ genetic variant) (401).   
Cardiovascular morbidity and mortality is prevalent among COPD patients. This 
observation seems to be independent of common risk factors such as smoking, 
gender and age (402-404).  A reasonable mechanistic link is the existence of a 
chronic inflammation in the both the lung and cardiovascular system (228, 404, 405), 
which was reported to be linked with endothelial dysfunction (405, 406). In addition, it 
was suggested that the phenomenon might be associated with loss of elastin (65, 
228, 407) and subsequent vascular calcification (408).  It has been suggested that 
persistent low-grade systemic inflammation might serve as the pathophysiological 
link between COPD and subsequent development of cardiovascular disease (409). 
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Moreover, several inflammatory markers including C–reactive protein (403, 404) are 
found to be elevated in COPD patients. There is enormous evidence suggesting a 
role for systemic inflammation in COPD. This due to increased level of inflammatory 
cytokines and acute phase proteins found in stable COPD subjects and the fact that 
exacerbation was associated with both pulmonary and systemic inflammation. This 
has been extensively discussed in the introduction section. Moreover, the role of 
hypoxia in COPD and subsequent cardiovascular complications such as pulmonary 
hypertension has been detailed in the introduction section of the thesis. The 
schematic diagram (Figure 3.1: schematic diagram showing the potential pathophysiology of 
COPD that leads to pulmonary hypertension. It highlights the role of contribution of inflammation, 
hypoxia and genetic factors in the disease pathogenesis. Adapted from (410)) summarises the 
potential contribution of inflammation due to smoke exposure and hypoxia COPD 
pathogenesis. 
 
 
 
Figure 3.1: schematic diagram showing the potential pathophysiology of COPD that leads to pulmonary hypertension. 
It highlights the role of contribution of inflammation, hypoxia and genetic factors in the disease pathogenesis. 
Adapted from (410) 
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Also, arterial stiffness (65, 228, 407), and thoracic aortic calcification (408) as well as 
impaired flow mediated vasodilation (406) were markedly elevated in COPD patients. 
These associations are independent of smoking status and correlated inversely with 
lung function as well as being directly connected to the extent of emphysema as 
measured by quantitative CT scanning (228, 402, 404, 408). This suggests that there 
is a direct link between the two pathologies. 
Arterial stiffness is a potentially adjustable characteristic with an added predictive 
value beyond what can be generated by using traditional cardiac risk factors (411-
413). Therefore, arterial stiffness has been the target of pharmacologic and exercise 
interventions in patients with COPD (414, 415). These studies have suggested a 
possible advantage with inhaled treatments and exercise. However, the benefit with 
pharmacologic intervention seems to be limited to those patients with a substantial 
augmentation in arterial stiffness (415). Hence, any process that could identify 
specific subjects who may potentially benefit from an intervention will add a 
significant value to phenotyping and targeting therapy (416).  
Pulse wave velocity (PWV) is the gold standard for measuring arterial stiffness and 
this can be measured from the aorta or carotid artery (417).  Arterial stiffness was 
shown to be increased in COPD patients (42, 418) and it can be used as an 
independent predictor of cardiovascular episodes and mortality in COPD patients 
(419)  and is positively associated with level of specific systemic inflammatory 
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makers (such as C–reactive protein level) found in healthy controls (420) and wider 
patient populations (421, 422). This is evident in the study that has shown a weak 
link between arterial stiffness and interleukin–6 as well as with soluble tumour 
necrosis factor receptor 1 (sTNFR1) but not with sTNFR2 (418).   
Finally, various interventional studies have investigated the influence of 
pharmacological intervention and exercise on arterial stiffness in COPD patients. 
However, these studies were focused on those patients with more elevated levels of 
arterial stiffness (416). In addition, some studies have looked at the predictors of 
increased arterial stiffness in patient with moderate to severe COPD (416).  
In this study, we aimed to identify predictors of increased arterial stiffness in an 
AATD cohort, who are genetically predisposed to develop COPD.  
Finally, it is established in the literature that both hypoxia and inflammation play a 
critical role in COPD disease prognosis and progression as well as in the 
pathophysiology associated with cardiovascular diseases. Therefore, we speculated 
that there might be an interaction between hypoxia and inflammation and this might 
be useful to predict the risk of cardiovascular disease in COPD. 
The aims of the investigations in this chapter are summarised below:  
In a cohort of patients with AATD:  
I. We aimed to identify the variables that related to: 
i. arterial stiffness measure (PWV) 
ii. the inflammatory markers (TNF–α, IL–8 & IL–1β) 
iii. oxygen level (PO2) 
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II. To identify predictors of arterial stiffness in AATD patient  
III. To evaluate interaction between inflammatory markers and hypoxia 
 
3.2 Methods 
3.2.1 Arterial Stiffness 
All the physiological measurements were conducted by a qualified respiratory clinical 
scientist at the Queen Elizabeth Hospital Birmingham and not by the author of this 
thesis. The author analysed the data and performed assays on the serum samples 
collected from the patients to measure cytokine levels as well as conducted 
animal.experiments disscussed in chapter 2 to complement the human data. The 
patient selection or recruitment, demographic and method used were disscused in 
Section 2.1. The arterial stiffness measure PWV, was done on the aorta or carotid 
artery thus the use of a systemic vessel in rats to compare the effects. Iliac artery 
experimenets reported in Chapter 4 were conducted prior to human study data been 
made available. It would have been more suitable to use corotid artery to assess 
stiffness in rats, however, it was not practically feasible to complete the task. 
Nonetheless, as we will be comparing a systemic vessel to another, and this makes 
a reasonable sense.   
3.2.2 ELISA  
ELISA was used to quantify level of cytokine in the serum samples of AATD 
subjects. Levels of TNF–α, IL–8 and IL–1β were measured.  Detailed explanation is 
given in the method section of the thesis (2.2).  
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3.2.3 Statistics 
Variables were initially tested for normality this determine which univariate analysis is 
conducted. Pearson correlation was used to analyse parametric variables, whereas 
Spearman’s correlation was used for non-parametric variable. Variables of interest 
and that one found to be associated with arterial stiffness at univariate level were 
included in the regression model. We have adopted significant when p value is less 
than or equal to 0.05. 
3.3 Results 
 
3.3.1 Baseline Demographic Characteristic within the Patient Population  
The demographic data shows the composition of men and women at 66 and 34 
percents respectively (Error! Reference source not found.).  Showing that there 
were about twice as many male participants in the study compared to female 
participants. All the different variants of alpha-1 antitrypsin deificiency (such as 
MMalton, Mprocida, Z null and Z phenotypes) were displayed by the participants. 
The Z variant constituted  of more than 92 percent of the cases, whereas the other 
phenotypes were much less or rarely observed.  
 71 percent of the patient population were ex-smokers, 24 percent were non-
smokers and 5 percent were current smokers (Table 3.3.1). Index case  and non-index 
case was used to refer to the way the patients were diagnosed with alpha-1 
antitrypsin deficiency. Index case referes to the that patients were discovered 
because a close family member was diagnosed with the disease and thus they were 
diagnosed because a family member was ill. However, the index case refers  to the 
fact that the patients were diagnosed with disease because they were ill themselves. 
Predominant cases of alpha-1 antitrypsin deficiency was discovered as non index 2, 
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hence more than three-quarter of the cases were diagnosed because the patients 
were ill.   
The mean age between male and female categories were similar with respect to 
smoking status. Non-smokers were an average age of 60 years in both male and 
female groups, ex-smokers were about 58 years in both categories and current 
smokers had a mean age of about 45 years (Table 3.3.1). 
The alpha-1 antitrypsin deficiency phenotypic variation between male and female 
showed a similar pattern as the Z phenotype was predominant in both catergories. 
However, count for Z phenotype among males was almost double that of the Z 
phenotypes observed among female patients. 
The minimum and maximum ages of patients were 24 and 79 years respectively. 
The mean age of the patient population was 55.7±0.79. The minimum and maximum 
BMI were 17 and 41 respectively and the mean BMI was 25.9±0.37. The blood PO2 
ranged from 5.5 to 12.6 (mmHg) and the mean 8.97±0.12, whereas the minimum 
and maximum PWV were 6 and 15 respectively. The mean TNF– α and IL–8  levels 
were 3.5±0.28 (pg/mL) and 24.8±2.23 (pg/mL) respectively. 
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Variables 
N Range Min Max Mean Std. 
Error 
Std. 
Deviation 
Age (Yrs) 176 55.68 24.15 79.83 55.6634 0.78754 10.44791 
Height (m) 176 0.41 1.51 1.92 1.7198 0.00679 0.09006 
Weight 
(Kg) 
176 81.00 42.00 123.00 76.7886 1.20532 15.99043 
BMI 176 24.12 16.56 40.68 25.9114 0.36807 4.88305 
Pack 
Years 
126 57.90 0.10 58.00 17.3424 1.11073 12.46791 
pH 156 1.95 7.35 9.30 7.4578 0.01225 0.15301 
PO2 156 11.02 5.5 12.62 8.9672 0.11545 1.44202 
TNF–α  
(pg/mL) 
149 23.56 -4.92 18.64 3.5347 0.27857 3.40036 
IL–8  
(pg/mL) 
142 203.68 -8.21 195.47 24.8334 2.22528 26.51723 
PWV 168 8.92 6.04 14.96 9.0941 0.12969 1.68104 
Table 3.3.1: Shows Descriptive statistics of the various relevant variables used in this chapter PO2 = Partial 
pressure of Oxygen, BMI= Body Mass Index, TNF–α = Tumour Necrosis Factor Alpha, IL –8 = Interleukin 8, 
PWV = Pulse Wave Velocity.  
3.3.2 Normality Test of Variables 
All relevant variables were explored to check for parametric or non-parametric 
distribution of the data and whether to reject or accept the null hypothesis that the 
data is significantly non-normal for each variable. Demographic variables such as 
Age, Weight, Height, BMI, St George’s (SG) quality of life score such as SG total, 
SG Impact and SG Symptoms were found to be significantly normal as k–s 
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statistics were ≤0.1 whereas pack years and SG activities were significantly non-
normal as k-s statistics were ≥ 1 (see Appendix 2).     
The test of normality of blood gases and cardiovascular variable indicated that BE, 
TLC, TLCO, RV, Stroke Volume, Systolic Pressure, Cardiac Output, Pulse 
Pressure, Aortic Pulse Pressure, Mean Arterial Pressure, Total Peripheral 
Resistance, and augmentation index were all significantly normal as k–s statistics 
were ≤ 0.1. On the other hand, the partial pressure of oxygen in the blood (PO2), 
partial pressure of carbon dioxide in the blood (PCO2), hydrogen carbonate (HCO3),  
pH, KCO were found to be significantly non–normal as k-s statistics were ≥ 1. 
The Test of normality indicated that Interleukin–1–Beta (IL–1β), Interleukin–8, 
Tumour Necrosis Factor Alpha (TNF–α), C–Reactive Protein (CRP) were all 
significantly non–normal because the k–s statistic were ≥ 1; whereas the 
Cholesterol was significantly normal due to the k–s statistic being ≤ 1.    
When a normality test was performed on the spirometry variables, it was could be 
concluded that forced expiratory volume in 1 second (FEV1), forced expiratory 
volume ratio (FEV1/FVC ratio) and forced expiratory volume percent predicted were 
all found to be significantly non–normal because k–s statistics were ≥ 1. However, 
forced vital capacity (FVC) and forced vital capacity percent predicted (FVC % 
Predicted) were normal                                                                                                                                                                                                                                                                                                                                                                     
3.3.3 Univariate Analysis 
Once all variables were tested for normality Univariate analysis was performed on 
the variables by conducting correlation between relevant variables using the 
Pearson’s correlation test for parametric and Spearman’s test for non-parametric 
data as described previously (Appendix 3). Our data has shown that pulse wave 
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velocity (PWV) significantly correlated with age, sex, TNF–α, FEV1, FEV1 % 
predicted, FEV1/FVC ratio, systolic pressure, pulse pressure, aortic pulse pressure, 
cardiac output, total peripheral resistance, TLCO and TLCO % predicted (Table 3.3.2). 
In contrast, there was no significant correlation between PWV and BMI, IL–8, IL–1β, 
FVC, PO2 and PCO2 because their p–values were all greater than 0.05 (Table 3.3.2Table 
3.3.2). 
From the our data, PO2 has significantly correlated with FEV1, FEV1 %, FEV1/FCV 
ratio, FVC, FVC % predicted, TLCO, TLCO % Predicted, Pulse pressure and aortic 
pulse pressure. However, PO2 did not indicate any strong correlation with TNF–α, 
IL–8, IL–1β, PCO2 and systolic pressure (Table 3.3.2). 
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3.3.4 Correlation of pulse wave velocity against measured variables 
 
Table 3.3.2: Correlation of pulse wave velocity against measured variables 
 
 
 Variables R p Value 
PWV Age 0.655 < 0.0001* 
 Sex N/A 0.010* 
 BMI -0.079 0.315 
 TNF-α 0.178 0.037* 
 IL-8 0.091 0.299 
 IL-1β -0.018 0.916 
 FEV1 -0.248 0.001* 
 FEV1  Percent Predicted -0.174 0.026* 
 FVC -0.086 0.274 
 FEV1 ratio -0.240 0.002* 
 Systolic Pressure 0.433 < 0.0001* 
 Pulse Pressure 0.34 < 0.0001* 
 Aotic Pulse pressure                   0.352 <0.0001* 
 Cardiac Output  0.317 < 0.0001* 
 Total Peripheral Resistance -0.156 0.043* 
 TLCO -0.366 < 0.0001* 
 TLCO  Percent Predicted  -0.315 < 0.0001* 
 PO2 -0.101 0.226 
 PCO2 -0.013 0.876 
    
PO2 FEV1 0.462 < 0.0001* 
 FEV1 Percent Predicted 0.469 < 0.0001* 
 FEV1  ratio 0.419 < 0.0001* 
 FVC 0.17 0.036* 
 FVC  Percent Predicted  0.225 0.005* 
 TNF-α -0.053 0.558 
 IL-8 -0.036 0.698 
 IL-1β 0.088 0.600 
 TLCO 0.426 < 0.0001* 
 TLCO  Percent Predicted 0.422 < 0.0001* 
 PCO2 -0.092 0.262 
 Systolic Pressure 0.091 0.263 
 Pulse Pressure 0.224 0.005* 
 Aotic Pulse Pressure 0.214 0.008* 
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3.3.5 Correlation TNF–α and IL–8 against measured variables 
Univariate analysis had indicated that IL–8 strongly correlated with pack years, 
whereas it did not indicate any correlation with FEV1 % predicted, FEV1 ratio, KCO, 
KCO % predicted, TLCO, TLCO % predicted, age, systolic pressure, aotic pulse 
pressure or SG total (Table 3.3.3). TNF-α had earlier shown to be correlated with PWV 
and has been shown to be significantly correlated with total peripheral resistance. On 
the other hand, TNF-α, through  univariate analysis, did not show a correlation with 
any other variable it  was  compared with such as FEV1, FEV1 % predicted, FEV1 
ratio, total peripheral resistance, KCO, KCO % predicted TLCO and age (Table 3.3.3).  
 Variables (units) R p Value 
IL-8 FEV1  0.044 0.603 
 FEV1 Percent Predicted 0.127 0.134 
 FEV1 ratio 0.099 0.245 
 Augmentation Index 0.054 0.526 
 Total Peripheral Resistance -0.075 0.373 
 KCO 0.064 0.373 
 KCO Percent Predicted 0.04 0.64 
 TLCO -0.029 0.733 
 TLCO Percent Predicted 0.037 0.666 
 Age 0.083 0.33 
 Pack Year -0.18 0.038* 
 Systolic Pressure -0.087 0.305 
 Aotic Pulse Press -0.049 0.566 
 SG total -0.081 0.349 
    
TNF-α FEV1 -0.016 0.851 
 FEV1 Percent Predicted 0.049 0.557 
 FEV1 ratio -0.002 0.982 
 Augmentation Index 0.027 0.742 
 Total Peripheral Resistance -0.205 0.012* 
 KCO -0.067 0.423 
 KCO Percent Predicted -0.06 0.471 
 TLCO -0.102 0.224 
 TLCO Percent Predicted  -0.038 0.644 
 Age 0.136 0.1 
 Pack Year  -0.002 0.983 
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 Systolic Pressure 0.059 0.478 
 Aotic Pulse Press 0.133 0.106 
 SG total 0.01 0.91 
Table 3.3.3: Correlation TNF-α and IL – 8 against measured variables 
3.3.6 Multivariate Analysis 
3.3.7 Multiple Linear Regression Analysis 
For this stage of analyses, variable were categorised into dependent and 
independent variables. The variable of interest that we hypothesised might be 
predicted by the independent variables (PWV) was entered as the dependent 
variable. Variables that indicated significance correlation with PWV and/or PO2 and 
TNF-α at univariate level were included in the regression model. The variables 
entered as independent variable included; age, gender, PO2, TNF–α, FEV1, systolic 
pressure and TLCO. Age, gender, FEV1, systolic pressure, and TLCO were included 
because they had shown a strong correlation with PWV. TLCO is also used as a 
determinant for emphysema. TNF–α was included as independent variable because 
it significantly correlated with PWV.  All above–mentioned target independent 
variables were entered into the regression model. 
From the model summary of the regression analysis, the adjusted r square (adjusted 
r2) represent the proportion of the total variability in dependent variable, PWV that is 
explained by the independent variables in the model. Our data shows that from the 
adjusted r2 values that age (r2 = 0.351), can predict 35% of the total variation in 
PWV. Age and gender (r2 = 0.366) can explain about 37% of the total variation in 
PWV. Age, gender and TNF–α (r2 =0.371) can predict 37% of the total variation in 
PWV. Age, gender, TNF–α and systolic pressure (r2 = 0.470) can explain 47% of the 
total variation observed in PWV.  Age, gender, TNF–α, systolic pressure and FEV1 
(r2 =0.480) can explain 48% of the total variation in PWV. Age, gender, TNF-α, 
systolic pressure, FEV1 and PO2 (r
2 =0.480) can explain 48% of the total variation in 
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PWV. Finally the independent variables entered into the multivariate linear 
regression model; age, gender, TNF-α, systolic pressure, FEV1, PO2 and TLCO (r
2 
=0.495) can explain about 50% of the variation observed in our dependent variable; 
PWV ( 
Table 3.3.4). 
The ANOVA table of the linear regression analysis indicates how well the regression 
model predicts the dependent variable and whether this was significant or not. The p 
values shown indicate statistical significance of the regression model that was run. If 
the p value is ≤ 0.05, this indicates that, statistically, it is acceptable to reject the null 
hypothesis of the F statistic of the regression ( 
Table 3.3.5). The null hypothesis of the F statistic of the regression is that the 
regression model has no explanatory power which means all the co–efficient of the 
independent variables are zero, which is the same as saying none of the 
independent variables help to predict the dependent variable (meaning the model is 
useless).  
A variety of regression models were tested to ascertain which parameters explain 
the greatest degree of variance in PWV. Overall, the multivariate regression model 
that entered TNF–α, systolic pressure, FEV1, PO2 and TLCO was found to 
statistically significantly predicts PWV (F=20.3, p value =0.0001).   
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Model R R Square Adjusted R 
Square 
Change Statistics 
R Square 
Change 
F Change Sig. F 
Change 
1 0.592
a
 0.351 0.345 0.351 61.655 0.0001 
2 0.605
b
 0.366 0.355 0.015 2.706 0.103 
3 0.609
c
 0.371 0.354 0.005 0.919 0.340 
4 0.686
d
 0.470 0.451 0.099 20.730 0.0001 
5 0.693
e
 0.480 0.456 0.010 2.070 0.153 
6 0.693
f
 0.480 0.451 0.000 0.000 0.983 
7 0.703
g
 0.495 0.462 0.015 3.117 0.080 
 
Table 3.3.4: Model summary of the multivariate regression 
a, b, c, d, e, f, g and h gives details of the stepwise addition of the independent variables, which represent PWV 
(dependent variable), age, sex, TNF-α, systolic pressure, FEV1, PO2 and TLCO respectively. The variable were 
added into the multivariate regression mdoel using step-wise manner so that impact of each individual 
variable could be established as well as the model as a whole. 
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ANOVA
a
 
Model Sum of 
Squares 
Df Mean 
Square 
F Sig. 
1 Regression 109.977 1 109.977 61.655 < 0.0001
b
 
Residual 203.348 114 1.784   
Total 313.325 115    
2 Regression 114.733 2 57.367 32.642 < 0.0001
c
 
Residual 198.592 113 1.757   
Total 313.325 115    
3 Regression 116.349 3 38.783 22.052 < 0.0001
d
 
Residual 196.976 112 1.759   
Total 313.325 115    
4 Regression 147.346 4 36.836 24.635 < 0.0001
e
 
Residual 165.979 111 1.495   
Total 313.325 115    
5 Regression 150.411 5 30.082 20.312 < 0.0001
f
 
Residual 162.914 110 1.481   
Total 313.325 115    
6 Regression 150.412 6 25.069 16.773 < 0.0001
g
 
Residual 162.913 109 1.495   
Total 313.325 115    
7 Regression 154.982 7 22.140 15.101 < 0.0001
h
 
Residual 158.343 108 1.466   
Total 313.325 115    
a. Dependent Variable: PWV 
b. Predictors: (Constant), Age 
c. Predictors: (Constant), Age, Sex 
d. Predictors: (Constant), Age, Sex, TNF 
e. Predictors: (Constant), Age, Sex, TNF, Systolic Pressure 
f. Predictors: (Constant), Age, Sex, TNF, Systolic Pressure, FEV1 
g. Predictors: (Constant), Age, Sex, TNF, Systolic Pressure, FEV1, PO2 
h. Predictors: (Constant), Age, Sex, TNF, Systolic Pressure, FEV1, PO2, TLCO 
 
Table 3.3.5 Shows the ANOVA table, which reports how well the regression equation fits the data (i.e., 
predicts the dependent variable) as reported above.  Significance: p value ≤ 0.05 
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Then we come to the co-efficient section of the multivariate linear regression 
outcome (Table 3.3.6). The co-efficient indicates the relationship between an 
independent variable and the dependent variable; hence, the co-efficient is the most 
important outcome of the multivariate linear regression. First we have looked at the t-
statistic whether there is enough evidence to reject the null hypothesis. The null 
hypothesis of the t-statistic states that “the co-efficient of an independent variable is 
zero. The same as saying that particular independent variable does not help predict 
the dependent variable. If the p value of the t-statistic ≤ 0.05, we reject the null 
hypothesis. Accordingly, when we reject the null hypothesis for the t-statistic, this 
means that particular independent variable has predictive ability for the dependent 
variable. Once it is established that the independent variable has predictive ability we 
can look at the unstandardized co-efficient of the independent variable, making note 
of the whether the direction of association (positive or negative) makes sense. In 
addition, based on the unstandardized co-efficient value, we can deduce level of 
increase or increase of the dependent variable by a particular independent variable. 
From my data, in the regression model 1, the t–statistic was found to be significant 
for age. In the regression model 2, age was observed to be significant whereas 
gender was not. In the regression model 3, the t–statistic for age was found to be 
significant whereas gender, and TNF–α were not significant.  The regression model 
4 indicates that age and systolic pressure were significant whilst gender and TNF–α 
did not show significance. Again in model 5, age and systolic pressure were 
observed to generate a significant t–statistics whereas other independent variables 
entered (gender, TNF–α, FEV1 did not show significance. Moreover, in the 
regression model 6, the t–statistic for age and systolic pressure were found to be 
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significant whereas gender, TNF–α, FEV1 and PO2. And in the overall model in 7, 
the statistic of gender, TNF–α, FEV1, PO2 and TLCO were all found to be non–
significant (Table 3.3.6).  
Coefficients
a
 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
B Std. 
Error 
Beta 
1 (Constant) 3.426 0.748  4.578 <0.001 
Age 0.102 0.013 0.592 7.852 <0.001 
2 (Constant) 4.057 0.836  4.852 <0.001 
Age 0.101 0.013 0.587 7.838 <0.001 
Sex -0.463 0.281 -0.123 -1.645 .103 
3 (Constant) 4.079 0.837  4.875 <0.001 
Age 0.099 0.013 0.576 7.590 <0.001 
Sex -0.494 0.283 -0.132 -1.743 0.084 
TNF 0.036 0.037 0.073 0.958 0.340 
4 (Constant) 0.356 1.124  0.316 0.752 
Age 0.086 0.012 0.500 6.952 <0.001 
Sex -0.448 0.261 -0.119 -1.713 .090 
TNF 0.036 0.034 0.074 1.049 0.297 
Systolic Pressure 0.031 0.007 0.324 4.553 <0.001 
5 (Constant) 0.928 1.187  0.781 0.436 
Age 0.081 0.013 0.471 6.321 <0.001 
Sex -0.512 0.264 -0.137 -1.941 0.055 
TNF 0.040 0.034 0.083 1.179 0.241 
Systolic Pressure 0.032 0.007 0.332 4.674 <0.001 
FEV1 -0.180 0.125 -0.104 -1.439 0.153 
6 (Constant) 0.912 1.389  0.657 0.513 
Age 0.081 0.013 0.471 6.292 <0.001 
Sex -0.514 0.274 -0.137 -1.873 .064 
TNF 0.040 0.035 0.083 1.168 0.245 
Systolic Pressure 0.032 0.007 0.332 4.618 <0.001 
FEV1 -0.182 0.149 -0.105 -1.220 0.225 
PO2 0.003 0.116 0.002 0.022 0.983 
7 (Constant) 1.698 1.445  1.175 .243 
Age 0.071 0.014 .413 5.086 .000 
Sex -0.580 0.274 -.155 -2.116 .037 
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TNF 0.035 0.034 .073 1.029 .306 
SystolicPressure 0.035 0.007 .359 4.931 .000 
FEV1 0.096 0.216 .056 .447 .656 
PO2 -.001 .115 -.001 -.013 .990 
TLCO -.185 .105 -.222 -1.766 .080 
Table 3.3.6: Co-efficient of the multivariate analysis. 
3.3.8 Analyses of Interaction between inflammation & hypoxia variables 
Our data has indicated that there no interaction between inflammation and hypoxia 
to modulate arterial stiffness biologically. 
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3.4 Chapter discussion 
3.4.1 Summary of key findings 
1) At the univariate level, our data showed that:  
a. PWV positively correlated with age, TNF–α, systolic pressure, pulse 
pressure and CO. PWV negatively correlated with FEV1, FEV1 % 
Predicted, FEV1/FVC ratio, total peripheral resistance, TLCO and TLCO % 
predicted. PWV did not correlate with IL–8, IL–1β and PO2. 
b. IL–8 and TNF–α correlated negatively with pack years and total 
peripheral resistance respectively. 
c.  PO2  positively correlated with FEV1, FEV1 % predicted, FEV1/FVC 
ratio, ,FVC, FVC % predicted, TLCO, TLCO % predicted, pulse pressure 
and aortic pulse pressure and PO2 did not correlate with TNF–α, IL–8 and 
IL–1β. 
2) The multivariate linear regression indicated that: 
a.  When age, sex, TNF–α, systolic pressure, FEV1, PO2 and TLCO were 
entered as independent variables, these variables accounted for 49.5 
percent of the variability observed in the dependent variable; PWV.  
b. Age and systolic pressure significantly predict PWV, whereas TNF–α, 
FEV1, PO2 and TLCO did not significantly predict PWV. From the ANOVA 
outcome of the regression, the independent variables that were entered 
into the model (TNF–α, systolic pressure, FEV1, PO2 and TLCO), together 
significantly predict PWV.   
c. From the co-efficient outcome, only age, sex and systolic pressure were 
found to effectively predict PWV. 
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PWV  
Pulse wave pressure refers to the propagation of pressure along arteries and is 
linked to the inherent elasticity of the arterial wall (423). Pulse wave velocity is a 
measure of arterial stiffness and serves as an independent predictor of 
cardiovascular events and mortality (423). Undeniably, cardiovascular complications 
is a main cause of death in several diseases including COPD (409). Among COPD 
patients, it has been shown that arterial stiffness is increased in a greater proportion 
of COPD subjects compared with healthy controls (409). Pulse wave velocity is 
known to be increased in stiffer arteries; a phenomenon known as arterial stiffness. 
This mean the artery wall has reduced capability to expand and contract in response 
to stimuli or changes in pressure (423). The main novel finding from the present 
study is that in alpha1 anti-trypsin deficient patients, pulse wave velocity is 
associated with the inflammatory marker, TNF-α. Similarly, another study has 
revealed a weak link between arterial stiffness and Interleukin–6 and soluble tumour 
necrosis factor receptor 1 (sTNFR1) in patient with COPD (418). However, the same 
study suggested no link between pulse wave velocity and soluble tumour necrosis 
factor receptor 2 (sTNFR2) (418).  Yasmin et al. have also shown that in healthy 
individuals, pulse wave velocity was associated with another inflammatory maker, 
CRP(420). However, we did not observe any association between pulse wave 
velocity and CRP. This might be due to the limited number of subjects with 
completed CRP readings; hence the sample size might not be sufficient to generate 
any statistically significant association. However, we have had more subjects with 
completed reading for TNF–α thus we have observed a significant correlation with 
PWV.  
117 
 
Contrary to our findings and substantive evidence from the literature indicating an 
association between various systemic inflammatory markers and arterial stiffness, 
Lowie and colleagues suggested that arterial stiffness in COPD subjects had no 
association with systemic inflammation (409). This group might have based their 
conclusion on various reasons. Firstly, Lowie et al  (409). suggest that aortic PWV 
did not correlate with CRP, IL–6, IL–8 and sTNFR2 in COPD patients. However, 
aortic PWV did correlate positively with sTNFR1 but this was obliterated after 
controlling for the co-founding factors such as age, mean blood pressure, sex and 
BMI (409). Secondly, most of the evidence in the literature suggesting association 
between arterial stiffness and inflammation has been either conducted in healthy 
controls or other diseases that might not reflect the phenomenon observed in 
subjects with COPD (420, 421). Nonetheless, arterial stiffness was suggested to be 
independently associated with emphysema severity in patients with COPD (228). 
Thirdly, according Lowie et al. a quarter of 213 eligible COPD patients were 
excluded from their investigation due to unsuccessful aortic PWV measurement. 
These patients with unsuccessful aortic PWV measurement were found to have 
significantly elevated BMI, fat free mass index, triglycerides, glucose and diffusion 
capacity of the lung for carbon monoxide (DLCO) compared to those where aortic 
PWV measurements were obtained. Therefore, this might render their results 
inconclusive as far as a COPD population is concerned.  
Regardless of the difference of opinion pertaining to the association between arterial 
stiffness and inflammation, we have established here that TNF–α has a strong 
correlation with arterial stiffness. Also, it can be deduced from our results that arterial 
stiffness is not related to PO2 as this was a key objective question we aimed to 
clarify in this chapter. This has not been demonstrated prior this observation. 
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 Our findings also have demonstrated a strong positive correlation between arterial 
stiffness with haemodynamic measurements such as systolic pressure, pulse 
pressure and cardiac output. This evidence was expected given the known 
relationship between arterial stiffness and cardiac events, such as myocardial 
infarction (MI) (424), and the similar profile observed for blood pressure and MI risk 
(425). An elevation of variables such as cardiac output and pulse pressure will 
certainly increase the blood pressure (as per blood pressure equation: BP= Cardiac 
Output (CO) x Total Peripheral Resistance, and CO= Stroke Volume x Heart rate). 
Hence, an increase in arterial stiffness will directly or indirectly result into increased 
systemic blood pressure physiologically, and we would expect that modulation of 
blood pressure will change arterial stiffness. Consistent with this observation that the 
mechanism of stiffness might be driven by blood pressure, Dudenbostel and Glasser 
(426) on their recently concluded review of antihypertensive trials, suggested that 
ACE inhibitors, calcium channel blockers and mineralocorticoid receptor antagonists 
showed a beneficial effect in reducing arterial stiffness and central blood pressure. 
However, some beta blockers such as atenolol might induce reverse effect (426).  
Moreover, our data has shown a strong negative correlation between arterial 
stiffness and FEV1, FEV1 percent predicted, TLCO and TLCO percent predicted. 
This means that an increase in arterial stiffness could result in a decrease of the 
pulmonary function and blood gas variables stated–above and vice versa. 
PO2 refers to the partial pressure of oxygen and this reflects the capacity of dissolved 
oxygen gas in the blood. In addition, PO2 is a primary measure of the effectiveness 
of the lungs in pulling oxygen into the blood stream from the atmosphere. Our 
findings have shown a strong positive correlation between PO2 and FEV1, FEV1 % 
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predicted, FEV1/FVC ratio, FVC, FVC % predicted, TLCO, TLCO % predicted, pulse 
pressure, aortic pulse pressure.  
In addition, TNF–α and IL–8 showed a strong positive association with total 
peripheral resistance and pack years respectively. However, the inflammatory 
markers did not show any correlation between with PO2. 
Multivariate Regression Analyses 
Moreover, we have performed further investigation of our data by conducting 
multivariate regression. Given the objectives of our investigations, we have carefully 
included among the independent variables, variables that have been shown to be 
associated with PWV from our univariate analyses or the literature (416). Therefore, 
we have included age, gender, TNF–α, FEV1, systolic pressure and TLCO as 
independent variables and PWV as the dependent variable. These six independent 
variables were entered into the multivariate regression model. Evidence from the 
analyses suggest that the independent variables together account for nearly 50% of 
the total variability observed in pulse wave velocity, the dependent variable. In 
addition, our findings have shown that age, sex, TNF–α and systolic pressure 
collectively can significantly predict pulse wave velocity.  
These findings were validated by the ANOVA outcome of the regression analyses. 
The ANOVA of the regression suggested that our model has a significant 
explanatory power to predict the dependent variable. Hence, the co-efficient of the 
independent variables was not zero and thus can predict pulse wave velocity. The 
co-efficient outcome suggests that individually, age, gender and systolic pressure 
can significantly predict pulse wave velocity.  Similarly, previous studies have shown 
age, gender, mean blood pressure to be independently associated with PWV in 
healthy individuals (420) and COPD subjects (409). However, our findings have 
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suggested that TNF–α, PO2, FEV1 and TLCO were not independently associated 
with PWV in patients with alpha-1 anti-trypsin deficiency. This might be due 
difference in population used. 
Alternatively, in another multivariate regression model, this time we replaced an 
independent variable TLCO with total peripheral resistance (data not shown). This 
was done to investigate further how our model might be affected by inclusion of a 
different independent variable. This based on the evidence in the literature 
suggesting an association between peripheral resistance and vascular stiffness 
physiologically.  This model included independent variables such as age, gender, 
TNF–α, FEV1, systolic pressure and total peripheral resistance, was found to 
account for 48.8% of the total variability observed in pulse wave velocity. Again, this 
regression model has shown that age, sex, TNF–α and systolic pressure collectively 
can significantly predict pulse wave velocity. The ANOVA outcome of the multivariate 
regression suggests that our model fit the purpose because all the independent 
variables demonstrated a significant explanatory power to predict PWV. In addition, 
the co-efficients have shown that age and systolic pressure were independently 
associated with PWV in AATD subjects. Further supporting our initial evidence from 
earlier model discussed. However, the independent variables in this latter model 
account for (49%) slightly less of the total variability in PWV compared to former 
model (50%) discussed. This variation might be due to collinearity as lower tolerance 
was observed in the latter model when some of the lung function variables were 
added, though the tolerance and VIF were still within accepted limits. 
Finally, to summarise our findings have shown a correlation between PWV and 
TNF–α in AATD. However, TNF–α is not an independent predictor of PWV, whereas 
age and systolic pressure were.  The findings suggest that arterial stiffness might be 
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related to the inflammatory mediators and that systemic inflammation could 
contribute to arterial stiffening.  Although, in this study, we did not investigate the 
possible mechanism by which inflammation might promote arterial stiffness, some 
studies have indicated that endothelial-derived nitric oxide is essential the regulating 
and modulating the function of systemic artery stiffness in vivo (427, 428). Hence, 
endothelial dysfunction might provide a clue as a potential mechanism linking arterial 
stiffness and inflammation. Further longitudinal studies whilst investigating an array 
of inflammatory mediators might be required to confirm the findings and to establish 
association between inflammation and arterial stiffness.  
3.4.2 Limitation of the investigations included in this chapter 
I. Only three inflammatory mediators where considered and this might not give a 
clear representative influence of systemic inflammation on arterial stiffness.  
II. It was not possible to obtain measurements for all inflammatory mediators the 
whole cohort. Therefore, it was not possible to include some of the 
inflammatory cytokines in the regression model due to missing values. 
III. The number of subjects with completed data points for the measured 
physiological variables also varied between subjects, as some variables had 
missing data points. These ultimately will affect the regression analysis. The 
regression analysis only took into account the completed data sets of the 
variables entered. 
IV. The ELISA kit might not be specific enough to measure the tiny quantity of the 
cytokine found in this serum samples. However, other techniques has there 
down sides too, thus it is well established in literature other group using 
ELISA to quantify cytokine levels in serum samples. 
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Chapter 4  
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4 INFLUENCE OF INFLAMMATION AND CHRONIC HYPOXIA ON 
VASCULAR REACTIVITY AND STIFFNESS OF ISOLATED ILIAC 
ARTERIES 
4.1 Introduction 
An involvement of inflammatory cytokines or mediator in vascular dysfunction is 
widely documented in the literature (125, 429, 430). Tumour necrosis factor alpha 
(TNF–α) and Interleukin–1beta (IL–1β) were suggested to act as a pro-coagulant 
and pro-inflammatory stimulus on the vascular endothelium (376, 431).  The role of 
TNF–α in vascular dysfunction has been discussed extensively in the thesis 
introduction section. See Figure 4.1 for the summary of TNF–α involvement in 
vascular dysfunction and possible mechanisms.  
Moreover, inflammatory mediators were noted be elevated in various disease 
conditions and this increase has been associated with increased oxidative stress that 
might modulate vascular dysfunction (430, 432-435). Inflammatory mediators might 
be contributing to the alteration of the endothelium function through several 
mechanisms. Dresler and Horning (436) have suggested that pro-inflammatory 
cytokines might alter the viability of endothelial nitric oxide synthase (eNOS) mRNA 
(435). In addition, pro-inflammatory cytokines such as IL–1β might cause increased 
production of superoxide anion within the arteries (376, 437), which has a high 
tendency to react rapidly with NO thus generating peroxynitrite (435, 438). The 
reaction of the superoxide anion with NO decreases bioavailability of NO, therefore 
leading to the impairment of the endothelium-dependent relaxation (157). Similarly, it 
was suggested that peroxynitrite might cause nitration of protein tyrosine residues, 
which could limit the function of the enzymes associated with endothelium relaxation 
(435). Elevation of cytokine levels was observed in a variety of cardiovascular 
pathologies like arterial stiffness, hypertension, diabetes, atherosclerosis and sepsis 
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where endothelial dysfunction was suggested to be a key contributor (435). Hence, 
peripheral vascular resistance disorders are common to various cardiovascular 
diseases. Therefore, it is important to investigate contribution of pro-inflammatory 
mediators to analyse effects of cytokines on endothelium dependent vasodilatation in 
systemic arteries (372).  It is widely known that cytokines stimulate vasoconstriction 
and either cause fall or rise of vasoconstrictor responses generated by variety of 
agonists (372). This might depend on the disparity in the local mediators released 
and responsiveness of different vascular beds. Besides, deficiency of endothelium-
dependent relaxation was shown in different vessel types, conduit and resistance 
arteries treated with pro-inflammatory mediators (372).  
 
Figure 4.1: Role of TNF-α in vascular dysfunction. Even though numerous risk factors, such as physical 
inactivity, smoking and over-nutrition, appear to contribute to the development of vascular dysfunction, normal 
aging is also an independent factor in the aetiology of cardiovascular diseases. There is evidence, however, that 
those seemingly diverse processes converge on modulating TNF-α signaling to lead to the generation of 
dysfunctional endothelium and the onset of vascular diseases. TNF-α induces the gene expression of various 
inflammatory cytokines and chemokines, either dependently or independently of the activation of transcriptional 
factors, such as NF-κB and AP-1 (activator protein 1). This TNF-α-mediated signaling initiates and accelerates 
atherogenesis, thrombosis, vascular remodeling, vascular inflammation, endothelium apoptosis, vascular 
oxidative stress and impaired NO bioavailability, which contribute to the blunted vascular function. Dietary 
supplements and exercise favourably reduce the risk of vascular dysfunction by inhibiting TNF-α production 
and (or) TNF-α-mediated signaling. Risk factors in orange those factors that converge on TNF-α to induce 
vascular dysfunction. Factors in green denote those that protect against vascular damage mediated by TNF-α 
expression and signaling. TNF-α-induced pathophysiological conditions related to vascular function are shown 
in blue. Both vascular risk factors and protective factors affect the regulation of vascular functions by 
modulating TNF-α production and downstream signaling. MCP-1, monocyte chemoattractant protein-1; MMP, 
matrix metalloproteinase; TF, tissue factor.  From Zhang et al. (125) 
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On the other hand, findings from exposure of systemic vasculature to chronic 
hypoxia generated conflicting outcome (439). Endothelial NOS expression and NO-
dependent vascular relaxation activity were noted to be elevated in sheep uterine 
arteries and fetal guinea pig hearts due to chronic hypoxia treatment (440, 441). 
Contrastingly, prolonged chronic hypoxia downregulated eNOS protein expression 
and reduced NO-dependent vasodilatation in isolated rat aorta (442). Similarly, CH 
has been linked to the increased vasoconstriction observed in the guniea pig middle 
cerebral arteries and this alteration was due to diminished NO expression (443). 
These contradictory findings might be due to a variety in species, vascular bed or 
different specific characteristic variation between conduit and resistance vessels 
(439).  
Furthermore, the concurrent association of elevated cytokine level and endothelial 
dysfunction with different cardiovascular diseases suggests a potential connection 
between inflammation and cardiovascular pathologies. Similarly, though inconsistent 
findings were reported, chronic hypoxia was suggested to be associated with 
vascular dysfunction and several cardiovascular diseases. Therefore, an 
understanding of the interaction between hypoxia and inflammation might unravel 
mechanism involved in vascular dysfunction.  
The Aims and Objectives from this chapter are to investigate the effects of: 
1. inflammatory mediators on iliac artery vasoconstriction 
2. inflammatory mediators on iliac artery vasodilatation 
3. chronic hypoxia (1 week) plus inflammatory mediators on iliac artery 
vasoconstriction 
4. chronic hypoxia (1 week) ± inflammatory mediators on iliac artery vasodilatation 
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5. inflammation on arterial stiffness of isolated iliac artery segments and finally 
compare the influence of hypoxia and inflammation in both the human study (in 
chapter 3) and animal model used here. 
 
4.2 Methods  
4.2.1 Effects of TNF–α on phenylephrine or thromboxane A2 agonist 
mediated vasoconstriction in isolated rat iliac arteries  
As described in the method section 2.5, isolated iliac artery was mounted on the 
myograph and incubated with TNF–α for 1 hour then the cumulative concentration 
curve vasoconstrictor was constructed. Results displayed in 4.3.1 & 4.3.2. The 
percentage maximum was calculated by dividing each of the individual dose 
responses by the response of the highest does of the vasoconstrictor and multiplied 
by 100. 
4.2.2 Effects of TNF–α on carbachol mediated vasodilatation in isolated 
rat iliac arteries  
In this section iliac vessels were pre-contracted with phenylephrine and then 
cumulative dose-response curve of carbachol was tested. The percentage maximum 
was calculated by dividing each of the individual dose responses of the vasodilator 
by the response of the pretone (vasoconstrictor) and multiplied by 100. The result is 
shown in section 4.3.3. 
4.2.3 Influence of chronic hypoxia ±TNF–α on carbachol mediated endothelium-
dependent vasodilatation in isolated rat iliac arteries 
In this section, animal incubated in chronic hypoxia for 1 week were exposed to 12% 
O2 for week. Then the iliac artery isolated and challenged with the cytokine in vitro. 
127 
 
4.2.4 Influence of TNF–α and anti-oxidants on vasoreactivity and stiffness of isolated 
rat iliac artery segments  
In this section, iliac artery was subject to TNF–α treatment for 6 hour in DMEM. Then 
the vessel was mounted on myograph. We used 6 hour incubation as 1 hour 
incubation with the cytokine did not show any effect. However, after several 
modifications of the protocol, 6 hours showed some changes vasodilatation in 
pulmonary arteries (to be discussed in later chapters) and we were in encouraged to 
follow similar method with the systemic vessel. The vessels were normalised and 
allowed stabilise then high K+ response tested twice. U46619 was then used to 
generate pretone followed by either 1uM CC or SNP. We expressed the vasodilator 
response as percentage of the pretone response. (see results in 4.3.5).  
4.3 Results  
4.3.1 Effects of TNF–α on phenylephrine mediated vasoconstriction in 
isolated rat iliac arteries 
 
Our data from healthy rats did not show any significant difference in the maximum 
percentage of the α–adrenergic agonist mediated vasoconstriction by phenylephrine. 
The average of the percentage of maximum PE vasoconstriction were 
50.35±12.14% (Mean±SEM), 47.78±11.99% and 52.27±12.16% for the Control Prior 
to TNF–α (quality control), Control–TNF–α (time control) and TNF–α treated 
respectively (Figure 4.3.1A, n=6).  
Similarly, there was no significant difference in the ratio of tension to the individual 
iliac artery weight (mN)/mg) generated by PE between the treated vessels and 
controls. The values for control prior to TNF–α, Control–TNF–α and Control+TNF–α 
were 4.264±1.060 (mN/mg), 4.430±1.098 and 4.391±1.010 respectively (Figure 
4.3.1B). 
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Figure 4.2:  Vasoconstriction by phenylephrine prior and post TNF-α treatment in isolated rat iliac arteries. 
The vessels segments were equilibrated and normalised then allowed to be stabilised for 45 minutes. Vessel 
viability was tested with KCL (80mM) and a control cumulative dose-response curves (10-11 – 10-5M) were 
generated for phenylephrine. Then the vessels were incubated with or without TNF-a (1000 U/L) for 1 hour 
then cumulative dose-response curves (10-11 – 10-5M) were generated  for phenylephrine response in IA ± 
TNF-a. Percentage maximum was calculated by taking response as percentage of the maximum PE response. 
The relative tension was generated by dividing individual PE tension by weight of the vessel.  
A) Shows percentage maximum of the PE   and   
B) Shows ratio PE tension by weight of the vessel.   
P > 0.05, n=6 
4.3.2 Effects of TNF–α on thromboxane A2 agonist mediated vasoconstriction in isolated 
rat iliac arteries 
 
Our data from iliac arteries isolated from healthy Wistar rats demonstrate that there 
is no significant difference in the maximum percentage of the thromboxane A2 
agonist mediated vasoconstriction by U46619. The average percentage of maximum 
vasoconstriction for control vessel minus TNF–α was 44.08±12.49 (Mean±SEM) and 
for TNF–α treated vessel was 42.49±12.44 (Figure 4.3.2, n=6).  
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Figure 4.3: Vasoconstriction by thromboxane A2 agonist (U46619) ±TNF-α treatment in isolated rat iliac 
arteries. The vessels segments were equilibrated and normalised then allowed to be stabilised for 45 minutes. 
Vessel viability was tested with KCL (80mM) and the control cumulative dose-response curves (0 – 10mM) 
were generated for U46619. Then the vessels were incubated ± TNF-α (1000 U/L) for 1 hour then a cumulative 
dose-response curves (0 – 10mM) were repeated for U46619 ± TNF- α. Percentage maximum was calculated 
by taking each vasoconstrictor response as percentage of the highest U46619 dose response.   P > 0.05, n=3 
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4.3.3 Effects of TNF–α on carbachol mediated vasodilatation in isolated rat iliac 
arteries 
The cumulative dose response curve of CC demonstrated a typical vasodilator 
response. Control Prior to TNF–α treatment, control without TNF–α and showed a 
maximum vasodilation of 35.10±6.01%, 23.27±7.09%, 28.86±6.04% (Mean ±SEM) 
respectively (Figure 4.3.3A). When the dose response curves were compared using 
one-way ANOVA, the data showed a significant difference between the TNF–α 
treated vessels Vs the quality control and time control (Figure 4.3.3A, p value 
<0.0001, n=7). The post hoc test (Bonferroni) did not indicate any significant 
difference between individual doses used. The results suggest that TNF–α increased 
endothelium-dependent vasodilation of pulmonary arteries isolated from healthy rats. 
In contrast, there was no significant difference in the ratio of tension to the individual 
iliac artery weight [Tension/Weight; (mN)/(mg)] generated by endothelium-dependent 
vasodilator; CC, between the TNF–α treated (4.58±0.58), control prior to TNF–α 
(5.48±0.53) and Control–TNF–α (5.29±0.46) PA segments (Figure 4.3.3B). 
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Figure 4.4:  Shows a cumulative dose-response of vasodilatation mediated by Carbachol prior and post TNF-
α treatment in isolated rat iliac arteries. The vessels segments were equilibrated and normalised then allowed 
to be stabilised for 45 minutes. Vessel viability was tested using KCL (80mM). Then phenylephrine (10
-4
M PE) 
was used to generate a pretone followed by a control cumulative dose-response curves (10
-11
 – 10
-5
M) for 
Carbachol. Then the vessels were incubated with ± TNF-α  (1000 U/L) for 1 hour and subsequently a 
cumulative dose-response curves (10
-11
 – 10
-5
M) were generated  for Carbachol ± TNF-α.   
A) Shows percentage maximum of the U46619 and  
B) Shows ratio U46619 tension by weight of the vessel.  
*** Vs Control Prior & Vs Control -TNF-a        p value< 0.0001, n=7 
 
4.3.4 Influence of chronic hypoxia ±TNF–α on carbachol mediated 
endothelium-dependent vasodilatation in isolated rat iliac arteries 
This preliminary data on chronic hypoxia (CH) rats did not show any significant 
difference in the maximum percentage of the endothelial dependent vasodilation by 
CC (CH prior to TNF–α = 55.15±10.05%, CH–TNF–α=70.23±4.90% and CH+TNF–
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α=62.43±2.82%; Figure 4.3.4C: p value >0.05, n=3). The statistic shows there was 
no significant effect for both chronic hypoxia and acute inflammation on systemic 
vascular endothelial-dependent relaxation. 
The mean tension generated within this experiment did not differ much between the 
treated and control groups CH prior to TNF–α =6.25±0.46 (mN), CH–TNF–α 
=6.96±0.44 (mN) and CH+TNF–α =5.89±0.51 (mN) Figure 4.3.4B) 
Similarly, CH ±TNF–α had no significant difference on the pretone generated by PE 
prior the cumulative dose-response of CC. The mean±SEM of PE generated were 
9.23±0.59(mN), 9.27±1.26(mN), 8.27±0.58(mN) for CH prior to TNF–α, CH –TNF–α 
and CH +TNF–α respectively (Figure 4.3.4A) 
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Figure 4.5: Shows influence of hypoxia ±TNF-α on iliac artery reactivity. Iliac arteries isolated from CH (1 
week at 12% O2) rats and the vessels subjected to TNF-α for 1 hour in vitro. This treatment had no significant 
effect on either constrictor or dilator response by PE and CC respectively. The increase at higher dose in C 
might be due the fact PE acting on the smooth muscle to cause contraction. 
p value > 0.05  n=3           
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4.3.5 Influence of TNF–α and anti-oxidants on vasoreactivity and stiffness of 
isolated rat iliac artery segments  
Iliac arteries isolated from healthy Wistar rats were initially subjected to incubation in 
DMEM ± TNF–α (1000U/L) AND ±Allopurinol (1mM) OR Tempol (1ɥM) for 6 hours. 
Then the vessels were mounted on myograph in a PSS solution (95% air, 5% CO2, 
37oC) and the protocol completed as discussed.  Our results has shown that there 
was no significant difference on the response if high K+ (80mM)  of the control iliac 
vessel segments versus TNF–α alone and versus TNF–α  plus allopurinol OR tempol 
(Figure 4.3.5). In addition, neither TNF–α nor Allopurinol and Tempol had any 
significant effects on thromboxane A2 mediated pretone generated prior to 
vasodilator treatment (Figure 4.3.6).  In addition, TNF–α plus Allopurinol or Tempol 
treatment did not alter CC mediated vasodilatations in isolated iliac artery vessels 
(Figure 4.3.7). Contrastingly, the results have indicated that SNP mediated 
vasodilatations in isolated iliac artery vessels were significantly affected by TNF–α 
and the anti-oxidants (Figure 4.3.8).  
 
From our data, we could deduce that incubation of iliac arteries with TNF–α (for 6 
hours) significantly reduced the internal circumference at 90% distended. This effect 
seems to disappear in the iliac vessels were treated with allopurinol or tempol 
(Figure 4.3.9). However, treatment of iliac arteries with TNF–α plus allopurinol or 
tempol had not altered the iliac artery vessel diameter or circumference (Figure 
4.3.10). Therefore, suggesting that TNF–α had not increase stiffness in systemic iliac 
vessel isolated from rats. 
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Figure 4.6: Shows the response of isolated iliac arteries to 80mM KCL (mN) Challenge. Isolated iliac artery 
vessels were incubated ± TNF-a (1000 U/l) AND/OR ± Allopurinol (1mM) or Tempol (1uM) for 6 hours.  
P value > 0.05 , n = 6  
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Figure 4.7: Vasoconstriction by U46619 post TNF-α treatment in isolated iliac arteries. The vessels segments 
were incubated ± TNF-a with/without Allopurinol (1mM) or Tempol (1uM) for 6 hours.  
P > 0.05, n=6 
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Figure 4.8: Show vasodilatation mediated by CC (1uM) after iliac arteries incubation ± TNF-α, AND/OR ± anti-oxidant for 
6hrs. The bars represent conditions as follows: Blue bar indicates control response after 6hrs; Red bar represents TNF-α 
(1000U/l) response alone after 6hrs; Black bar represents TNF-α (1000U/l) + Allopurinol (1mM) after 6hrs; Light grey bar 
represent TNF-α (1000U/l) + Tempol (1ɥM) after 6hrs. There was no significant difference between any of the categories, 
p value > 0.05, n = 6 
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Figure 4.9: Show vasodilatation mediated by SNP [1uM] post iliac arteries incubation ± TNF-α, AND/OR ± 
anti-oxidant for 6hrs. The bars represent conditions as follows: Blue bar indicates control response after 6hrs; 
Red bar represents TNF-a (1000U/l) response alone after 6hrs; Black bar represents TNF- α  (1000U/l) + 
Allopurinol (1mM) after 6hrs; Light grey bar represent TNF-α (1000U/l) + Tempol (1mM) after 6hrs.  
* Control Vs +TNF- α , TNF-α +Allopurinol and TNF-α +Tempol response, p value < 0.05; n = 6 
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Figure 4.10: Show IC90 of iliac arteries post incubation ± TNF-α, AND/OR ± Allopurinol/Tempol for 6hrs. The 
bars represent conditions as follows: Blue bar indicates control response after 6hrs; Red bar represents TNF-a 
(1000U/l) response alone after 6hrs; Black bar represents TNF-α (1000U/l) + Allopurinol (1mM) after 6hrs and 
Light grey bar represents TNF-α (1000U/l) + Tempol (1mM) after 6hrs. IC90 was derived from the IC100 for 
each category which was then averaged to draw this graph. No significant difference between the control and 
TNF-α treated category, p value < 0.05, n = 6. 
IC90= Internal Circumference of the vessel at 90 percent 
IC100= Internal Circumference of the vessel at 100 percent 
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Figure 4.11: Shows circumference and diameter of Iliac arteries post incubation ± TNF-α, AND/OR ± Allopurinol/Tempol 
for 6hrs. The bars represent conditions as follows: Blue bar indicates control response after 6hrs; Red bar represents TNF-a 
(1000U/l) response alone after 6hrs; Black bar represents TNF-a (1000U/l) + Allopurinol (1mM) after 6hrs and Light grey 
bar represents TNF-a (1000U/l) + Tempol (1ɥM) after 6hrs. IC90 was derived from the IC100 for each treatment category, 
the normalisation values graphed and curve drawn.  
The iliac artery (A) circumference and (B) Diameter were deduced from the equation. There was no significant difference 
between any of the treatment categories. p value > 0.05, n = 6.  
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4.4 Discussion 
 
Contribution of cytokines to the instigation and development of vascular disease is 
widely documented in literature (125, 444-447). This has been extensively discussed 
in the thesis introduction, and to some extent in the introduction of this chapter. 
Elevated levels of inflammatory mediators such as cytokines (e.g IL–6 and TNF–α), 
cell adhesion molecules (e.g soluble ICAM-1) and downstream acute phase 
reactants (e.g CRP), were shown to be associated with increased risk of 
cardiovascular disease (65, 405, 409, 444, 447-450). TNF–α is a primary cytokine 
expressed in injured vasculature and plays multiple roles in regulating the production 
platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), 
fibroblast growth factor, adhesion molecules and other cytokines, and directly 
modulate vascular smooth muscle cell growth and migration. Also, a variety of 
cytokines such as IL–1β, IL–6 and TGF–β contribute to the pathogenesis of specific 
vascular disease (444).  
4.4.1 Summary of the findings 
a) Influence of TNF–α  on vasoconstrictor response on isolated iliac arteries 
Both phenylephrine and U46619 mediated vasoconstriction was not altered by 
TNF–α treatment 
b) Influence of TNF–α   on vasodilator response on isolated iliac arteries 
TNF–α had significantly increased endothelium-dependent vasodilatation 
mediation by CC in iliac arteries. Hence, there was a significant difference 
between the CC-cumulative dose response curves of the TNF–α treated vessel 
compared to the untreated controls (Figure 4.3.3).  
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However, there was no significant difference in the ratio of the tension 
generated to weight of vessel (mN/mg) between the TNF–α treated vessel and 
the controls (Figure 4.3.3). This suggests that TNF–α had not affected the 
specific tension of the systemic vessel. However, measuring the exact weight of 
the tiny vessels was a struggled and values obtained were not consistent. 
Several attempted was made to resolve the matter but it persisted. Therefore, 
we ceased to undertake vessel weight measurement in the latter experiments 
due to inconsistency. 
 
c) Effect of hypoxia & TNF–α on iliac artery reactivity of isolated iliac arteries 
The combination treatment of rats with chronic hypoxia for one week then subject the 
isolated iliac vessel in vitro to TNF–α for an hour, had neither altered endothelium-
dependent vasodilatation mediated by CC, nor did it affect PE pretone generated by 
isolated iliac arteries. Besides, chronic hypoxia and TNF–α did not affect the specific 
tension generated by CC. 
d) Effect of TNF–α  & anti-oxidants on vascular reactivity and stiffness on 
isolated iliac arteries 
The IC90 was significantly altered by TNF–α which has not been reversed by neither 
allopurinol nor tempol treatment. However, the circumference and diameter of the 
isolated arteries were not significantly affected by TNF–α plus Allopurinol or Tempol 
treatment. Stiffness is a measure of the instantaneous slope of the pressure–volume 
relationship (ΔP/ΔV)(382). Due to lack of pressure myograph, we were unable to 
measure arterial stiffness directly. Therefore, we used manual methods to calculate 
the diameter and circumference of the iliac vessel both of which will have an 
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influence on the propagation of pressure and/or volume travelling along a vessel 
segment to provide us glimpse of stiffness.  
Moreover, incubation of iliac arteries with TNF–α plus Allopurinol or Tempol had a 
significant effect on endothelium-independent vasodilatation (Figure 4.3.8). 
However, TNF–α plus Allopurinol or Tempol treatments had no significant effect on 
high K+ and thromboxane A2 agonist responses and endothelium-dependent 
vasodilatation.  
 
4.4.2 Short term TNF – α on iliac arteries 
In this study, a short term incubation of iliac artery segments in TNF–α for 1 hour had 
no significant effect on α-adrenergic mediated vasoconstriction by phenylephrine. 
Similarly, thromboxane A2 agonist mediated vasoconstriction was not affected by 
acute TNF–α treatment in isolated rat iliac artery segments. Previous investigations 
have reported that inflammatory mediators were associated with vascular 
dysfunction (125, 164, 247), therefore, we expected that TNF–α treatment would at 
least increase the vasoconstriction of systemic iliac artery. It is possible that the short 
exposure period of cytokine treatment conducted was not sufficient to alter the 
mechanisms responsible for vascular contraction in this systemic vessel.   
However, in vivo studies of human forearm resistance artery revealed that exposure 
to TNF–α for 1 hour has resulted into increased baseline vascular resistance due to 
elevation of baseline vasoconstrictor prostanoids bioavailability and diminished NO 
bioavailability (373).  Moreover, exposing isolated rat aorta to IL–1β treatment for 1 
hour had increased the vasoconstrictor activity of angiotension II via mechanisms 
that include prostaglandin H2/TxA2 (374).   
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Moreover, incubation of iliac artery pre-contracted with TNF–α for 1 hour caused a 
significant increase of endothelial dependent vasodilation mediated CC compared to 
controls. This has not been shown in iliac artery prior to this observation.  The 
association between inflammatory mediators and vascular dysfunction has been 
widely recognised in the literature. This result confirms that TNF–α might reduce 
endothelial function in systemic iliac arteries isolated from Wistar rats. Similarly, 
Wimalasundera et al. (376) has demonstrated that in mesenteric arteries pre-
contracted with PE, TNF–α caused impairment of acetylcholine mediated 
vasodilatation by significantly shifting the dose-response curve of acetylcholine to the 
right. In addition, TNF–α induced impairment of bradykinin mediated relaxation by 
significantly reducing the concentration-response curve (376). However, TNF–α did 
not affect endothelium-independent vasodilatation mediated by SNP (376). In this 
study we did not look at the SNP mediated vasodilation in iliac artery. However, our 
current results with the endothelium-dependent vasodilation agrees with 
Wimalasundera et al’s (376) observation in systemic arteries. Again, the same group 
(376) showed that in mesenteric arteries pre-constricted with high K+ (80mM), TNF–α 
significantly reduced vasodilatation of acetylcholine but not SNP (376). 
Contrary to our findings, Gillham et al (451), showed that incubation of pre-
constricted systemic omental arteries (isolated from healthy humans) with TNF–α 
(1nM) for 1 or 2 hours had not affected endothelium-dependent vasodilatation 
mediated by bradykinin. However, TNF–α had significantly reduced endothelium-
dependent vasodilatation when NO/prostacyclin or endothelial-derived 
hyperpolarising factor were blocked with L-NNA and indomethacin incubation 
respectively (451).  
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4.4.3 Treatment with chronic hypoxia (1 week) with short term TNF–α 
(in vitro) 
Healthy Wistar rats were exposed to chronic hypoxia (12% O2 for 1 week, in 
normobaric chamber). The systemic iliac vessels isolated from rats were then 
subjected to TNF–α treatment for 1 hour in vitro. TNF–α plus hypoxia exposure did 
not affect high K+ and vasoconstrictor response in iliac artery, suggesting that CH 
had not augmented the cytokine response. The combined hypoxia and TNF–α 
treatment has not been done before in a systemic vasculature such as iliac artery. 
Chronic hypoxia (12% O2 for 1 week) with or without TNF–α (1hour) had not altered 
α–adrenergic mediated pretone by phenylephrine. This suggests that chronic 
hypoxia and acute inflammatory challenge do not influence vasoconstriction in 
isolated iliac artery from rats. There too much variability within the data probably due 
low power of the experiment, hence this was just a preliminary data.  
Furthermore, chronic hypoxia and acute inflammatory challenge had not affected 
endothelium-dependent vasodilatation by CC in iliac arteries isolated from healthy 
Wistar rats. Previous publications on the subject of exposure of systemic vasculature 
to chronic hypoxia generated conflicting outcomes (439). For instance, exposure to 
hypoxia resulted in an elevation of endothelial nitric oxide synthase (eNOS) and 
increased NO-dependent vasodilatory effects in sheep uterine arteries(440) and fetal 
guinea pig hearts (439, 441).  However, exposure to a prolonged hypoxia caused a 
reduction of eNOS expression and NO-dependent vasodilatation in rat aorta (442). 
Similarly, chronic hypoxia has induced increase contractility of the middle cerebral 
arteries due to reduced generation of NO in guinea pigs (452). These varying 
observations reveal the distinct nature of different vascular beds or variation between 
conduit and resistance vessels. Gonzales et al (453) has suggested that following 
chronic hypoxia exposure, resistance mesenteric arteries exhibited blunted vascular 
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reactivity similar to those demonstrated by intact animals. The variability of our 
chronic hypoxia plus or minus acute inflammatory challenge data might be due to 
limited number of animal used for the experiments. Contrary to earlier thought, we 
found that hypoxia and inflammation have no interaction to induce vascular 
endothelium.   
Furthermore, Pro-inflammatory cytokines have the potential to exert a rapid 
vasoactive influence on the blood vessels possibly via the receptors found on the 
endothelium and the smooth muscle cells of the vessel (372). Interestingly, Inversen 
et al.(454) and Van der Poll and lowry et al. (455), have demonstrated the presence 
of receptors for TNF–α and IL–1β on the endothelium and the smooth muscle cells. 
Moreover, it has been shown that increased concentrations of TNF–α, IL–6 and IL–
10 stimulated vasoconstriction in distal human internal mammary arteries (454). The 
vasoconstrictor response was shown to be mediated by endothelin-A (ETA), thus it 
might be endothelium dependent.  Contrary to this finding, TNF–α and/or IL–1β had 
no effect on pre-contracted resistance arteries isolated from human (456). In rat 
skeletal muscle arterioles incubated with IL–1β and IL–6 for 1 hour resulted in 
generation of strong vasodilator response in vivo although it did not produce the 
same effect in vitro (457, 458). 
4.4.4 Prolong exposure to TNF–α on iliac arteries  
Additionally, our findings discovered that incubation of isolated rat iliac arteries in 
DMEM with or without TNF–α AND/OR allopurinol/tempol for 6 hours had not altered 
high K+ and thromboxane A2 agonist response in iliac artery. In addition, the long-
term incubation of iliac arteries with TNF–α plus allopurinol OR tempol had not 
caused any significant alteration of the endothelium-dependent vasodilatation by CC. 
However, TNF–α seemed to affect endothelium-independent vasodilatation mediated 
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by SNP and the effect was not affected by neither allopurinol nor tempol. 
Contrastingly, Jiménez-Altayó et al (435) reported that long-term incubation of 
mesenteric arteries with IL–1β significantly blunted both endothelium-dependent and 
endothelium-independent relaxation mediated by acetylcholine (Ach) and sodium 
nitroprusside (SNP) respectively. In agreement to our data, we have both observed 
impairment of endothelium-independent vasodilatation by SNP. The group also 
observed increased production of superoxide anion (O2−·), nitrite, inducible nitric-
oxide synthase (iNOS) and xanthine oxidase, all of which are known to contribute to 
vascular dysfunction (435). Interestingly, IL–1β treatment of mesenteric arteries had 
not altered expression levels of NOS and soluble guanylate cyclase proteins (435).  
These varying observations might be due divergent properties between conduit and 
resistance arteries or the distinctive features of some vascular beds (439).  
Arterial stiffness has been long considered a significant measure of pulse pressure 
and recently it has been recognised as a determinant of several cardiovascular 
diseases (381). Several epidemiological investigations of morbidity and mortality with 
cardiovascular diseases have led to the emergence of arterial stiffness as an 
independent predictor of cardiovascular risk (381). In this chapter, we had deduced 
arterial stiffness measure from the internal circumference at 90 percent of optimum 
tension of individual vessels from the step-by-step micrometre tension increment to 
derive diameter and circumference of the vessel (protocol explained in 2.5.10). Our 
results have shown that neither TNF–α nor Allopurinol or Tempol had any significant 
effect on IC90, diameter and circumference; hence the stiffness was not altered in 
these setting. Contrary to our observation, previous studies has suggested a link 
between decreased endothelial-dependent production of NO and the elevation of 
arterial stiffness in vivo in the iliac artery of humans and sheep (381, 459, 460). 
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Similarly, McEniery et al (461) has shown endothelin-1 caused increased stiffness in 
common iliac artery. However, this effect was abolished when endothelin-A receptor 
was blocked. The group measured PWV by using the foot-to-foot methodology to 
measure two pressure waveforms simultaneously recorded with a high-fidelity, dual 
pressure-sensing catheter placed in the common iliac artery (461). 
Among the original aim of the present study was, first, to determine the effect of 
short-term and long-term incubation with TNF–α on endothelium-dependent 
relaxation of rat iliac arteries and, second, to analyse the mechanisms involved in the 
effect of TNF–α thoroughly. However, due to predominantly negative data achieved, 
the exact mechanisms underlying the impaired vascular activity in systemic arteries 
remain unresolved and there is no current scientific consensus (125). Therefore, 
further investigation is required to explore the possible role of TNF–α or cytokine 
mediated effects on the systemic vasculature.  
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5 EFFECTS OF INFLAMMATION ON VASCULAR REACTIVITY 
IN ISOLATED PULMONARY ARTERIES: A MODEL FOR 
VASCULAR DISEASES ASSOCIATED WITH COPD? 
5.1  Introduction 
Endothelial dysfunction and inflammation is associated with cardiovascular 
complications in several disease conditions including COPD (52, 372, 435). COPD is 
characterised by chronic airway inflammation, which represents a key component of 
disease development and pathogenesis (3). Studies of bronchoalveolar lavage have 
reported elevated inflammatory cells, such as neutrophils, in sputum from COPD 
patients compared with controls (52). Keatings et al (52) also found significant levels 
of inflammatory cytokines such as interleukin–8 (IL–8) and tumour necrosis factor–
alpha (TNF–α) in sputum from COPD patients compared with healthy smokers and 
non-smoking controls, suggesting these are implicated in COPD (52). Numerous 
other studies have confirmed these findings (6, 53-58), although significant day to 
day variability occurs (58).  
Furthermore, the relationship of pulmonary to systemic inflammation is not yet clear. 
Several studies have reported elevation of various inflammatory markers such as 
TNF–α, IL–8, IL–6 and CRP in the serum (59-61) of patients with stable COPD 
suggesting that inflammation is not confined to the lungs. The level of inflammation 
might be aggravated during exacerbation events in COPD patients thereby 
promoting cardiovascular events (62). This suggests that systemic inflammation 
promotes advancement of cardiovascular diseases(63). In COPD this is thought to 
occur by various mechanisms including endothelial dysfunction (64), arterial stiffness 
(65) and increased platelet activation (66). 
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Previous animal studies have established that inflammatory mediators and hypoxia 
promote endothelial damage causing an imbalance between vasodilator and 
vasoconstrictor intermediaries, thus altering vascular tone (462). These lead to 
increased smooth muscle cell proliferation and vasoconstriction as well as vascular 
remodeling and subsequently result in an increased pulmonary arterial pressure1, 2. 
Progressively, cardiovascular complications occur including pulmonary hypertension 
associated with chronic obstructive pulmonary disease (Figure 5.1).  
IL–8 is also known as CXCL8 is a chemoattractant inflammatory cytokine mainly 
expressed by macrophage, endothelial cells, monocytes and T cells possibly via NF-
κB activity. IL–8 acts through its receptors (IL–8RA & IL–8RB) present on 
neutrophils, T cells and monocytes to induce pro-inflammatory activity, chemotaxis, 
leucocyte arrest and atherogenic activities (444). The first line of the body defence 
mechanism during tissue injury is neutrophil. Infected or injured tissue trigger 
increased expression of IL–8, which then stimulate neutrophils to travel to the injured 
site. IL–8 targets selective IL–8RA and IL–8RB receptors located on the surface of 
neutrophils that cause activation of the receptors leading secretion of variety of 
chemotactic mediators and subsequent local inflammation (463). Therefore, 
neutrophils and IL–8 play a critical role in the initial pro-inflammatory response 
following endothelial damage, which promote the invasion of other inflammatory cells 
such as monocytes, macrophages and T cells in the setting of acute vascular injury 
(463). 
The exact mechanism for the involvement of pro-inflammatory cytokines such as 
TNF–α, IL–1β and IL–8 and other that were found to be elevated in COPD patient in 
the pathogenesis of cardiovascular disease is unknown. However, in systemic 
vessels, it is suggested that TNF-α acts through inhibition of enzymatic activity of 
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eNOS thereby minimising NO production and promote removal of NO by increasing 
NADPH-dependent superoxide production to react with NO to form peroxynitrite 
(125). As a result, TNF–α decreases the bioavailability of NO that could then reduce 
vasodilatation of the vascular smooth muscle cell (125). Thereby causing imbalance 
of between vasoconstrictors and vasodilator that potentially could be damaging to 
the endothelium. This will mostly tilt the favour towards increased vasoconstrictor 
activities, which if prolonged could result in increased blood pressure and 
subsequently hypertension.  
 
Figure 5.1: Shows diagrammatic representation of the mechanism of inflammation on vascular diseases. 
Cigarette smoke components or inflammation damages endothelial cells and causes endothelial dysfunction. 
This results in imbalance between vasoactive and growth factors that promote proliferation of SMC. Hypoxia, 
inflammation, and shear stress amplify and perpetuate these effects, further contributing to the development 
of pulmonary hypertension. Inflammatory mediators promote vascular endothelial damage which alters 
vascular tone. (Adapted and modified from (429).   
 
eNOS= endothelial-derived nitric oxide,  
PGIS= prostaglandin I2 Synthase  
HIF= Hypoxia-induced factor 1  
VEGF= Vascular endothelial growth factor 
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5.1.1 The aims of the investigations in this chapter are: 
1) To investigate effects of TNF–α  on phenylephrine mediated vasoconstriction in 
PA 
2) To investigate effect of  TNF–α and IL–8 on thromboxane A2 agonist, U46619 
mediated vasoconstriction in PA 
3) To investigate effects of TNF–α and IL–8 on CC and SNP mediated 
vasodilatation in PA 
We hypothesised that TNF–α and IL–8 contributes to pulmonary vascular endothelial 
dysfunction which impairs mechanisms that effect vasodilatation. 
5.2 Method  
.In these set of experiments, Wistar rats (as described in 2.5.2) were euthanized by 
overdose of anaesthesia with cervical dislocation. Pulmonary artery vessels were 
isolated cleared from any adventive tissue and then cut into small segment (~2mm in 
length). The myograph was normalised and vessels were allowed to stabilise for 
about three quarter of an hour (2.5.6).   
A cumulative dose response of a vasoconstrictor phenylephrine (PE) or U46691 
(U46) or a pretone generated by PE or U46 (EC80 ) followed by a cumulative dose 
response of a vasodilator   CC, SNP. Then a pro-inflammatory cytokine  TNF-α or IL-
8 or IL-1β (1000U/ml, 50ng/ml, 20 or 50ng/ml respectively) added for 1 hour and 
vasoconstrictor or dilator response re-assessed. 
5.2.1  Effect of TNF-α on Phenylephrine on vasoconstriction of rat 
pulmonary artery 
In the following experiments, pulmonary arteries from healthy Wistar rats were 
exposed to phenylephrine (PE) with or without TNF-α to investigate the effects of 
inflammation on vasoconstriction.  The results are presented as a percentage of 
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maximum PE response (%Max of PE) to determine sensitivity and relative tension to 
compare potency of specific tension (mN tension/mg vessel wet weight). We have 
compared three conditions;  
a) PE response prior to TNF-α treatment (Control prior to TNF–α),  
b) PE response after TNF-α treatment, without TNF-α for 1 hour (–TNF–α, Time 
Control) 
c) PE response after TNF-α treatment, with TNF-α for 1 hour (+TNF–α, treated) 
The vessels were subjected to an increasing concentration of PE until the dose-
response curve plateau. The tension generated (mN) was used to calculate 
percentage maximum (% Max) by dividing the each tension by the maximum tension 
(after subtracting baseline values) and multiplying by 100. The percentage maximum 
of PE was plotted against individual PE concentration (expressed as –[Log]M) and 
specific tension (mN/mg) was used to compare drug potency. As discussed in the 
previous chapter (4.2.1), we achieved inconsistent data with vessel weighing which 
remained unresolved. Therefore we only completed this protocol for only the early 
studies conducted and later ceased weight the vessels due to inconsistency.   
5.2.2  Effects of TNF–α on U46619–mediated Vasoconstriction of Rat 
Pulmonary Artery 
The pulmonary vessels were subjected to an increasing dose concentration of 
U46619 (20–1000nM) until the dose-response curve plateau. The tension generated 
(mN) were used to calculate percentage maximum (% Max) by dividing the each 
tension by the maximum tension (after subtracting baseline values) and multiplying 
by 100. The percentage maximum of U46619 was plotted against individual U46619 
dose concentration in the myograph chamber. (see results in section 5.3.2). 
153 
 
5.2.3  Effects of TNF–α on Vasodilatation Mediated by Carbachol in Rat 
PA  
In the following experiments, isolated rat PA vessels were exposed to cumulative 
doses of carbachol (CC; a stable analogue of acetylcholine) to investigate their 
vasodilatation and effect of TNF–α on the response. Subsequent to inducing 
vasoconstriction by PE [at EC80 = 300nM (3*10-7m)], the vessels were treated with 
increasing CC doses. Figure 5.3.3, represents vasodilator response ±TNF–α.  After 
normalising for baseline, the tension generated by individual doses of CC was 
divided by the maximum tension generated by PE pretone and multiplied by 100 to 
calculate percentage maximum response (%Max) then plotted the %Max against CC 
concentration (-[Log]M). See section 5.3.3 for the results. The EC80 quoted above 
was the PE pretone used for all isolated PA vessels throughout this thesis. 
5.2.4  Effects of IL–8 on vasodilatation mediated by Carbachol in rat PA  
Result from this section, isolated rat PA vessels were exposed to cumulative doses 
of carbachol (CC; a stable analogue of acetylcholine) to investigate their 
vasodilatation and effect of interleukin–8 (IL–8) on the response. Subsequent to 
inducing pre-contraction with U46619 (400nM), the vessels were treated with 
increasing CC doses. We used U46619 instead of PE as the latter was shown to 
generate inconsistent results as described in chapter 2 (section 2.5.7). Figure 5.3.4, 
represents vasodilator response ±IL–8.  After normalising for baseline, the tension 
generated by individual doses of CC was divided by the maximum tension generated 
by U46619 and multiplied by 100 to calculate percentage maximum response 
(%Max) then plotted as %Max versus Log of CC concentrations (-[Log]M). See 
section 5.3.4 for the results.  
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5.2.5  Effects of IL–8 on vasodilatation mediated by SNP in rat PA 
In this section, isolated rat PA vessels were exposed to cumulative doses of Sodium 
Nitroprusside (SNP) to investigate influence of interleukin–8 (IL–8) on endothelium-
independent vasodilatation of pulmonary arteries. In PA vessels, pretone was 
generated with U46619 (400nM) which was followed by cumulative dose of SNP 
addition to generate a dose dependent curve. Figure 5.3.5, represents vasodilator 
response ±IL–8.  After normalising for baseline, the tension generated by individual 
doses of CC was divided by the maximum tension generated by U46619 and 
multiplied by 100 to calculate percentage maximum response (%Max) then plotted 
as %Max against CC concentration (-[Log]M).  
5.2.6 Effects of 2 or 6 hours TNF-α treatment on pulmonary artery 
vascular responses 
In the following experiments, isolated rat PA vessels were first incubated in DMEM 
medium with or without TNF–α for 2 or 6 hours. The vessels were then mounted on 
the myograph. The TNF–α treated and untreated pulmonary vessel segments in the 
myograph were then subjected to high K+ (80mM) to check pulmonary vessels 
viability. This was followed with pretone generation by U46619 (400nM) that was 
then exposed to cumulative doses of either CC or SNP to effect relaxation. This was 
done to investigate the short-term and prolonged effects of TNF–α on vasodilatation 
response as well as on KCL and pretone (U46619) responses. The results for short-
term and long-term exposure to TNF–α treatment are shown in sections 5.3.6 and 
5.3.7 respectively. 
5.2.7 Influence of anti-oxidant on TNF–α mediated reduction of 
relaxation in PA 
In these set of experiments, isolated rat PA vessels were first incubated in DMEM 
medium in four catergories: Control, Control+TNF–α, TNF–α+allopurinol and TNF–
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α+tempol, in a normoxic chamber (95% O2, 5% CO2, 37
0C) for 6 hours. The vessels 
were then mounted on the myograph and normalised (PSS, 95% air, 5% CO2, 37
0C). 
The TNF–α treated and untreated pulmonary vessels in the myograph were then 
subjected to KCL (80mM) to check viability of the vessels. This was followed with 
pretone generation by U46619 (400nM) that was then exposed to cumulative doses 
CC or SNP mediated relaxation. The percentage maximum of CC or SNP 
vasodilatation was calculated for the control, control+TNF–α, TNF–α+allopurinol and 
TNF–α+tempol and their cumulative dose response curve were constructed. This 
was done to investigate influence of antioxidants on TNF–α mediated inhibition of 
CC or SNP–mediated vasodilatation.  
5.2.8 Statistic 
GraphPad (Prism 5) was used for analysis and plotting graphs. KaleidaGraph and 
Prism 5 were used to calculate EC50 of agonists. We used two-way ANOVA or One-
way ANOVA depending on the number of the groups to be compared.  At times, t-
test (unpaired) has been used. The statistical tests were followed by Bonferroni's 
multiple comparison post hoc tests. Significance was taken at p value ≤ 0.05. 
5.3 Results 
 
5.3.1 Effect of TNF-α on Phenylephrine on vasoconstriction of rat 
pulmonary artery 
PAs were activated at lower PE doses and continue to increase gradually until it 
reached maximum at -[Log] M=7.5; equivalent to 30nM, at where the dose-response 
curves began to decline. There was no significant different in the dose-response 
curve of PE between the TNF-α treated and untreated controls (Figure 5.3.1, p> 
0.05). From Figure 5.3.1, we have shown that there was a significant difference in 
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the relative tension of PE–mediated vasoconstriction between TNF–α treated and 
untreated control (p value < 0.05). Though there was a significant difference in the 
relative tension (tension due to agonist/weight of vessel (mN/mg)) of PE–mediated 
vasoconstriction, we have not included the results as the data appear to be 
inconsistent due to difficulty measuring the weight of tiny pulmonary artery 
segments. 
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Figure 5.2 :  Vasoconstriction by phenylephrine (PE) prior and post TNF-α treatment in isolated rat 
pulmonary arteries. The vessels segments were equilibrated and normalised then allowed to be stabilised 
for 45 minutes. Vessel viability was tested with high K
+
 (80mM) and the control cumulative dose-response 
curves (10
-11
 – 10
-5
M) were generated for PE. Then the vessels were incubated with or without TNF-α (1000 
U/L) for 1 hour and then cumulative dose-response curves (10
-11
 – 10
-5
M) for PE response repeated in PA ± 
TNF-α. Percentage maximum was calculated by taking each PE dose response as percentage of the 
maximum PE response. Higher dose of PE might be acting on cause relaxation in PA. p > 0.05, n=6. 
 
5.3.2 Effect of TNF-α on U46619 vasoconstriction of rat pulmonary 
artery 
U46619 activated vasoconstriction of pulmonary arteries at lower doses and 
continued to increase with increasing of the dose until the response plateau at 
1000nM (of U46). Our findings have shown that in all vessels regardless of the 
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treatment conditions, responded similarly to the U46619 exposure. Hence, there was 
no significant different in the dose-response curve of U46619 between the TNF–α 
treated and untreated control pulmonary arteries as well as between control PA prior 
to TNF–α treatment and control PA without TNF–α (Figure 5.3.2 p value > 0.05).  
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Figure 5.3:  Vasoconstriction by thromboxane A2 agonist (U46619) prior and post TNF-α treatment in 
isolated rat pulmonary arteries. The vessels segments were equilibrated and normalised then allowed to be 
stabilised for 45 minutes. Vessel viability was tested with KCL (80mM) and the control cumulative dose-
response curves (20 -1000nM) were generated for U46619. Then the vessels were incubated ± TNF-α (1000 
U/L) for 1 hour then a cumulative dose-response curves (20 -1000nM) were repeated for U46619 ± TNF-a. 
Percentage maximum was calculated by taking response as percentage of the maximum U46619 response. 
The relative tension was generated by dividing individual U46619 tension by weight of the vessel segment. p 
value > 0.05,  n =6 
 
5.3.3 Effects of TNF-α on vasodilatation mediated by Carbachol in rat PA  
As cumulative CC concentrations mediated vasodilatation of PA vessels from all the 
conditions as they all demonstrated graded relaxation. At the highest dose applied 
they were both reduced by more than 40%. There was a significance difference in 
CC–mediated vasodilatation in PA between the control prior to TNF–α addition, 
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compared to time control without TNF–α (p value < 0.05), as well between the 
control prior to TNF–α treatment and TNF–α treated (p value < 0.05). However, there 
was no significant difference between the TNF–α treated and time control without 
TNF–α (p value > 0.05) (Fig. 5.3.3).  
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Figure 5.4:  Shows a cumulative dose-response of vasodilatation mediated by Carbachol prior and post TNF-
α treatment in isolated rat pulmonary arteries. The vessels segments were equilibrated and normalised then 
allowed to be stabilised for 45 minutes. Vessel viability was tested with high K
+
 (80mM). Then 
phenylephrine (3*10
-7
M equivalent to 300nM) was used to generate a pretone followed by a control 
cumulative dose-response curves (10
-11
 – 10
-5
M) for Carbachol. Then the vessels were incubated ± TNF-α 
(1000 U/L) for 1 hour and subsequently cumulative dose-response curves (10
-11
 – 10
-5
M) were repeated for 
Carbachol ±TNF-α.  
*  Control Prior TNF-α Vs Time control and TNF-α treated, p < 0.05, n=7 
TNF-α treated Vs Time control, p > 0.05, n=7 
 
5.3.4 Effects of IL –8 on vasodilatation mediated by Carbachol in rat PA  
As cumulative CC concentrations mediated vasodilatation of PA vessels from both 
the IL–8 treated and untreated conditions as they both induced gradual 
vasoconstriction. However, the vessels were not greatly relaxed even at highest 
dose applied, both relaxed by just about 30%. IL–8 had no significant effect on the 
46991 pretone and KCL responses. Our results showed that there was a significance 
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difference in CC–mediated vasodilatation in PA between the IL–8 treated compared 
to control without IL–8 (p value < 0.05) (Fig. 5.3.4).  
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Figure 5.5:  Shows a cumulative dose-response of vasodilatation mediated by CC post IL-8 treatment in 
isolated rat pulmonary arteries. The vessels segments were equilibrated and normalised then allowed to be 
stabilised for 45 minutes. Vessel viability was tested with high K
+
 (80mM). Then the vessels were incubated ±IL-
8 (50nM) for 1 hour and subsequently U46619 (400nM) was used to generate a pretone followed by a 
cumulative dose-response curves (10
-11
–10
-5
M) for CC ±IL-8. Percentage maximum was calculated by taking 
individual CC dose responses as percentage of the U46619 pretone. The log of the CC-mediated vasodilatation 
expressed as % maximum of U46619 plotted against the log of the [CC]M.  
*Control vs IL-8 treated, p < 0.05, n=11  
5.3.5 Effects of IL–8 on vasodilatation mediated by SNP in rat PA 
In this section, isolated rat PA vessels were exposed to cumulative doses of Sodium 
Nitroprusside (SNP) to investigate influence of interleukin–8 (IL–8) on endothelium-
independent vasodilatation of pulmonary arteries. In PA vessels, pretone was 
generated with U46619 (400nM) which was followed by cumulative dose of SNP 
addition to generate a dose dependent curve. Figure 5.3.5, represents vasodilator 
response ±IL–8.  After normalising for baseline, the tension generated by individual 
doses of CC was divided by the maximum tension generated by U46619 and 
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multiplied by 100 to calculate percentage maximum response (%Max) then plotted 
as %Max against CC concentration (-[Log]M).  
As cumulative SNP concentrations mediated vasodilatation of PA vessels from both 
the IL–8 treated and untreated conditions as they both demonstrated gradual 
vasoconstriction. At highest dose applied, in both conditions were relaxed by 50–55 
%.  
We have observed a significance difference in SNP–mediated vasodilatation in PA 
between the IL–8 treated compared to control without IL–8 (p value < 0.05) (Figure 
5.3.5). Again, IL–8 had no significant effect on the U46619 pretone and KCL 
responses. 
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Figure 5.6:  Shows a cumulative dose-response of vasodilatation mediated by SNP post IL-8 treatment in 
isolated rat pulmonary arteries. The vessels segments were equilibrated and normalised then allowed to be 
stabilised for 45 minutes. Vessel viability was tested with high K
+
 (80mM). Then the vessels were incubated ±IL-
8 (50nM) for 1 hour and subsequently U46619 (400nM) was used to generate a pretone followed by a 
cumulative dose-response curves (10
-11
–10
-5
M) for SNP ±IL-8. Percentage maximum was calculated by taking 
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individual SNP dose responses as percentage of the U46619 pretone. The log of the SNP-mediated 
vasodilatation expressed as % maximum of U46619 plotted against the log of the [SNP]M.  
*** Control vs IL-8 treated, p <0.0001, n=8 
 
 
5.3.6 Effects of 2 hours TNF-α treatment on pulmonary artery vascular responses 
In Figure 5.3.6 A & B, there was no significant effect of TNF-α on KCL response 
and the U46619 generated pretone (p value > 0.05). Our finding indicated that, there 
was a significant difference in both CC and SNP mediated vasodilatation (Figure 
5.3.6 C & D). However, There was no significant difference in EC50 dose for both 
CC and SNP regardless of whether the vessels were treated with TNF-α or not 
(Figure 5.3.6 E & F). 
 
5.3.7 Effects of 6 hours TNF-α treatment on pulmonary artery vascular 
responses 
In Figure 5.3.7 A & B, there was no significant effect of TNF-α on KCL response 
and the U46619 generated pretone (p value > 0.05). Our finding indicated that, there 
was a significant difference in both CC and SNP mediated vasodilatation (Figure 
5.3.7 C & D). Though, there was no significant difference in EC50 dose for both CC 
and SNP regardless of whether the vessels were treated with TNF-α or not (Figure 
5.3.7 E & F). 
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Figure 5.7: Shows cumulative dose-responses of CC or SNP-mediated vasodilatation post TNF-α treatments 
in isolated rat pulmonary arteries. The isolated vessels segments were first incubated in DMEM medium ± 
TNF-α (1000 U/L) for 2 hours then mounted on the myograph. The myograph was equilibrated and normalised 
and the vessels were allowed to be stabilised for 45 minutes. Vessel viability was tested with high K
+
 (80mM). 
Then U46619 (400nM) was used to generate a pretone followed by a cumulative dose-response curves (10
-11 
– 
10
-5
M) for CC and SNP (± TNF-α). Percentage maximum was calculated by taking CC or SNP response as 
percentage of the U46619 pretone.  
A) High K
+
(80mM) response (mN)                                  p  >0.05, n=10  
B) Pretone generated by U46619 (400nM) (mN)        p >0.05, n=10                              
C) Shows percentage maximum of CC-mediated vasodilatation       p < 0.05*, n=10 
D) Shows percentage maximum of SNP-mediated vasodilatation    p < 0.05*, n=10 
E) Log EC50 of CC ±TNF-α, 2hours            p >0.05, n=10 
F) Log EC50 of SNP ±TNF-α, 2hours         p >0.05, n=10 
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Figure 5.8:  Shows a cumulative dose-response of vasodilatation mediated by CC or SNP post TNF-α treatments in 
isolated rat pulmonary arteries. The isolated vessels segments were incubated in DMEM medium ± TNF-α (1000 U/L) for 6 
hours then mounted on the myograph. The myograph was equilibrated and normalised and the vessels were allowed to be 
stabilised for 45 minutes. Vessel viability was tested with high K
+
 (80mM). Then U46991 (400nM) was used to generate a 
pretone followed by a cumulative dose-response curves (10
-11
 – 10
-5
M) for CC and SNP (± TNF-α, 6hours). Percentage 
maximum was calculated by taking CC or SNP response as percentage of the U46991 pretone. Prism 5 was used to analyse 
the data and to plot graphs while KaleidaGraph was used to calculate the EC50 of the agonists. 
A) High K
+
 (80mM) response (mN)                                      p > 0.05, n=7 
B) Pretone generated by U46991 (400nM) (mN)     p > 0.05, n=7 
C) Shows percentage maximum of CC mediated vasodilatation      p < 0.05, n=7 
D) Shows percentage maximum of SNP mediated vasodilatation   p < 0.05, n=7 
E) Log EC50 of CC ±TNF-α, 6hours            p > 0.05, n=7 
F) Log EC50 of SNP ±TNF-α, 6hours         p > 0.05, n=7 
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5.3.8  Influence of anti-oxidant on TNF–α reduction of relaxation in PA 
5.3.8.1 TNF–α ± Allupurinol or Tempol  did not affect  constrictor responses 
in PA 
Our results had shown that treatment of pulmonary artery with TNF–α alone, TNF–α 
± Allupurinol OR Tempol had no significant difference between the treated groups 
and control on the KCL reponse (80mM). In addition, there was significant effect on 
the pretone generated by U46619 (Figure 5.3.8 A & B). This indicates that neither 
TNF–α, nor antioxidant treatment significantly affected constrictor response in 
pulmonary arteries. 
165 
 
0
1
2
3
4
TNF- - +
DMEM 6hr 6hr
+ +
6hr6hr
TEMPOL
Allu - -- +
- -- +
H
ig
h
 K
+
 8
0
m
M
 (
m
N
)
0.0
0.5
1.0
1.5
2.0
2.5
TNF- - +
DMEM 6hr 6hr
+ +
6hr6hr
TEMPOL
Allu - -- +
- -- +
P
re
to
n
e
 U
4
6
6
1
9
 (
m
N
)
Control
TNF-  +6H
TNF-  +Allo (1M)
TNF-  +Tempol (1mM)
A
B
Figure 5.9:  Shows vasoconstriction of PA incubated with TNF-α in DMEM for 6 hours. The isolated vessels 
segments were first incubated in DMEM medium ± TNF-α (1000 U/L) AND ± allupurinol OR tempol for 6 
hours then mounted on the myograph. High K+ response tested then U46619 pretone generated.  
A) High K
+
 (80mM) response (mN)  
B) U46619 Pretone (mN)        p > 0.05, n=6  
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5.3.8.2  Allopurinol reversed TNF–α reduction of CC–mediated relaxation in 
PA 
Statistical test indicated that there was a significant difference between control group 
and TNF–α treated group as well as TNF–α+tempol category. However, there was 
no significance difference between the control category and TNF–α+allopurinol 
group. In addition, there was a significant difference between TNF–α treated group 
versus TNF–α+allopurinol category.  The results suggest that treatment PA with 
TNF–α for 6 hours, again, significantly blunted CC–mediated vasodilatation. 
Incubation of PA with TNF–α+tempol did not alter the effect of TNF–α whereas TNF–
α+allopurinol treatment completely reversed the effect of TNF–α on the pulmonary 
vessel (Figure 5.3.9). 
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Figure 5.10:  Shows a cumulative dose-response of vasodilatation mediated by CC post PA incubation with 
TNF-α plus allopurinol or tempol  in DMEM for 6 hours. The isolated vessels segments were first incubated in 
DMEM medium ± TNF-α (1000 U/L) AND allopurinol (1mM) OR tempol (1mM) for 6 hours then mounted on 
the myograph. The myograph was equilibrated and normalised and the vessels were allowed to be stabilised 
for 45 minutes. Vessel viability was tested with KCL (80mM). Then U46619 (400nM) was used to generate a 
pretone followed by a cumulative dose-response curves (10
-11
 – 10
-5
M) for CC (of all treatment groups). 
Percentage maximum was calculated by taking CC dose responses as percentage of the U46619 pretone.         
*** Control Vs TNF-α treated, p <0.0001, n=6 
*Control Vs TNF-α+Tempol, p > 0.05, n=6   
 TNF-α +allopurinol Vs TNF-α treated, p > 0.05, n=6   
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5.3.8.3 Allopurinol & Tempol did not alter TNF–α reduction of SNP–mediated 
relaxation in PA 
In these set of results, isolated rat PA vessels were first incubated in DMEM medium 
±TNF–α AND allopurinol OR tempol for 6 hours. We used the same protocol as 
explained in the last section (5.3.8.2). This was done to investigate influence of 
antioxidants on TNF–α mediated inhibition of SNP–mediated vasodilatation. 
The statistical analyses we have applied, suggest that there were significant 
differences between the control compared to the TNF–α, TNF–α+allopurinol and 
TNF–α+tempol treated groups. Besides, there was no difference between the treated 
groups when compared to each other. These results indicated that incubation of PA 
with TNF–α plus allopurinol OR tempol had not altered TNF–α–mediated inhibition of 
pulmonary relaxation by SNP (Figure 5.3.10). 
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Figure 5.11: Shows cumulative dose-response of vasodilatation mediated by SNP post PA incubation with 
TNF-α plus allopurinol or tempol  in DMEM for 6 hours. The isolated vessels segments were first incubated in 
DMEM medium ± TNF-α (1000 U/L) AND allopurinol (1mM) OR tempol (1mM) for 6 hours then mounted on 
the myograph. The myograph was equilibrated and normalised and the vessels were allowed to be stabilised 
for 45 minutes. Vessel viability was tested with KCL (80mM). Then U46619 (400nM) was used to generate a 
pretone followed by a cumulative dose-response curves (10
-11
 – 10
-5
M) for SNP (of all treatment groups). 
Percentage maximum was calculated by taking SNP dose responses as percentage of the U46619 pretone.         
* Control Vs TNF-α treated, TNF-α +allopurinol and TNF-α+tempol, p > 0.05, n=4   
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5.4  Chapter discussion 
5.4.1 Summary of key findings 
1. Effects treatment with TNF–α OR IL–8  (1 hour) on vasoconstriction of 
pulmonary arteries isolated from healthy Wistar rats: 
TNF-α treatment (for 1 hour) had no significant effect on phenylephrine and 
U46619 mediated vasoconstriction of pulmonary arteries. 
2. Effects treatment with TNF–α or IL–8  (1 hour) on vasodilatation of pulmonary 
arteries isolated from healthy Wistar rats: 
a) TNF-α (1hour) treatment on CC-mediated vasodilatation had no   
significant effect on CC–mediated vasodilatation in PA compared to the 
time control without TNF–α (p value > 0.05). 
b) IL–8 treatment (for 1 hour) of isolated PAs had a significant difference 
CC–mediated vasodilatation (p-value = 0.0043). 
c) IL–8 treatment (for 1 hour) of isolated PAs had a significant difference on 
SNP–mediated vasodilatation. 
3. Effects of pre-incubation of isolated healthy pulmonary arteries  in DMEM ±TNF-
α for 2 hours 
a) TNF–α significantly reduced both CC and SNP mediated vasodilatation 
isolated PAs, however, had no effect on the EC50 obtained. 
b) TNF–α did not affect the vasoconstrictor responses by KCL & U46619  
4. Effects of pre-incubation of isolated healthy pulmonary arteries  in DMEM ±TNF-
α for 6 hours 
a) Prolonged TNF–α incubation of isolated PAs significantly reduced CC 
and SNP mediated vasodilatation. Again TNF–α had no effect on the 
EC50s. 
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b) TNF-α did not affect the vasoconstrictor responses of KCL and U46619 
 
5. Effects of pre-incubation of isolated healthy pulmonary arteries  in DMEM 
±TNF–α ± Allopurinol OR Tempol for 6 hours 
a) Allopurinol completely reversed TNF–α inhibition of CC–mediated 
relaxation in pulmonary artery. 
b) Tempol did not significantly affect TNF–α inhibition of CC–mediated 
relaxation in pulmonary artery. 
c) Neither Allopurinol, nor Tempol had any significant effect on TNF–α 
inhibition of SNP–mediated relaxation in pulmonary artery 
d) Neither Allopurinol, nor Tempol had any significant effect on the 
pulmonary artery vasoconstrictor response by KCL and U46619. 
5.5 Discussion 
 
The endothelium is regarded as the functional barrier that is located between the 
blood vessel and the blood stream (125, 233, 367, 372, 429). Endothelial cells are 
known to play various functions within the vasculature ranging from fibrinolysis, 
coagulation, maintenance of vascular tone to growth and immune response (125). In 
a healthy vascular environment, these functions are regulated via several factors 
including endothelium dependent relaxing factor, endothelium-dependent contracting 
factor and endothelium-dependent hyperpolarizing factor. When these factors fail to 
regulate the vascular function, it could lead to vascular endothelial dysfunction which 
is associated with a plethora of diseases including COPD and atherosclerosis (125). 
Inflammation and endothelial dysfunction contribute to the pathogenesis and 
development of pulmonary hypertension (42, 125, 233, 367, 372, 445-447). In COPD 
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patients increased level of various cytokines were discovered in both the serum and 
the sputum (52, 68, 464) and was discussed in chapter 1. The presence of these 
cytokines was associated with increased arterial stiffness and poor disease 
prognosis (447, 449, 450). The mechanism for this link between inflammation and 
endothelial dysfunction and subsequently right heart failure is not clearly known, and 
therefore, we used animal models in an attempt to further elucidate part of this 
association. 
   
In this chapter, the effects of the vasoconstrictor; phenylephrine (an α-1 receptor 
agonist) and vasodilator; Carbachol (a cholinomimetic drug that binds and activates 
the acetylcholine receptor) on the vascular reactivity of pulmonary vessels freshly 
isolated from healthy Wistar rats was investigated. In addition, the effects of 
inflammatory cytokines such as TNF–α and IL–8 on the PE and CC responses were 
assessed.  
  
It has been shown that two major excitation-contraction coupling mechanisms 
contribute in regulating pulmonary vascular tone. Hence, in this chapter, we have 
addressed agonist-mediated pulmonary contraction (pharmacomechanical coupling 
induced by PE and CC) and depolarisation-mediated contraction (electromechanical 
coupling induced by high potassium solution) (465). 
In this chapter, the results obtained for pulmonary artery sensitivity to phenylephrine 
were similar to previous studies (465-467). Our results demonstrated that there is no 
significant difference between the sensitivity of acute (1 hour) TNF–α treated and 
untreated pulmonary arteries to phenylephrine vasoconstrictor. The effect of TNF–α 
on pulmonary artery vasoconstriction mediated by phenylephrine has not been 
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previously reported in the literature. The other studies that have investigated similar 
protocol were focused on vasodilatation (435, 451). Therefore, we have established 
here that short TNF–α challenge does not significantly affect α–1 receptor agonist 
response. Similarly, our findings also indicated that short term challenge of TNF–α 
on pulmonary artery did not significantly affect thromboxane A2 agonist response. 
There was no significant different in vasoconstriction mediated by U46619 between 
TNF–α treated and controls.  
This finding might be physiologically relevant given that, when blood vessels 
constrict, the flow of blood is restricted or decreased, thus, retaining body heat and 
increasing vascular resistance. Therefore, if TNF–α treatment results into increased 
vasoconstriction in pulmonary arteries, this will caused localised decline in blood flow 
that might subsequently diminish oxygen to the tissues. Thus the observed lack of 
significant of short term TNF–α treatment on vasoconstrictor response of pulmonary 
artery certainly conform to vascular physiology.  
 
Moreover, PAs treated with TNF–α and untreated controls showed a similar 
sensitivity to endothelial-dependent NO release. Our findings suggest that there was 
a significant difference between TNF–α treated PAs compared to Control PAs prior 
to TNF–α treatment. This observation might suggest that TNF–α influenced 
endothelial–dependent vasodilatation mediated by CC in PA. However, when we 
compared control groups, control PA prior to TNF–α and control PA without TNF–α, 
there was a significant difference between them even though both control were 
without the influence of TNF–α activity. One of the controls was used as a quality 
control and the other as time–control for the treatment group, hence, it was not 
anticipated to observe any significance or variation between the two controls. This 
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might suggest that the earlier supposed effect of TNF–α observed is due another 
factor. Hence, the difference might be due to time delay factors AND/OR TNF –α, 
which might be explained by the fact that this was the earliest result obtained when 
operator was still learning the techniques. In addition, there was no significant 
difference between TNF–α treated PAs and time–control PAs samples without TNF–
α, though pulmonary vascular vasodilatation was reduced in TNF–α treated vessels. 
This observation further strengthens the view that the effect observed in this 
particular case might not be due to TNF–α alone. Therefore, we are not going to 
merely conclude the effect of TNF–α on endothelial–dependent vasodilatation 
mediated by CC, based on the current observation alone, as further investigation is 
required to verify the findings. 
Similarly, a previous studies have shown that TNF–α incubation did not affect 
endothelial–dependent relaxation in omental arteries, a systemic small arteries 
obtained from healthy pregnant women (451). However, when the capacity for 
vasodilatation is halted then TNF–α incubation promote endothelial damage (451). 
 
Since we were not able to confirm the effect of TNF–α on endothelial–dependent 
relaxation of PAs, we decided to investigate the effect of another inflammatory 
mediator, IL–8 on pulmonary vascular reactivity. The PAs presented similar in vitro 
sensitivity to endothelial NO release. Our findings have shown that IL–8 significantly 
affected vasodilatation of PAs. However, the observation is contrary to our 
hypothesis as we expected IL–8 to blunt the NO mediated relaxation in PA 
compared the control without IL–8. Interestingly we have observed increased 
vasodilatation in PAs treated with IL–8 compared to control. Additional investigation 
might be required to ascertain this phenomenal manifestation. In addition, we have 
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investigated effects of IL–8 on endothelial-independent vasodilatation mediated by 
sodium nitroprusside. Our findings have demonstrated a significant reduction in 
endothelial–independent vasodilatation in IL–8 treated vessels compared to the 
control. This is a novel finding and has not shown in the literature previously.   
 
Furthermore, we have extended PA incubation in TNF–α to two hours, to investigate 
whether this might augment the effect observed in one hour incubation in the same 
cytokine. Interestingly, unlike in the 1 hour treatment, two hours TNF–α incubation of 
pulmonary artery segments, has significantly diminished both endothelial–dependent 
and endothelial–independent vasodilatation mediated by CC and SNP respectively. 
This means that both endothelial and smooth muscle cell mediated relaxations were 
altered by the incubation of PAs in TNF–α for two hours. Similarly, an extend 
incubation of PAs in TNF–α for 6 hours has further attenuated both endothelial–
dependent and endothelial–independent vasodilatation mediated by CC and SNP 
respectively. The long term incubation period of PAs in TNF–α has almost doubled 
the difference between the TNF–α treated vessel and untreated ones.  
 
Though the extended and long term incubation of PA segments in TNF–α (for 2 and 
6 hours respectively) has altered vasodilatation in healthy pulmonary vasculature, 
the same treatments had no significant effect on neither the U46619; thromboxane 
A2 agonist response nor on the KCL response, hence, vasoconstriction or 
contraction of PAs was not altered by TNF–α treatment. In addition, both 2 and 6 
hour TNF–α treatment had not caused a significant change in pEC50 of both CC and 
SNP mediated vasodilatations. 
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From this chapter, we have established that inflammatory mediators such as TNF–α 
predominantly reduced both endothelial–dependent and endothelial–independent 
vasodilatation in pulmonary arteries. Interestingly, this is the first time, to report such 
an observation in this sort of protocol in PA. From the literature, is known that 
inflammation can be triggered by infection, trauma, hypoxia at times immunological 
processes (372) and research evidence has suggested a strong association between 
inflammation and the risk of developing cardiovascular diseases (367, 369, 371).  
Cytokines mainly interact together in synergy to initiate of the inflammatory cascade 
that triggers expression of intermediary factors (369). Hence, cytokines has the 
ability to express cytokine receptors and other cytokines and chemokines to promote 
the inflammatory cascade. Besides, inflammatory mediators can trigger the 
expression of various enzymes, like the inducible NO synthase (iNOS) and 
cyclooxygenase–2 (COX–2). The induction of these enzymes can lead to the 
production of mediators that can act at the vascular bed which can promote 
inflammatory response (372).  
Several lines of indirect evidence suggest that, in COPD patients, vascular changes 
result from endothelial dysfunction and NO insufficiency. First, endothelium–
dependent vasodilatation is impaired in patients with COPD (468). Second, inhibition 
of NO synthase potentiates the vasoconstrictor effect of hypoxia (469), suggesting 
that NO serves to prevent excessive hypoxic vasoconstriction, which has been linked 
to the pathogenesis of cor pulmonale in COPD (470). Third, structural changes in 
pulmonary arteries of patients with COPD resemble those observed in response to 
endothelial denudation and vascular injury, i.e., after angioplasty (471).  
We have shown that thromboxane A2 agonist (U46619) pre-constricted PAs derived 
from healthy Wister rats have demonstrated both agonist–mediated endothelial–
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dependent and endothelial–independent vasodilatation. This observed relaxation 
was mediated by NO and potentially EDHF–dependent pathways. This observation 
is normal to be expected in healthy animals, because the rats will ensure vascular 
relaxation is optimum thus will utilise all available mechanisms (451). When the 
pulmonary arteries were pre–incubated with TNF–α for either 2 or 6 hours, there was 
a significant change in the overall profile of both the endothelial–dependent and 
endothelial–independent relaxation.  
In the same way, Hughes et al (376), has shown that TNF–α pre-incubation caused 
inhibition of both acetylcholine and bradykinin mediated relaxation in rat mesenteric 
arteries. However, their results showed that TNF–α treatment did not alter non-
endothelial dependent relaxation by SNP in rat mesenteric arteries (376). In addition, 
Gillham et al (451)., has shown that TNF–α incubation for 1 hour caused no 
alteration to the endothelial–dependent vasodilation in omental arteries obtained 
from healthy pregnant women. Our current study revealed a similar observation as 
reported earlier in this chapter. 
In contrast, a similar study protocol reported no changes in endothelial–dependent 
vasodilatation profile in healthy omental arteries incubated with TNF–α  for 2 hours 
(451), though they did not test the long term (6 hours) incubation period adopted in 
our study. The difference might be due to the fact that vessels obtained from rats 
and human do display diverse endothelial responses to TNF–α   treatment even 
under similar condition. 
Hughes et al (376) has also shown that the endothelial–independent vasodilation 
(mediated by NO donor; sodium nitroprusside) of the mesenteric arteries was not 
affected after incubation with TNF–α. This is contrary to the observation we have 
revealed in this study as both 2 and 6 hour incubation of pulmonary arteries with 
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TNF–α   had a significant reduction on vascular relaxation. It may be that systemic 
and pulmonary vessels isolated from rats might exhibit different endothelial 
sensitivities to TNF–α. Hughes and colleagues suggested that the attenuation of the 
endothelial–dependent vasodilatation observed with acetylcholine and bradykinin 
might be as consequence of TNF–α lowering the synthesis or release of NO from the 
endothelial cells (376, 451). We assume that this suggestion might also apply to our 
investigations reported in this chapter on rat pulmonary arteries. Our results showed 
a greater proportion of pulmonary vascular relaxation was not affected by TNF–α 
incubation thus allowing normal vascular relaxation. However, other pathways that 
effect relaxation in the vasculature such as EDHF might be play a role in maintaining 
both the endothelial–dependent and independent vasodilatation of vessels incubated 
with TNF–α (451).  Therefore, this issue might be addressed with the usage of EDHF 
pharmacological inhibitors.  
These data support the hypothesis that TNF–α might worsen pre-existing endothelial 
dysfunction as well as in intact pulmonary vessels. This is due to the observation 
cytokine affected both endothelial and non–endothelial mediated vasodilatation 
which suggest that plasma TNF–α level could trigger endothelial dysfunction. Future 
studies should focus on identifying the mechanisms by which TNF–α exert its 
inhibitory effect on the pulmonary vascular relaxation.   
Investigating the mechanism of TNF–α inhibition of vasodilatation in pulmonary 
arteries, we have used Allopurinol; a xanthine oxidase inhibitor and Tempol; a 
membrane–permeable radical scavenger. Interestingly, Allopurinol has completely 
reversed TNF–α inhibition of CC–mediated relaxation in pulmonary artery, though 
Tempol did not significantly affect TNF–α inhibition of CC–mediated relaxation in 
pulmonary artery.  
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A meta-analysis conducted by Kanbay et al (472). on endothelial function  suggested 
that Allopurinol had significantly increased endothelium–dependent vasodilatation in 
human subjects. All the studies included in this study assessed effect of allopurinol 
on endothelial–dependent which was evaluated using  flow–mediated dilatation 
(FMD) and forearm blood flow (FBF) response to acetylcholine or flow-dependent 
flow assessment (472). In contrast, Kanbay and colleagues (472) indicated that 
Allopurinol has no significant effect on the endothelium–independent vasodilation 
mediated by SNP. Interestingly, our current findings though from different species 
and set-up, demonstrated a similar observation. 
The result suggests that TNF–α inhibition of CC–mediated relaxation in pulmonary 
artery was via Xanthine Oxidase pathways. Xanthine Oxidase is a form of Xanthine 
oxidoreductase; an enzyme that generates reactive oxygen species. The enzyme 
can catalyze the oxidation of hypoxanthine to xanthin (473) .  Aslo, it can further 
catalyze the oxidation of xanthine to uric acid (473). XO was shown to be elevated in 
the epithelial lining fluid of COPD patients compared to healthy controls (434). It was 
suggested that XO activity is mainly regulated by its gene expression (434). Another 
study has indicated that pro-inflammatory cytokines; TNF–α, IL–1β and IFT–γ 
significantly stimulated XOR gene expression in rat alveolar macrophages (474), 
bovine renal epithelial cells (475) and human mammary epithelial cells (476). In 
addition, Wright et al.(477) has shown that infusion of IL–1 and IFT–γ in a rat model, 
resulted into elevation XO activity in the lungs. Considering these evidence, it 
appears that pro-inflammatory cytokines might play a significant role in enhancement 
of the XO gene expression in COPD airways (434). Furthermore, Komaki et al (434), 
found a strong positive association between the levels of TNF–α or IL–1β and XO 
activity, hence, an added evidence for the proposition.  
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On the other hand, neither Allopurinol, nor Tempol significantly affected TNF–α 
inhibition of SNP–mediated endothelial–independent relaxation in pulmonary artery. 
Moreover, like TNF–α, Allopurinol and Tempol had no effect on the pulmonary 
vasoconstrictor responses mediated by U46619 and KCL.  
Our data have shown that inflammation might negatively affect No mediated vascular 
relaxation in pulmonary artery isolated from healthy rats. This finding once verified 
could open probable or potential therapeutic target for treatment of pulmonary 
hypertension associated with COPD. It might be possible to further investigate NO 
compared to non-NO mediated effects on vessels and investigate whether specific 
manipulation of NO or cGMP signal transduction system might be beneficial in 
patients with COPD. Further experiments would need to test the contribution of NO 
by comparing NO donor responses with those of endothelium-derived NO release, 
and blockade of NOS activity.  
5.5.1 Limitation of the study 
The limitation of myography was discussed in earlier chapters. The same applies in 
this chapter. Temperatures of the individual myograph chambers are controlled 
collectively, but we noticed that not all chambers were heated at the same rate and 
sometimes a slight difference in the bath temperature was observed between 
chambers. Different vessels types, vasoconstrictors, vasodilators and cytokines were 
therefore randomly selected to be mounted on various myograph chambers to avoid 
any predisposition. In addition, the chambers were allowed to reach optimum 
temperature (370C) before any protocol was started and the equipment was 
calibrated frequently to maintain consistency of the data generated.  This limitation 
did not seem to affect data generated, as the results were consistent for individual 
vessels types.  
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 When TNF-α or IL–8 was used to treat the pulmonary vessels, this does not mean 
that the inflammatory mediator remained in the myograph bath throughout the 
protocol. The vessel was incubated with the inflammatory mediator either on the 
myograph bath for 1 hour or in petri dish in DMEM for 2 or 6 hour in normoxic 
chambers (then mounted on the myograph). In addition, the saline solution in the 
myograph does get replaced with fresh warm solution regularly between different 
stages of the protocol as the vessels get washed. This process might cause the 
vessels to become desensitised from the effect of the inflammatory mediator, though 
we have not noticed any major different between treated and untreated vessels due 
to this activity. We have ensured to keep our protocols short as possible to ensure 
this has not become an issue for our experiment.  
There is a chance of mechanical damage to the pulmonary arteries during the 
dissection and isolation process, however, careful proven steps reported in past 
literature was applied to ensure the vessel integrity was maintained and damage to 
the isolated vessels minimised or prevented (249, 393, 478, 479). In addition, high 
K+ challenge was performed to check vessel viability and only PA vessel that 
generated 1mN or more were used for the experiments.  
The values obtained for weighing individual PA vessels segments post completion of 
the experimental protocol were not consistent. At times, no reading was obtained 
and even when obtained sometimes it does not look to be the right value. Hence, it 
was difficult getting reliable weight value for the tiny PA vessel segments used in this 
experiment. We have used alternative weight machines the same issue persisted 
and reliable data could not be achieved. Therefore, we have excluded these data 
from the analyses due to inconsistence and unpredictable weight values obtained. 
Also, the vessel weight measurement was not conducted for latter experiments.  
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CHAPTER 6   
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6 INFLUENCE OF CHRONIC AND/OR ACUTE HYPOXIA AND PRO-
INFLAMMATORY CYTOKINES ON PULMONARY VASCULAR 
REACTIVITY  
 
6.1   Introduction 
Chronic exposure to alveolar hypoxia is known to cause to constriction in pulmonary 
arteries. Prolong exposure to hypoxia can cause luminal narrowing of the pulmonary 
vasculature which progressively results in increased pulmonary arterial pressure, as 
a consequence of both structural remodeling of the pulmonary vasculature and 
sustained active vasoconstriction of pulmonary arterial smooth muscle (205, 480, 
481). Oka et al. (240) have shown that exposure to simulated high altitude (17 000 ft) 
for 3–4 weeks  significantly induced right ventricular hypertrophy which has 
increased the right ventricular (RV) ratio over the left ventricular plus septum (LV+S) 
ratio from 0.32 to 0.58 in low altitude and chronic hypoxic rats respectively (240) . In 
addition, high altitude resulted in elevation of Ppa from 19mmHg to 41 mmHg (240, 
468). Intravenous infusion of acetylcholine in patient with COPD stimulated a rapid 
decline of mean Ppa from 31 mmHg to 28 mmHg, as well as breathing in NO, 
caused reduction in Ppa in a concentration–dependent manner (468).  
Chronic hypoxia is known as a common trigger for development of clinical pulmonary 
hypertension (482). Prior to causing structural and functional vascular reactivity 
damage, chronic hypoxia was suggested to promote various inflammatory  
challenges specific to the pulmonary vasculature that included perivascular 
inflammatory cell infiltration and elevation of the expression of various inflammatory 
mediators, such as cytokines, chemokines and differentiation factors (482, 483). In 
addition, hypoxia stimulated increase of adhesion molecules such as intercellular 
adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1. These 
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adhesion molecules perform a critical role in mononuclear cell recruitment under 
hypoxia in lung tissue (482, 483). Madjdpour et al (484) has reported elevated level 
of macrophages in the bronchoalveolar fluid of rats exposed to 10% oxygen for a 
period between 1 and 8 hours as well increased mRNA levels of TNF-α, macrophage 
inflammatory protein (MIP)-1β, and monocyte chemoattractant protein (MCP)-1 
within the intial 2 hours of being in the hypoxic environment (484). In addition, they 
have showed increased mRNA levels of hypoxia-inducible factor (HIF)-1α and ICAM-
1 between 1 and 6h. The mechanism of chronic hypoxia interaction with 
inflammation is not well defined. Hence, further investigations are required to 
elucidate the mechanism underlying the observed association.  
Moderate physiological hypoxia (~20–60 mmHg PO2) is known to cause constriction 
in pulmonary arteries, whilst leading to vasodilatation in systemic arteries and this 
observation is commonly referred as to hypoxic pulmonary vasoconstriction (HPV) 
(205, 249, 485). This physiological difference between the pulmonary and systemic 
circulations plays an important role within the body. HPV is crucial for the regulation 
and maintenance of the ventilation–perfusion ratio in the event of localised hypoxia 
(485). On the other hand, global hypoxia in disease conditions might cause a 
damaging effect of elevated total pulmonary vascular resistance and thus increase 
load on the right side of the heart (249, 485). It is credible that both local hypoxia and 
global hypoxia might play key role at various stages in chronic lung diseases such as 
COPD (486). The role of inflammation on vascular dysfunction has been extensively 
covered in the previous chapters. Inflammation was found to be associated with 
COPD as well cardiovascular event associated the disease pathogenesis (233, 429, 
487, 488).  In addition, both hypoxia and inflammation were recognised as possible 
culprits in promoting vascular dysfunction associated with COPD (233, 486, 487). 
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Endothelial dysfunction is a key feature of PH and this might be detrimental to the 
pulmonary vascular tone due to reduced vasodilator mediators and anti-proliferative 
factors (488). These coupled with increased vasoconstrictors and proliferative factors 
in long term could promote cardiovascular complications.  
Therefore, it is useful to investigate how inflammation might influence HPV in order 
to identify probable mechanisms that might be utilised in future therapeutic 
development.  
We have previously discussed the influence of inflammation alone on pulmonary 
vascular reactivity (see Chapter 5). In this chapter, we will be investigating the 
combined effects of hypoxia and inflammation together on vascular reactivity. 
 
The aims of the investigations in this chapter are summarised below: 
a) Effects of chronic hypoxia (1 or 2 weeks at 12% oxygen)  and inflammation  
i. To investigate effects of chronic hypoxia AND TNF–α OR IL–8  on 
pulmonary artery vasoconstriction mediated by phenylephrine or 
U46619 thromboxane A2 agonist in PA 
ii. To investigate effect of  chronic hypoxia AND TNF–α OR IL–8 on CC 
and SNP mediated vasodilatation in PA 
b)  Effects of chronic hypoxia (2 weeks) on cytokine expression in rat 
i. Quantify level of inflammatory mediator in the bronchoalveolar lavage 
of hypoxic rats 
ii. Identify possible link between elevated pro-inflammatory mediator and 
chronic hypoxia 
c) Effects of acute inflammation on HPV 
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Investigate influence of TNF–α (1 hour) on HPV phase 1 & 2 
d) Effects of concurrent short term hypoxia AND inflammation (1 hour) on 
vascular reactivity  
i. Investigate effects of hypoxia AND TNF–α (1 hour) in vitro treatment on 
vasoconstriction mediated by U46619. 
ii. Investigate effects of hypoxia AND TNF–α (1 hour) in vitro treatment on 
both endothelium-dependent and endothelium-independent 
vasodilatation mediated by CC and SNP respectively. 
 
We hypothesised that hypoxia (short term OR long term) plus TNF-α AND/OR IL–8 
will promote pulmonary vascular endothelial dysfunction which impairs mechanisms 
modulating vasodilatation as well as impact on vasoconstriction. 
 
6.2 Methods 
6.2.1 Animal, treatments, tissue isolation, preparation, drug & cytokine treatment 
for myograph 
Detailed description provided in chapter 2. Male Wistar rats (~250–300g) were 
exposed to 12% O2 for  either 1 or 2 week(s). Upon the completion of this protocol, 
rats were killed by an overdose of anaesthesia with cervical dislocation, as approved 
by the UK Home Office. Immediately after death, the chest cavity was opened, the 
lungs were dissected then placed in ice-cold Krebs solution (393).   
Pulmonary arteries were dissected, isolate and mounted on myograph in a PSS 
solution (95% air, 5% CO2, 37
oC) (355, 393). The vessel was allowed to equilibrate  
for 45 minutes then treated with a pretone generated by PE or U46 (using EC80 from 
the cumulative dose response curve of the vasoconstrictor followed) by a cumulative 
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dose response of a vasodilator   CC, SNP. Then a pro-inflammatory cytokine  TNF-α 
or IL-8 (1000U/ml, 50ng/ml respectively) added for 1 hour and vasoconstrictor or 
dilator response re-assessed.  
6.2.2 HPV & TNF–α  treatment 
Healthy Wister rats (~250 – 300g) were anaesthetised with sodium pentobarbitone 
(55 mg kg−1, intraperitoneal injection) and killed by cervical dislocation (355). PA 
vessels was isolated and mounted on myograph in a PSS solution (95% N2, 5% 
CO2, 37
oC) (355, 393). High K+ response tested. Prostaglandin F2α (3 – 7ɥM)  (393, 
479, 489) used to generate pretone then control HPV generated twice before the 
vessels were treated with TNF–α  for 1 hour. Then the HPV challenge was repeated 
to test hypoxia treatement effects. We used the second control HPV generated and 
HPV post TNF-α to assess effects of the inflammatory challenge.  HPV phase 1 and 
2 were taken as percentage of the high K+ response (see results 6.3.5).  
6.2.3 Concurrent Short term hypoxia AND TNF–α  treatment  
Helathy Wister rats were killed by an overdose of anaesthesia with cervical 
dislocation. PA vessels was isolated and moutnted on myograph in a PSS solution 
(95% air, 5% CO2, 37
oC). High K+ response tested. Then vessel incubated with 
TNF–α in PSS solution (95% N2, 5% CO2, 37
oC) for 1 hour. Then vasodilator CC and 
SNP were tested. Responses were plotted as percentage of the U46619 pretone 
(see results in 6.3.6).  
6.3 Results 
6.3.1 Chronic Hypoxia Induced RV Hypertrophy in Rats 
In three categories of rats, there was a significant difference in the right ventricle 
ratio to left ventricle plus septum ratio between the healthy controls and chronic 
hypoxia exposed rats for 1 and 2 week(s) (Figure 6.3.1, p value < 0.001). Also there 
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was a significant difference in the right ventricle ratio to left ventricle plus septum 
ratio between the chronic hypoxia exposed rats for 1 week and two weeks 
accordingly (Figure 6.3.1, p value < 0.01). This suggests that chronic hypoxia 
induced right ventricular hypertrophy in rats which is augmented by the longer 
duration the animal remained in the hypoxic environment. 
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Figure 6.1: Shows effects of chronic hypoxia on right ventricular hypertrophy. Rats were divided into three 
groups: healthy controls, chronic hypoxia for 1 week and chronic hypoxia 2 weeks. The hypoxia groups were 
subjected to fixed 12% oxygen for either 1 or 2 week(s) whereas healthy control remained at room air.  
* Vs Control  
φ Vs CH 1 Week 
 CH =chronic hypoxia, RV= right ventricular, LV+S= left ventricular + Septum 
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6.3.2 Influence of Chronic Hypoxia for 1 Week (IL–8 for 1hr) on Isolated 
PA Vasoconstriction and Vasodilatation 
Exposing rats to chronic hypoxia (CH) for 1 week followed by treatment with or 
without IL–8 for 1 hour (±IL–8, 1hr) in the myograph chamber did not cause any 
significant difference in the thromboxane A2 agonist generated pretone. This implies 
that IL–8 had no significant effect on the U46619 mediated vasoconstriction in rats 
subjected to chronic hypoxia for 1 week (Figure 6.3.2, p value > 0.05).    
Our results showed that CH for 1 week ±IL–8 (for 1hr) did not significantly affect CC–
mediated endothelial vasodilatation in rats (Figure 6.3.3 A & B, p value >0.05). In 
addition, it has been shown that neither CH treatment for 1 week nor IL–8 exposure 
for 1 hour in vitro, had any significant effect on the SNP–mediated endothelial 
independent vasodilatation in rats (Figure 6.3.4 A & B, p value > 0.05).  
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Figure 6.2: Demonstrates influence of hypoxia (1 week at 12% O2) ±IL–8.  Rats exposed to hypoxia (12%) for 1 week. PA 
vessels were isolated and mounted on myograph then subjected to IL-8 treatment for 1 hour and pretone was generated 
with U46619 (400nM). IL-8 and hypoxia had no significant effect on the pretone, p value >0.05; n=6. 
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Figure 6.3: Shows effects of CH ±IL–8 on CC-mediated vasodilatation in isolated PAs.  Rats exposed to hypoxia 
(12% O2) for 1 week. PA vessels were isolated and mounted on myograph and then subjected to IL-8 treatment 
for 1 hour and pretone was generated with U46619 (400nM) followed by CC-mediated vasodilation. CC dose 
responses taken as percentage of the pretone. CH1=chronic hypoxia for 1 week. 
A) Shows absolute tension by CC-mediated vasodilatation  
B) Shows CC-mediated vasodilatation (as %Max of pretone, U46619)            p value >0.05, n=6. 
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Figure 6.4: Shows effects of CH ±IL–8 on SNP-mediated vasodilatation in isolated PAs. Rats exposed to 
hypoxia (12% O2) for 1 week. PA vessels were isolated and mounted on myograph and then subjected to IL-8 
treatment for 1 hour and pretone was generated with U46619 (400nM) followed by CC-mediated vasodilation. 
CC dose responses taken as percentage of the pretone. CH1=chronic hypoxia for 1 week. 
A) Shows absolute tension by SNP-mediated vasodilatation  
B) Shows SNP-mediated vasodilatation (as %Max of pretone, U46619)  p value >0.05;  n=6 
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6.3.3 Influence of Chronic Hypoxia for 2 Weeks (± TNF-α or IL-8 for 1hr) 
on Isolated PA Vasoconstriction and Vasodilatation 
 
We have also exposed rats to 12% oxygen for 2 weeks then rats euthanized and 
pulmonary arteries isolated and mounted on myograph. Our results showed that CH 
treatment for 2 week ±TNF–α  exposure for 2 hours  did not significantly affect CC–
mediated endothelial vasodilatation in rats (Figure 6.3.5, p value >0.05). Also, our 
data has shown that neither CH treatment for 2 weeks nor ±TNF–α exposure for 1 
hour in vitro, had any significant effect on the SNP–mediated endothelial 
independent vasodilatation in rats (Figure 6.3.6, p value > 0.05). We have also 
shown ±TNF–α did not alter KCL or U46619 mediated vasoconstrictions in 2 weeks 
CH exposed rats (Figure not shown).  
11 10 9 8.5 8 7.5 7 6.5 6 5.5 5
40
60
80
100
CH2 -TNF- (6)
CH2 +TNF- (6)
- Log [CC] M
%
 p
re
to
n
e
 (
U
4
6
6
1
9
)
 
Figure 6.5: Shows CC-mediated vasodilatation in rats exposed to chronic hypoxia (2 weeks) ± TNF-a (in vitro). 
Rats were exposed to hypoxia (12% O2) for 2 weeks. PA vessels were isolated and mounted on myograph and 
then subjected to IL-8 treatment for 1 hour and pretone was generated with U46619 (400nM) followed by CC-
mediated vasodilation. CC dose responses taken as percentage of the pretone. Neither CH nor TNF-α had any 
significant effect on vasodilatation. CH2=chronic hypoxia for 2 weeks. 
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Figure 6.6: Shows SNP-mediated vasodilatation in rats exposed to chronic hypoxia (2 weeks) ± TNF-α (in 
vitro). Rats were exposed to hypoxia (12% O2) for 2 weeks. PA vessels were isolated and mounted on 
myograph and then subjected to IL-8 treatment for 1 hour and pretone was generated with U46619 (400nM) 
followed by CC-mediated vasodilation. CC dose responses taken as percentage of the pretone. Neither CH nor 
TNF-α had any significant effect on vasodilatation. CH2=chronic hypoxia for 2 weeks.  
 
6.3.4 Influence of Chronic Hypoxia on Cytokine Profile of 
Bronchoalveolar Lavage in Rats 
In another experimental set up, 12 rats were divided into two groups of 6. One group 
were placed in a hypoxic chamber set at 12% oxygen for two weeks and the other 
remained at room air for two weeks. AT the end of the week, the rats were 
euthanized by overdose of Euthatal® (pentobarbital sodium, 200 mg ml-1, Merial 
Animal Health Ltd), and bronchoalveolar lavage collected. Then assayed to quantify 
cytokine level levels and compare the control with hypoxia treated animals detailed 
in the methods (section 2.3).  The results have shown that chronic hypoxia 
significantly down regulated the level of expression of cytokines such as CINC –1, 
CINC–2ab, sICAM–1, LIX, L–Selectin and Thymus (Figure 6.3.7A, B & C)  
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Figure 6.7: Shows influence of hypoxia on rat cytokine/chemokine (x29). Rats were exposed to hypoxia (12% 
O2) for 2 weeks then euthanized with overdose of sodium pentobarbital. Bronchoalveolar lavage collected 
from the rats and Proteome Profiler Rat Cytokine Array Kit, Panel A (that measure level 29 different cytokine 
antibodies) was used to quantify level of cytokines and chemokines. Hypoxia significantly down regulated 
CINC –1, CINC–2ab, sICAM–1, LIX, L–Selectin and Thymus. p value < 0.01, n=6 
CH=chronic hypoxia for 2 weeks. 
 
6.3.5 Effects of Acute TNF–α Treatment on HPV of Isolated PAs 
Incubation of PA with TNF–α for 1 hour  did not alter the raw tension (mN) generated 
in HPV phase 1 and 2 as there was no significant difference between the control and 
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the treated vessels (Figure 6.3.8A).  Similarly, the results have shown that treatment 
with TNF–α has not caused any significant effect on the HPV phase 1, though 
constriction in the TNF–α treated vessel was less. Similarly the same vein, there was 
no significant different in HPV phase 2 vasodilatation observed between TNF–α 
treated and controls (Figure 6.3.8B). 
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Figure 6.8 A&B: Shows the influence of acute TNF-α treatment on hypoxic pulmonary vasoconstriction. 
Isolated rats PAs were mounted on two channel myograph. High K
+
 response performed and then HPV 
generated twice prior to TNF-α exposure for 1 hour (one chamber) and the HPV repeated (TNF-α treated & 
control). HPV phase 1 and 2 were expressed as percentage of the high K
+
 (80mM) for both the control and 
TNF-α treated.  
A) Sample Raw trace of HPV 
B) Shows raw tension of HPV phase 1 and 2 ±TNF- α,  p values >0.05 
C) Shows HPV phase 1 and 2 ±TNF-α,      p value >0.05 
 
6.3.6 Effects of Concurrent Hypoxia ± Acute TNF-α Treatment on Isolated 
PAs in Vitro 
Myograph mounted PA vessels isolated from healthy control rats were subjected to 
hypoxia (95% N2, 5% CO2, 37oC) plus TNF –α at the same time for 1 hour. This 
treatment had no effect on the pretone generated (Figure 6.3.9A). However, hypoxia 
plus TNF–α together had significant effect on both endothelium-dependent and 
endothelium-independent vasodilatations mediated by CC and SNP respectively 
(Figure 6.3.9B & C).  
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Figure 6.9 A-C: Shows concurrent effects of hypoxia AND TNF–α on isolated rat PAs (in vitro). PAs were 
mounted on myograph. High K
+
 (80mM)  response tested.  Vessels exposed to hypoxia (95% N2, 5% CO2, 37
o
C) 
plus or minus TNF-α for 1 hour simultaneously then U46619 pretone and cumulative dose response curve 
generated for CC and SNP for hypoxia ±TNF-α.   
A) U46619-mediated vasoconstriction expressed as percentage of high K
+
 (p value > 0.05, CC n=7, SNP n=6) 
B) CC mediated vasodilatation expressed as percentage of U46619 pretone (p value <0.0001, n=7) 
C) SNP mediated vasodilatation expressed as percentage of U46619 pretone (p value <0.0001, n=6) 
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6.4 Chapter Discussion 
6.4.1 Summary of Key Findings 
6.4.1.1  Right Ventricular Hypertrophy 
There was a significant difference in RV hypertrophy between healthy control, 1-
week hypoxia and 2 weeks hypoxia thus indicating that the healthy rats have 
adapted to hypoxic medium. 
6.4.1.2 Myograph data of 1 week chronically hypoxic rats 
1. CH1 ±TNF–α had no effect on a selective α1-adrenergic receptor agonist 
mediated vasoconstriction in pulmonary arteries. Both percentage maximum 
of vasoconstriction and specific tension data suggested no significant 
difference the animal were treated with CH with or without TNF–α. 
2. Similarly, CH1 ± IL–8 OR TNF–α had no significant effect on thromboxane A2 
receptor agonist mediated vasoconstriction in pulmonary artery segments. 
3.  Following hypoxia treatment for 1 week and PE pretone, ±TNF–α had no 
significant effects on either PE vasoconstriction or CC vasodilatation in PAs 
(data not shown). There was no significant difference in specific tension due 
to TNF–α in PAs.  
4. Following hypoxia treatment and U46619 pretone generation, both TNF–α 
and IL–8 had no effect on CC or SNP mediated vasodilatation in PAs. 
6.4.1.3  Myograph results of 2 weeks chronically hypoxic rats 
1. Hypoxia treatment of rats (for 2 weeks) had not significantly altered CC–
mediated endothelial dependent or SNP–mediated endothelial independent 
vasodilatations in isolated rat PAs. 
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2. TNF–α (1 hour) had not significantly augmented chronic hypoxia to effect 
changes in CC–mediated endothelial dependent vasodilatation and SNP–
mediated endothelial independent vasodilatation in isolated rat PA segments.  
3. Neither CH treatment for 2 weeks nor TNF–α (1 hour) addition had any 
significant effects on thromboxane A2 agonist mediated vasoconstriction in 
isolated PAs. 
6.4.1.4  Bronchoalveolar lavage of 2 weeks chronically hypoxic rats 
Chronic hypoxia treatment for 2 weeks has significantly down regulated the level 
of expression of cytokines such as: CINC–1, CINC–2ab, sICAM–1, LIX, L–
Selectin and Thymus.  
6.4.1.5  Acute inflammatory challenge on HPV 
HPV ±TNF-α treatment (1 hour) had no significant effect on HPV phase 1 and phase 
2, suggesting that acute inflammation had no effects on HPV. 
6.4.1.6 Concurrent acute hypoxia and inflammation on pulmonary vascular 
reactivity 
Hypoxia treatment of isolated pulmonary arteries ±TNF–α has altered both the 
endothelium–dependent and endothelium–independent vasodilatations mediated by 
CC and SNP respectively. 
6.5 Discussion 
Our findings from the chapter have confirmed that chronic hypoxia induces a right 
ventricular hypertrophy. This has been shown in literature and in different species 
(483). Minamino et al (483) have shown that the ratio of the right ventricle weight to 
left ventricle plus septum weight [RV/(LV + S)]  to be significantly increased with 48 
hours  up to 3 weeks of exposure to hypoxia (8–12% O2 environment) in healthy 
mice. The increase was in the RV hypertrophy was exhibited in a time dependent 
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manner and attained plateau at 2 weeks of hypoxia (483). This RV to LV plus 
septum ratio was used to verify development of RV hypertrophy and adaptation of 
animal to hypoxia (483). Right ventricular hypertrophy suggests pulmonary 
hypertension that develops due to right ventricle pressure overload (483).  Our 
findings have revealed that chronic hypoxia for both 1 and 2 weeks had no 
significant effects on the both the high K+ response and thromboxane A2 mediated 
vasoconstriction. It would not be expected that chronic hypoxia would alter high K+ 
response; however, we expected that hypoxia might augment pulmonary 
vasoconstriction in this model.  IL–8 or TNF–α addition slightly increased the 
vasoconstriction to chronic hypoxia but the effect was not statistically significant.   
Moreover, chronic hypoxia for 1 or 2 weeks and with or without IL – 8 or TNF–α (for 
1 hour) had no significant effect on neither the endothelium dependent 
vasodilatation, nor on the endothelium independent vasodilatation mediated by CC 
and SNP respectively. Adnot et al (240). have shown that acetylcholine caused 
reduction of pulmonary artery pressure in lungs excised from rats exposed to 
hypoxia for 1 week (240). However, this vasodilatory effect of was not observed in 
the lungs of the rats exposed to hypoxia for 3 weeks, hence a continuous rise of 
pulmonary artery pressure was noted. This group further showed that the absence of 
both the receptor mediated (acetylcholine) and non-receptor (ionophore A23187) 
mediated endothelium dependent vasodilatation in rats exposed to 3 weeks hypoxia 
was reversed when the animal were allowed to recover  at room air for 48 hour 
(240).   
In contrast to our findings, a recent publication has shown that rats exposed to 2 
weeks hypobaric hypoxia developed pulmonary hypertension as results indicated a 
significant increase of the mean pulmonary artery pressure in chronic hypoxic rats 
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compared to the controls (490).  This difference from our results seen might be 
attributed to difference in the experimental setup as well as use of hypobaric hypoxic 
chamber in their study rather than the normobaric hypoxic chamber used in our 
study. This might be due to the fact that both hypobaric pressure at normal air and 
oxygen- poor air at normal pressure can stimulate to animals exposed the 
environment. These treatments have the tendency to cause muscularization of 
resistance vessels that are hypersensitive to limited or low oxygen levels (491). The 
muscularization of pulmonary arteries or arterioles due exposure to hypoxia and 
vasoconstriction is a process that can be reversed with the restoration of normal 
oxygen levels as demonstrated by several studies (240, 490, 491). Hence, the 
phenomenon might act as an adaptive measure to increased pulmonary artery 
pressure (491). It came as surprise that 2 weeks chronic hypoxia exposure of rats 
did not significantly alter vasodilatation in our current experiment. Whether this was 
due to insufficient length of exposure to hypoxia or recovery of rats once the animal 
were taken out of hypoxic chamber into room air could not be elucidated. Though, 
we suggested it might be due the former proposition. Interestingly, development of 
hypoxaemia in patients with COPD is indeed associated with vascular changes, 
including medial hypertrophy of muscular pulmonary arteries, as well as migration 
and proliferation of vascular smooth muscle cells into normally non-muscular vessels 
of the pulmonary circulation (470).  
Chronic hypoxia has been known to upregulate the expression of pro-inflammatory 
cytokines (492). Lam et al. (493) has reported that chronic hypoxia stimulated 
increased expression of pro-inflammatory cytokines such as interleukin (IL)–1 
receptor, IL–6 receptor, IL–1β, IL–6 and TNF–α in carotid body of rats exposed to 
chronic hypoxia (493)  
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Previous studies have revealed the extensive contribution of inflammatory mediators 
to vascular dysfunction in both chronic lung disease in humans and animal models 
(3, 42, 52, 63, 68, 125, 372, 376, 409, 429, 430, 449, 450, 494-496). This has been 
discussed in chapter 5 in the introduction and discussion sections. In this chapter, 
as mentioned at beginning, we aimed to investigate influence of inflammation and 
hypoxia on pulmonary vascular reactivity of rats in vitro. This was essential to 
exclude other factors that might be influencing the response in vivo. Hence, it might 
reduce confounding factors. Surprisingly, just like chronic hypoxia for 1 or 2 week(s) 
had no significant effect on vascular dilatation, addition of TNF–α or IL–8 (for 1 hour), 
did not induce any significant alteration on the pulmonary vascular relaxation. 
Though it came out negative, this is the first time the interaction of hypoxia and 
inflammation had been tested on isolated pulmonary artery vasodilatation in vitro. In 
addition, chronic hypoxia with or without TNF–α or IL–8 had no significant effect on 
the pretone generated by thromboxane A2 or KCl response. 
A synchronised contribution of several mediators such cytokines, chemokine and 
adhesion molecules are responsible for the regulation of lung inflammatory response 
(484). Leucocyte migration via the endothelium is facilitated by the activities of cell 
adhesion molecules like selectins, integrins and immunoglobulin gene super family 
(484, 497). In addition, cytokines and chemokines play a key role in leukocyte 
chemoattractant process and coordination of the complex cellular interaction 
involved in the cell migration. Besides, chemokines are also known to mediate 
various stages of migration process of leukocyte within the endothelium (484, 497).  
Continuing on the investigation of the interaction of hypoxia and inflammation to 
cause vascular dysfunction, we had subjected rats to chronic hypoxia for two weeks 
and then collected bronchoalveolar lavage from the rats and subsequently measured 
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cytokine levels. The outcome of our investigations indicated that there was a 
significant difference between the chemokine levels found between the normoxic 
control and normobaric hypoxic chamber treated rats. Rat cytokine-induced 
neutrophil chemoattractant-1 (CINC-1) protein and cytokine-induced neutrophil 
chemoattractant-2-alpha/beta (CINC-2-αβ) were significantly downregulated in 
normobaric hypoxic chamber treated compared to the normoxic control rats. These 
CINC proteins as their names signify play a critical role in neutrophil chemotaxis 
process and neutrophils comprise of major proportion of leukocyte (white blood cells) 
blood and probably the first leukocyte to respond to infection or inflammation within 
the body. Hence, decrease of these CINC chemokines in chronic hypoxic 
environment might diminish the potential of the body to fight against and infection 
and inflammation thus allowing inflammation to progress without a proper check.   
Also, the current study has showed a significant decrease of soluble intercellular 
adhesion molecule (sICAM)–1, lipopolysaccharide-induced CXC chemokine (LIX) 
and L–Selectin; adhesion molecule, in the BAL of rats subjected to chronic hypoxia 
compared to the control. Soluble ICAM-1 is the form of ICAM-1 (CD54) in the 
circulation which might be either be constitutively expressed or could be stimulated 
on the cell surface of various cell line (498). ICAM-1 structurally is classed among 
the immunoglobulin superfamily and predominantly acts as counter receptor for the 
lymphocyte function-associated antigen (LFA-1) thus the interaction between ICAM-
1 and LFA-1 enables leukocyte adhesion and migration along the endothelium (498). 
LIX is a pro-inflammatory chemokine which plays an important role in neutrophil 
movement along the endothelium during leukocyte migration. In addition, L-selectin 
is known to be accountable for constitutive regulation of lymphocyte movement to 
the lymph nodes and payer’s patches as well as lead lymphocytes and neutrophils to 
203 
 
the location of inflammation (499). Together, blocking these pro-inflammatory 
chemokines and adhesion molecules might influence inflammatory events due to the 
impaired production of mediators we have reported here (499). For example; L-
selectin deficient mice (CD62L−/−) offers a valuable alternative to investigate CD62L 
contribution within the inflammatory settings in comparison to the L-selectin sufficient 
mice. Among the host of dysfunction observed in the L-selectin deficient mice was 
reduced T cell proliferation and cytokine expression (499). Therefore, the knockout 
mice data suggests that L-selectin plays a crucial role in trafficking the leukocytes to 
the location of the inflammation (499, 500). Moreover, our current investigation has 
shown diminished level thymus production in the BAL of rats exposed to chronic 
hypoxia compared to the control. Thymus is a dedicated primary lymphoid organ of 
the immune system and within it, T lymphocytes develop is mature. This 
development and maturation of the T cells is critical for the maintenance of the 
adaptive immune system that enables the body to identify and fight foreign bodies.  
Furthermore, the impact of TNF–α on HPV was assessed in this chapter. In patients 
with lung disease and those who had to use one-lung ventilation, HPV fixes 
mismatch in lung ventilation-perfusion ratio (485, 501). This is brought about through 
the reflex constriction of pulmonary vascular smooth muscle cell’s reaction to 
diminished local partial pressure of oxygen (PO2) (501). Our results demonstrated 
similar pattern to the bi-phasic pattern reported in literature (501). However, we have 
not observed any significant effect of TNF–α on HPV as both phase1 and phase 2 
were not affected by the treatment. Regardless of lack of observing a desired 
outcome, this phenomenon has not been reported in the literature before. It appears 
as if there might have been an effect, however, the results were variable and the 
different has not reached significance. It might be sensible to carefully repeat the 
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experiment to confirm our findings. Investigating HPV is complex process due variety 
of associated biological mechanisms and this can cause between studies 
discrepancies in whole animals, isolated lungs, vessels or cells (205, 501). It was 
suggested that data derived from animal investigations of HPV contain substantial 
variability between species as well as the length of hypoxia period thus making it 
challenging to compare different studies even from the same species (501). In 
addition, investigating HPV in humans is also challenging due to complication 
associated of measuring the pulmonary arterial pressure (PAP), the impact of 
pathology and drugs (501). 
In another group of animals, we have shown that concurrent treatment of isolated PA 
vessel with acute hypoxia plus TNF–α has significantly altered pulmonary 
vasodilatation. Both endothelium-dependent and endothelium-independent 
vasodilatations were affected by the inflammatory mediator. This is the first time 
such an observation has been reported in pulmonary vessels. As hypothesised, we 
suggest that there might be an interaction between hypoxia and inflammation to 
induce vascular dysfunction in the pulmonary artery. Thought some of the earlier 
results obtained not indicate this link, with a slight changes of experimental setup (by 
simultaneously treating PA segments with hypoxia and inflammation), we are able to 
demonstrate this notable association. Future studies should investigate the 
mechanisms involved in this interaction between hypoxia and inflammation leading 
to pulmonary vascular dysfunction. Hence, it will increase our understanding 
regarding pulmonary artery dysfunction and open new therapeutic avenues to be 
tested especially where chronic lung disease is concerned.   
205 
 
6.5.1 Limitations 
1. No test conducted to check whether manipulation during experiment have 
caused endothelial damage. Though the process was handled with care n 
caution to ensure vessel integrity  
2. Some of the pulmonary arteries isolated from CH1 rat did not respond to 
phenylephrine as pretone though the same phenylephrine stock stimulated a 
pretone in systemic iliac arteries isolated from the same CH1 rats. This was 
rather unexpected, however, the experiment was repeated with U46619 
thromboxane A2 agonist as pretone and pulmonary vessels responded. 
3. The temperature of the myograph chambers might not be properly regulated 
as expected (as discussed in detail in chapter 5). The chambers were 
allowed to reach optimum temperature (370C) before any protocol is started 
and the machine was calibrated once every month to maintain consistency of 
the data generated.  This limitation does not seem to affect data generated, 
as the results were consistent for individual vessels types.  
4. The effect of hypoxia on the animal might seem to disappear once the rats 
were out of the hypoxic chamber.  In order to ensure the animal did not 
recover before the protocols were completed. We ensure the protocols were 
short and the times for dissection and isolation process were kept short. 
Besides, it has been shown that rats recovered from hypoxic treatment after 
48 hour recovery period and our protocol time is less than 3 hours.  
5. All the other limitations mentioned in chapter 5 are relevant to the results in 
this chapter. 
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7 General Discussion   
Inflammation and hypoxia can both play a crucial role in vascular dysfunction that is 
associated with the pathogenesis of a variety of vascular, cardiovascular and 
respiratory disorders such as arterial stiffness, hypertension, myocardial infarction, 
stroke, COPD and many others. This thesis explored the role of inflammation and 
hypoxia on rat vascular reactivity as a model of vascular complications associated 
with COPD. Additionally, we examined the effects of hypoxia and inflammation on 
arterial stiffness in AATD subjects genetically predisposed subjects to COPD.  
7.1 Do Hypoxia and Inflammation Interact to Effect Changes in 
Arterial Stiffness in Patients with α1–antitrypsin Deficiency and 
on Isolated Rat Iliac Artery Vascular Reactivity? 
 
Stiffening of arteries can occur as a consequence of aging and/or arteriosclerosis 
and increased stiffness of the arteries can determine cardiac work rate. Arterial 
stiffness is therefore a potentially adjustable factor to predict cardiovascular events. 
Hence, increased arterial stiffness has been linked to increased risk of 
cardiovascular events such as stroke and myocardial infarction, the two leading 
cause of mortality in developed countries. Increased arterial stiffness was also 
suggested to be elevated in COPD patients. However, this increase was not 
dependent on the smoking status but did correlate inversely with lung function and 
directly linked to emphysema severity. Therefore, arterial stiffness is a target of 
pharmacological and exercise intervention in COPD. PWV is the gold standard for 
measuring arterial stiffness and this can be measured from the aorta or carotid artery 
(417).   
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We have shown (see Chapter 3) that arterial stiffness positively correlated with age, 
systolic pressure, pulse pressure and CO. However, arterial stiffness was inversely 
correlated to FEV1, FEV1 percent predicted, total peripheral resistance, TLCO and 
TLCO percent predicted. Although early studies were focused on diastolic pressure, 
current practise recognises that systolic and pulse (systolic minus diastolic) 
pressures contribute a greater role, particularly with evolving age. Thus, for decades 
blood pressure has been known as a vital risk factor for coronary, cerebrovascular 
and cardiovascular diseases (106, 420, 424, 502). Our current findings and those of 
others suggest that the systolic pressure is influenced by arterial stiffness and might 
advance continually with age (420). This illustrates that our observation is in line with 
the knowledge currently available.  The fact that our current data reported strong 
positive correlation with haemodynamic parameters such as systolic pressure, pulse 
pressure and cardiac as expected, confirmed a known relationship, given the role 
arterial stiffness play as an independent predictor of cardiovascular events and 
mortality in disease such as myocardial infarction (424). A similar contour was 
observed for myocardial infarction and blood pressure (420, 425). Building on these 
associations, an increased arterial stiffness could potentially cause high blood 
pressure, directly or indirectly. Therefore, we suggest that pharmacological 
modulation of the blood pressure might alter arterial stiffness. Interestingly, in a 
recently concluded review of hypertensive trials by Dudenbostel and  Glasser (426), 
suggested that angiotensin converting enzyme inhibitors, calcium blockers and 
mineralocorticoid receptor antagonists significantly reduced arterial stiffness and 
central blood pressure. However, some beta blockers such as atenolol might 
stimulate an opposite effect. Dudenbostel and Glasser (426) have also, suggested 
that most of studies  on beta blockers have examined the effects of atenolol and 
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there is insufficient data available regarding the effects of vasodilating beta blockers 
(426). 
More importantly, we have found arterial stiffness to be positively correlated with 
TNF–α. This was a novel finding, as it has not been demonstrated before with this 
patient population.  This suggests that there is an association between arterial 
stiffness and TNF–α that support our hypothesis.  Similar to this observation, Sabit et 
al (418) have demonstrated a weak correlation between arterial stiffness and 
sTNFR1 and IL–6, although no link was shown between PWV and  sTNFR2 in 
COPD patients. However, the same study suggested no link between PWV and 
soluble tumour necrosis factor receptor 2 (sTNFR2) (418).  Yasmin et al. have also 
shown that in healthy individuals, pulse wave velocity was associated with another 
inflammatory maker, CRP (420). CRP is mainly used in clinical investigations as a 
measure of inflammation in the blood. These findings coupled with our own suggest 
a role for inflammation in arterial stiffness. Moreover, we found that there is no 
correlation between arterial stiffness and IL–8 and IL–1β. However, both TNF–α and 
IL–8 were found to be inversely correlated with total peripheral resistance and pack 
years respectively.  
Contrary to our findings, evidence from the literature indicates an association 
between various systemic inflammatory markers and arterial stiffness. Vanfleteren et 
al. (409), have suggested that arterial stiffness in COPD subjects had no association 
with systemic inflammation. This alternative finding has been extensively discussed 
previously (see Chapter 3). However, according to Vanfleteren et al.(409), a quarter 
of 213 eligible COPD patients were excluded from their investigation due to 
unsuccessful aortic PWV measurement. These patients with unsuccessful aortic 
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PWV measurement were found to have significantly elevated BMI, fat free mass 
index, triglycerides, glucose and diffusion capacity of the lung for carbon monoxide 
(DLCO) compared to those where aortic PWV measurements were obtained. This 
might therefore render their results inconclusive as far as a COPD population is 
concerned. 
We investigated the impact of decreases in PO2, to understand the role of hypoxia in 
COPD where the need for use of long-term oxygen therapy and/or ambulatory 
oxygen in often seen in this subset of patients. Contrary to our expectation, we 
established that there was no correlation between arterial stiffness and PO2, No 
previous literature had shown any relationship (positive or negative) prior to this 
demonstration. Interestingly, and unexpectedly, PO2 correlated proportionally with 
almost all lung function measure (such as FEV1, FEV1 percent predicted, FEV1/FVC 
ratio, FVC, FVC percent predicted), lung gas transfer factors (such TLCO and TLCO 
percent predicted) and some cardiovascular measures (such as pulse pressure, and 
aortic pulse pressure).  
In our multivariate linear regression model the entered independent variables 
included age, sex, TNF–α, PO2, systolic pressure, FEV1 and TLCO, whereas the 
PWV was added as dependent variable. The overall outcome showed that these 
variables together can account for about 50% of variability observed in the 
dependent variable. Individually, among the dependent variables, only age and 
systolic pressure could significantly predict PWV. However, the regression analysis 
suggested that our model had a significant explanatory power to predict the 
dependent variable. Hence, the co-efficient of the independent variables was not 
zero and thus the model can predict PWV. Other models were explored to 
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investigate which variable predict PWV best. However, these models accounted for 
less variability in the dependent variable than the one reported above.  
We analysed for a possible biological interaction between TNF–α and PO2. This was 
to account for what might happen in vivo. Our analyses indicated that there was no 
interaction between TNF–α and PO2.   
Following incubation of isolated systemic iliac artery vessels with TNF–α for 1 hour, 
we found that TNF–α significantly altered vascular relaxation in isolated iliac artery. 
This has not been shown in iliac artery prior to this observation. Elevation of the 
levels of pro-inflammatory cytokines (such as TNF–α) has been associated with 
endothelial dysfunction in different cardiovascular diseases such as congestive heart 
failure, atherosclerosis, septic shock, diabetes, hypertension and aging (366-371). 
The inflammatory mediators might influence impairment of the endothelium-
dependent relaxation there by precluding the endothelium response to circulating 
autacoids or hormones. Therefore, this makes the vessel susceptible to spasm, 
thrombosis and/or atherogenesis (372).  
So far our data has confirmed that link between inflammation and systemic vascular 
related disease pathogenesis in both human and rats. TNF–α was associated with 
arterial stiffness as well as endothelial dysfunction in AATD patients and healthy iliac 
arteries isolated from rats. Hence, our human and animal data were in agreement 
with regard to TNF–α role in vascular disease pathogenesis.  The association 
between inflammatory mediators and vascular dysfunction has been widely 
recognised in the literature. This result confirms that TNF–α might influence 
endothelial function in systemic iliac arteries isolated from Wistar rats. Similarly, 
Wimalasundera et al. (376) has demonstrated that in mesenteric arteries pre-
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contracted with PE, TNF–α caused impairment of acetylcholine mediated 
vasodilatation by significantly shifting the dose-response curve of acetylcholine to the 
right. In addition, TNF–α induced impairment of bradykinin mediated relaxation by 
significantly reducing the concentration-response curve (376). 
Furthermore, combination treatment of isolated iliac arteries to chronic hypoxia (1 
week at 12% O2) and TNF–α (1 hr in vitro) had not augmented the effect observed 
with TNF–α alone. Again, though contrary to our expectations, the human and 
animal data were in accordance. This was due to fact that we have not observed an 
interaction between hypoxia and inflammation in both settings. However, the animal 
data on chronic hypoxia might be regarded as a preliminary due to limited sample 
size.   
7.2 Effects of Inflammation and Hypoxia on Vascular Reactivity in 
Isolated Pulmonary Arteries: A Model for Vascular Diseases 
Associated With COPD? 
7.2.1 Short-term inflammatory challenge ±hypoxia (acute chronic) 
The current investigations revealed no effect of short-term TNF–α (1 hr) treatment on 
pulmonary vasoconstriction and vasodilatation. The vasoconstriction responses of 
phenylephrine and U46619, as well as the CC-mediated vasodilatation were not 
altered by the TNF–α challenge. On the other hand, IL–8 treatment for 1 hour had a 
significant effect on both the endothelium-dependent and endothelium-independent 
vascular relaxation mediated by CC and SNP respectively. This suggests that short-
term exposure to IL–8 might play a role in endothelial dysfunction in pulmonary 
arteries. Similarly, Gillham et al (451) has shown that TNF–α incubation for 1 hour 
caused no alteration to the endothelial–dependent vasodilation in omental arteries 
obtained from healthy pregnant women. 
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Moreover, combination of chronic hypoxia for 1 or 2 week(s) plus short term TNF–α 
treatment of pulmonary artery segments in vitro had affected neither vasoconstriction 
nor vasodilation in isolated pulmonary arteries. Similarly, IL–8 treatment (1 hr) did 
not  affect vasodilatation in rats exposed to chronic hypoxia for 1 week. In addition, 
CH plus TNF–α or IL–8 did not alter the pretone generated by PE (selective α1-
adrenergic receptor agonist) or U46619 (thromboxane A2 agonist). Therefore, this 
suggests that hypoxia (1 or 2 weeks at 12% O2) and inflammatory mediators had no 
influence on the vasoconstrictor response of pulmonary vessels, at least in this 
experimental setting.  A recently concluded review by Pugliese et al (247) suggested 
that hypoxia has the potential to start inflammation and stimulate a significant effect 
on local pulmonary vascular cells. They also postulated that the pathological 
changes induced in an hypoxic PH animal model (up to 5 weeks exposure) and 
many types of PH in human generally can resolve rapidly with seemingly relative 
normoxia (247). It is probable that these suggestions might be applicable to our CH 
experiments as we have observed adaptation of the rats to hypoxia with increased 
RV hypertrophy but no effect on vascular reactivity. 
In our study of the bronchoalveolar lavage of rats exposed to chronic hypoxia for two 
weeks, we found a significant reduction in the expression levels of some cytokines 
found. These include CIN –1, CINC–2ab, sICAM–1, Lix, L–selectin and thymus. The 
role of these cytokines or chemokines in the vascular function was discussed in 
Chapter 6 (6.5). Our results indicated that CINC-1, CINC-2 and Lix as that are 
neutrophil chemoattractant were reduced in the CH rats compared to the controls 
suggesting a possible delay to neutrophil response to the site of infection or 
inflammation under chronic hypoxia conditions. Also there level of adhesion 
molecules such as sICAM-1 was reduced in chronic hypoxic rats that lead to 
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reduced leukocyte adhesion and migration along the endothelium. In addition, T cell 
development and maturation might be affected in chronic hypoxic condition due to 
reduced level thymus observed in CH rats. 
Concurrently subjecting isolated rat pulmonary artery segments to acute hypoxia and 
TNF–α (1 hr) in vitro significantly altered both endothelium-dependent and 
endothelium-independent vascular relaxation. However, TNF–α (1hr) treatment had 
no impact on hypoxic pulmonary vasoconstriction in isolated pulmonary arteries from 
healthy Wistar rats. TNF–α had no significant effect on either the phase 1 or phase 2 
of the HPV.   
It is important to note that development of hypoxaemia in patients with COPD is 
associated with vascular changes, including medial hypertrophy of muscular 
pulmonary arteries, as well as migration and proliferation of vascular smooth muscle 
cells into normally non-muscular vessels of the pulmonary circulation (470) and 
impaired NO production promotes in situ thrombosis, which can also worsen 
pulmonary hypertension. In addition to its hemodynamic effects, NO might contribute 
a pivotal role in preventing pulmonary vascular remodeling and enlargement of the 
right ventricle. At least in vitro, NO regulates many functions of vascular smooth 
muscle cells that modulate intimal thickening of pulmonary arteries, including 
vascular smooth muscle cell proliferation, migration, apoptosis, and extracellular 
matrix formation (503, 504). NO also modulates platelet adhesion and aggregation, 
leukocyte recruitment and activation, and cytokine-induced endothelial cell activation 
(503, 504). Experimental studies also suggest that continuous inhalation of NO 
prevents hypoxic vasoconstriction and reduces pulmonary arterial remodeling and 
RV hypertrophy in rats exposed to chronic hypoxia (505, 506).  
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7.2.2 Prolonged inflammatory challenge  
Isolated pulmonary vessels were incubated with TNF–α for 2 and 6 hours then 
vascular reactivity was measured with wire myography. The finding from this study 
showed that prolonged TNF–α (2 and 6 hrs) exposure had significantly reduced both 
endothelium-dependent and endothelium-independent vasodilation in the pulmonary 
artery segments mediated by CC and SNP respectively with the effect being 
augmented by the 6 hour exposure. These results suggest that TNF–α exposure 
might result in vascular dysfunction in rat pulmonary arteries. Our studies illustrated 
that TNF–α exposure impaired both endothelial and pulmonary artery smooth muscle 
cell NO-mediated relaxations. Similarly, TNF–α was shown to inhibit relaxation 
mediated by acetylcholine and bradykinin, although SNP mediated vasodilatation 
was not affected (376). This was discussed in detail in Chapter 5 (5.4). In contrast, a 
similar study protocol reported no changes in endothelial–dependent vasodilatation 
profile in healthy omental arteries incubated with TNF–α  for 2 hours (451). 
7.2.3 Investigating Potential Mechanism involved in TNF–α mediated 
vascular dysfunction 
Investigating the mechanism of TNF–α inhibition of vasodilatation in pulmonary 
arteries, we used allopurinol, a xanthine oxidase inhibitor and Tempol, a membrane–
permeable radical scavenger. Interestingly, allopurinol completely reversed TNF–α 
inhibition of CC–mediated relaxation in pulmonary artery, though Tempol did not 
significantly affect TNF–α inhibition of CC–mediated relaxation in pulmonary artery. 
Our result suggests that TNF–α impaired endothelial-mediated relaxation in isolated 
PAs via XO mediated increase of ROS. Similarly, Kanbay et al (472) reported that 
allopurinol had significantly increased endothelium–dependent vasodilatation in 
human subjects. All the studies included in this study assessed effect of allopurinol 
on endothelial–dependent vasodilatation which was evaluated using  flow–mediated 
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dilatation (FMD) and forearm blood flow (FBF) response to acetylcholine or flow-
dependent flow assessment (472). Interestingly, our current findings though from 
different species and set-up, demonstrated a similar observation. The result 
suggested that TNF–α inhibition of CC–mediated relaxation in pulmonary artery was 
via xanthine Oxidase pathways. Xanthine oxidase is a form of xanthine 
oxidoreductase, an enzyme that generates reactive oxygen species. The enzyme 
can catalyze the oxidation of hypoxanthine to xanthin (473) .  Also, it can further 
catalyze the oxidation of xanthine to uric acid (473). XO was shown to be elevated in 
the epithelial lining fluid of COPD patients compared to healthy controls (434). 
Another study has indicated that pro-inflammatory cytokines; TNF–α, IL–1β and IFT–
γ significantly stimulated XOR gene expression in rat alveolar macrophages (474), 
bovine renal epithelial cells (475) and human mammary epithelial cells (476). In 
addition, Wright et al.(477) showed that infusion of IL–1 and IFT–γ in a rat model 
resulted in elevation of XO activity in the lungs. Considering these evidences, it 
appears that pro-inflammatory cytokines might play a significant role in enhancement 
of the XO gene expression in COPD airways (434). Furthermore, Komaki et al (434), 
found a strong positive association between the levels of TNF–α or IL–1β and XO 
activity.  
On the other hand, we have showed that neither allopurinol, nor tempol significantly 
affected TNF–α inhibition of SNP–mediated endothelial–independent relaxation in 
pulmonary artery. SNP is an NO donor and acts on PASMC to mediate relaxation. 
The fact that SNP-mediated relaxation was impaired in isolated rat PAs as a results 
of TNF–α treatment, suggest that the inflammatory cytokine might impair PASMC 
mechanism that bring about the NO-mediated vasodilatation. Also, Kanbay and 
colleagues (472) indicated that allopurinol had no significant effect on the 
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endothelium–independent vasodilation mediated by SNP. Our results combined with 
other suggest that the TNF–α impairment of the endothelium-independent 
vasodilatation is not dependent on increase in ROS generation. Therefore, the 
impairment might be induced through other mechanisms (apart from the ROS 
mediated pathways that are normally inhibited by tempol or allopurinol) such as 
impairment to cGMP activation or downstream signaling component that mediates 
vasodilatation with the smooth muscle cells. Further research might be required to 
unravel this potential mechanism.  
 
7.3 Conclusion & Future Research 
7.3.1 Human 
Our findings have shown a correlation between PWV and TNF–α in AATD. However, 
TNF–α did not independently predict PWV, whereas age and systolic pressure has 
the ability to independently predict PWV.  The findings suggest that arterial stiffness 
might be related to the inflammatory mediators and that systemic inflammation could 
contribute to arterial stiffening. Further longitudinal studies whilst investigating an 
array of inflammatory mediators might be required to confirm the findings and to 
establish association between inflammation and arterial stiffness.  
7.3.2 Animal 
These data support the hypothesis that TNF–α might worsen pre-existing endothelial 
dysfunction as well as in intact pulmonary vessels. This is due to the observation that 
cytokine affected both endothelial and non–endothelial mediated vasodilatations 
which suggest that plasma TNF–α level could trigger endothelial dysfunction. Future 
studies should focus on identifying the mechanisms by which TNF–α exert its 
inhibitory effect on the pulmonary vascular relaxation. There was some evidence that 
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IL–8 might be involved in mediating endothelial dysfunction in the pulmonary arteries 
from rats. Due to the fact that many cytokines act in synergy with other cytokines, a 
possible combinational cytokine challenge might be useful in understanding the 
pulmonary vascular dysfunction. 
 
To answer the question posed by the title of this thesis, namely, is our combined 
inflammatory and hypoxic insult an appropriate model for COPD-associated vascular 
disease, the answer must be conditional. Therefore, within the limits of our protocols 
we did see evidence of cardiac remodeling, indicative of a hypoxic response as well 
as evidence of cytokine-mediated effects on vascular dysfunction that was reversed 
by antioxidant. Contrary to our expectation, we saw little, if any, combinational 
effects of the two stimuli acting together when the hypoxia was delivered in vivo for 1 
or 2 weeks. Thus, vascular function was not worsened by in vivo hypoxia when 
challenged subsequently in vitro with cytokine.  However, when hypoxia was 
delivered in vitro for just one hour in combination with cytokine (TNF-α), we did 
observe vascular dysfunction that was due a reduced vasodilatory capacity. On the 
face of it, this suggests that a purely in vitro model of combinational hypoxia and 
cytokine might have advantage over in vivo hypoxia as a model of COPD. However, 
we did not examine combinational hypoxia plus inflammation in vivo and our in vitro 
findings suggest that this may be a better model for future studies.  
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